Immunohistochemistry Guide Book From Dako

PATHOLOGY
Dako provides cancer diagnostic

Education Guide Immunohistochemical Staining Methods products for leading reference
Fourth Edition
laboratories, hospitals and other
clinical and research settings.
Our instrumentation portfolio is

complemented by a full line of
antibodies, pharmDx™ assays,
detection systems and ancillaries.
Consider Dako for all your
laboratory needs.
PATHOLOGY
Dako provides cancer diagnostic
Education Guide Immunohistochemical Staining Methods products for leading reference
Fourth Edition
laboratories, hospitals and other
clinical and research settings.
Our instrumentation portfolio is

complemented by a full line of
antibodies, pharmDx™ assays,
detection systems and ancillaries.
Consider Dako for all your
laboratory needs.
Immunohistochemical Staining Methods,
Fourth Edition
Editor
Marc Key, Ph.D.
Key Biomedical Services ° Ojai, CA, USA
Contributors
Karen Atwood, B.S. MT (ASCP) CLS
Dako ° Carpinteria, CA, USA
Kirsten Bisgaard, B.S.
Dako ° Glostrup, Denmark
Kenneth J. Bloom, M.D.
Clarient ° Aliso Viejo, CA, USA
Thomas Boenisch, M.S.
Nanna K. Christensen, M.S., Ph.D.
A.J. Farmilo, Ph.D.
Dako ° Mississauga, Ontario, Canada
Richard Harvey, Ph.D.
University of New Mexico School of Medicine ° Albuquerque, NM, USA
Jim Hudson, Ph.D.
Mehrdad Nadji, M.D.
University of Miami School of Medicine ° Miami, FL, USA
W. Roy Overton, Ph.D.
GCAT Inc. ° Fort Collins, CO, USA
Gale E. Pace, B.S. MT (ASCP) I
Dako ° Carpinteria CA, USA
Ole Feldballe Rasmussen, M.S., Ph.D.
Andreas Schønau, M.S., EBA
Helle Grann Wendelboe, M.S.
Lars Winther, M.S., Ph.D.
Ron Zeheb, Ph.D.
The Lahey Clinic ° Burlington, MA, USA

© Copyright 2006 Dako, Carpinteria, California. All rights reserved. No part of this book may be
reproduced, copied or transmitted without written permission. US $50
Immunohistochemical Staining Methods
Legend for Schematics
primary antibody secondary antibody F(ab1)2 tissue

antibody antibody secondary antigen
antibody
HRP AP biotin streptavidin biotinyl fluorescein DBA Fast Red polymer

enzyme enzyme label tyramide label
ii
Table of Contents
Preface VI
Part I: Theory
Chapter 1 ° Antibodies
Thomas Boenisch
Introduction 1, Immunoglobulins 1, IgG 2, IgM 3, Polyclonal Antibodies 5,
Monoclonal Antibodies 6, Antibody Affinity 7, Antibody Cross-Reactivity 9,
Antibody Reaction Rates 10, Antibody Stability 10, Handling of Antibodies 12
Chapter 2 ° Basic Immunochemistry

Thomas Boenisch
Introduction 15, Antibody Titer 15, Antibody Dilution 15, Antibody Incubation 17
Chapter 3 ° Basic Enzymology

Thomas Boenisch
Introduction 19, Enzymes 19, Substrates and Chromogens 22, Suggested
Procedures for Substrate-Cromogen Reagents 23
Part II: Processing
Chapter 4 ° Fixation and Processing

A.J. Farmilo
Introduction 27, Fixation 27, Tissue Handling 29, Specialized Tissue
Preparations 31
Chapter 5 ° Molecular-Friendly Tissue Processing

Mehrdad Nadji
Why Molecular Pathology 35, Complete Molecular-Friendly Histology
Platforms 35, Fixation 35, Processing 36, Validation 37, Summary 37,
Conclusion 39
Chapter 6 ° Antigen Retrieval

Marc Key and Thomas Boenisch
Introduction 41, Short History of Antigen Retrieval 41, Principle and Technique 42,
Mechanism of Action 43, Cytology 43, Target Retrieval for In Situ Hybridization 44,
Antigen Retrieval and Its Use in Double Staining 44, Conclusion 44
iii
Part III: Methodologies
Chapter 7 ° Immunohistochemistry Staining Methods

Marc Key
Introduction 47, Immunohistochemistry 47, Avidin-Biotin Immunohistochemistry
48, Polymer-Based Immunohistochemistry 50, Tyramide Amplification 51, Cycled
Tramide Amplification 52, Fluorescyl-Tyramide Amplification 52, Rolling Circle
Amplification 52, Conclusion 53
Chapter 8 ° Immunofluorescence
W. Roy Overton, Revised by Jim Hudson and Karen Atwood
Introduction 55, Fading, Quenching and Photobleaching 57, Fluorescein 57
Chapter 9 ° Multi-Staining Immunohistochemistry

Nanna K. Christensen and Lars Winther
Introduction 61, Advantages of Multiple Staining 61, Technical Challenges 62,
Pretreatment 62, Staining Method Selection 63, Dye Selection 65, Other Labels
67, Automated Image Acquisition and Analysis 67, Conclusion 67
Chapter 10 ° Ancillary Methods in Immunohistochemistry

Gale E. Pace
Introduction 71, Endogenous Enzyme Blocks 74, Antibody Diluents 79, Wash
Buffers 82, Chromogen Enhancers 86
Chapter 11 ° In Situ Hybridization

Richard Harvey, Revised by Andreas Schønau
Introduction 89, Types of Probes 89, Types of Samples 91, Detection of High-Risk
HPV Infections in a Cervical Smear 93, Conclusion 93
Chapter 12 ° Methods of Immunocytology for Slide-Based

Cellular Analysis
Marc Key
Introduction 95, Sample Preparation 97, Fixation 98, Immunostaining Methods 99,
Controls 100
Chapter 13 ° Automating Immunohistochemistry

Ron Zeheb
Introduction 103, Choosing the Right IHC Stainer 103, Maintaining IHC
Stainers 104, Economics of IHC Stainers 104, Flexibility and Ease of Use 104,
Workflow and Data Management 105
iv
Chapter 14 ° Virtual Microscopy and Image Analysis

Kenneth J. Bloom
History 107, Scanning Slides 108, Viewing the Virtual Slide 109, Capturing
Images for Image Analysis 110
Chapter 15 ° Controls
Ole Feldballe Rasmussen
Introduction 113, Reagent Controls 113, Negative Controls 114, Tissue
Controls 114, Cell Line Controls 116, Control Programs 117, Future Aspects 118
Chapter 16 ° Background
Helle Grann Wendelboe and Kirsten Bisgaard
Introduction 119, Background Associated with Detection Methods 119, Double
Staining 121, General Factors 123, Natural and Contaminating Antibodies 125,
General Aspects 129
Chapter 17 ° Troubleshooting
Karen Atwood and Dako Technical Support Group
Introduction 131, Section One: Inadequate Staining 132, General Background 137,
Limited Background 140, Undesired Specific Staining 144, Miscellaneous 145,
Section Two: Background Staining 146, Section Three: Tissue Specimen 150,
Section Four: Using a Typical Specification Sheet for an IVD Antibody 152
Glossary 157
Index 161

Preface to the Fourth Edition of the Dako Educational

Guide to Immunohistochemical Staining Methods
It is my pleasure to introduce this fourth edition of Dako’s Guidebook to

Immunohistochemical Staining Methods. This unique reference is provided by Dako
to academic research investigators, pathologists, histopathologists and students
from medical and scientific disciplines around the world as part of their continuing
commitment to foster excellence in the fields of immunology and histopathology.
In order to provide the most up-to-date information in these fields, Dako periodically
revises this book’s content to reflect advancements in these disciplines. For example,
this edition, like previous ones, contains relevant information on the well-established
theoretical basis and methodology that is employed for these techniques. Of equal
importance, contemporary approaches in automation, image analysis, molecular
diagnostics and multi-staining have been updated and expanded in this edition. Finally,
of great practical importance, knowledgeable practitioners have provided very helpful
information related to interpretation of staining results and troubleshooting to resolve
unexpected problems that can arise.
On behalf of Dako, I would like to thank all the contributors to this fourth edition. Most
of the authors are Dako employees directly active in the development of these methods
providing unique insights in this highly specialized field. The other authors, Thomas
Boenisch, Marc Key, Mehrdad Nadji, Kenneth Bloom, W. Roy Overton and Ron Zeheb
are recognized experts in their fields and greatly respected by all of us here at Dako.
We value their individual contributions highly and appreciate the fact that they would
participate so fully in this endeavor.
All available copies of previous editions of this handbook have been distributed. It is
our goal to continue this practice in order to expand knowledge in this area and serve
interested scientists around the world. We hope you find this edition to be as useful as
the prior ones and we ask that you share your learning with your colleagues.
Dennis E. Chenoweth, Ph.D., M.D.
Corporate Vice President, Business Development
vi
Chapter 1 ° Antibodies
Thomas Boenisch
Introduction
The pivotal reagent common to all immunohistochemical* techniques is the antibody.
The availability of new antisera, their immunoglobulin fractions and monoclonal
antibodies to an ever-increasing number of clinically useful tissue antigens has
expanded the quantity and quality of the immunohistologic repertoire enormously. To
better comprehend the potential of immunohistochemical staining methods as well as
associated problems, it is necessary to have a basic knowledge of antibodies, their
potentials and their limitations.
Immunoglobulins
Antibodies belong to a group of proteins called immunoglobulins (Ig) that are present
in the blood of immunized animals. The removal of cells and fibrin from blood is used to
collect the serum fraction frequently referred to as antiserum. Listed in order of decreasing
quantity found in plasma or serum, immunoglobulins comprise five major classes:
Immunoglobulin G (IgG), IgA, IgM, IgD and IgE. Each is composed of two identical
heavy chains (H) and two identical light chains (L). The H chains differ in antigenic
and structural properties, and determine the class and subclass of the molecule. The
two L chains are either of type kappa (κ) or lambda (λ). Distribution of κ and λ chains
differs in all Ig classes and subclasses, as well as between different species. Covalent
interchain disulfide bridges join L to H and H to H chains. By participating in the tertiary
structure, they confer greater stability to the immunoglobulin molecule.
Figure 1.1. Diagram showing the structure of an immunoglobulin molecule. It comprises two identical heavy (H) chains
and two identical light (L) chains. Inter- and intrachain disulfide bonds (|—•—|) contribute to the structure and stability
of the molecule.

Of the five classes of immunoglobulins, IgG and IgM will be considered in more detail
here, as these antibodies are utilized by far the most frequently in immunohistochemistry.
Unless otherwise noted, most of what is described of the IgG structure in this text was
learned from studies with human IgG of subclass IgG1.
IgG
The heavy chains of IgG are denoted as gamma (γ) chains. IgG has the general formula
of γ2 κ2 or γ2 λ2, which denotes that one molecule of IgG (MW = 150 kD) is composed
of two γ heavy chains, and two light chains of either type κ or type λ (Figure 1.1). The
structure of the IgG molecule has been determined in part by proteolytic digestions
and reductive dissociation of the molecule (Figure 1.2). Digestion by papain results
in the cleavage of a susceptible bond on the N-terminal side of the inter-heavy chain
disulfide bridges. This yields two monovalent antigen-binding fragments (Fab) and
one crystalline fragment (Fc). Pepsin cleaves the γ chains on the C-terminal side of the
inter-heavy chain disulfide bridges, resulting in one bivalent antigen-binding fragment,
F(ab’)2. In this case, the Fc fragments are destroyed. Reductive dissociation of an IgG
molecule splits the interchain disulfide bridges, and if the free sulfhydryl groups are
blocked, results in the formation of two H chains (molecular weight 50 kD each) and
two L chains (25 kD each).
Figure 1.2. Diagram showing the structure of rabbit IgG (which exists as a single major subclass). The heavy (H) and
light (L) chains are composed of variable (V) and constant (C) domains and are linked by inter- and intrachain disulfide
bonds (|—•—|). Proteolytic digestion with papain (– – – –) yields two antigen-binding fragments (Fab)2 and one
crystalline fragment (Fc), whereas digestion with pepsin (• • • • •) yields one F(ab’)2 fragment.
The IgG molecule can be divided further into so-called domains, namely the variable
domains (V) and the constant domains (C). Each domain contains 110 to 120 amino
acids and one intrachain disulfide bond. The amino terminals of the immunoglobulin

Antibodies
molecule are located on the variable domain of the light chain (VL), and on the variable
domain of the heavy chain (VH). Together, VL and VH form the antigen-combining site.
Several hypervariable (HV) regions are located within the VL and VH domains of the
antibody. During their reaction with antigens, HV regions are brought into close proximity
to the antigenic determinant (epitope). The distance between the antigen and HV regions
of the antibody is approximately 0.2 to 0.3 nm.
Unique structural specificities called idiotypic determinants are located in this region.
Each antibody clone expresses its own idiotype. Each L chain also has one constant
domain (CL) in addition to the VL domain. The H chain also has three constant domains
(CH1, CH2 and CH3) and carries the carboxyl terminal portion of the immunoglobulin.
Located on the CH2 domain is the carbohydrate moiety of the IgG molecule and several
strongly hydrophobic neutral aromatic amino acids. The hinge regions are located
between the CH1 and CH2 domains of the H chains. Minor differences within these
hinge regions contribute to the subclass specificity of immunoglobulin G. The same are
designated by subscripts as in IgG1, IgG2a, IgG2b, IgG3 and IgG4. Whereas in human
IgG the overall ratio of κ to λ is 2:1, in the subclasses IgG2 and IgG4, for example, the
ratios are 1:1 and 8:1, respectively. Mice have approximately 95 percent κ chains, and
therefore most monoclonal IgG antibodies from this species have κ chains. The number
of disulfide bridges linking the heavy chains also varies among the IgG subclasses. IgG1
and IgG4 each have two, while IgG2 and IgG3 have four and five, respectively. Because
of the flexibility of the hinge region, the angle that both Fab fragments form can vary to
accommodate a range of distances between identical antigenic determinants.
IgM
IgM is a pentamer (MW approximately 900 kD) consisting of five subunits of
approximately 180 kD each (Figure 1.3). The general formula can be expressed as (μ2
κ 2) or (μ 2 λ 2)5. Each subunit is linked by a sulfhydryl-rich peptide, the J chain (15 kD),
and consists of two heavy chains μ and two light chains of type κ or λ. The J-chains
contribute to the integrity and stability of the pentamer. As with IgG, IgM subunits can
be fragmented by enzymatic and reductive cleavage into F(ab’)2, Fab and Fc portions,
as well as heavy and light chains, respectively. The Fc fragment of IgM is a cyclic
pentamer (molecular weight approximately 340 kD). Treatment of pentameric IgM with
0.1 percent mercaptoethanol cleaves the disulfide bridges between the subunits to
yield five monomers. Subclasses of IgM1 and IgM2 have been reported.
Whereas IgG is the most abundant antibody in the hyperimmunized host, in the
newly immunized animal, IgM is the first humoral antibody detectable. The primary
antibody formation proceeds in several major stages. Injected immunogen first reaches
equilibrium between extra- and intravascular spaces, then undergoes catabolism
resulting in smaller fragments, and finally is eliminated from the intravascular spaces
by the newly formed antibodies. The period from the introduction of an immunogen
until the first appearance of humoral IgM antibodies is called the latent period and may
last approximately one week. Within two weeks, or in response to a second injection,

IgG class antibodies usually predominate. Like all proteins, antibodies are subject to
catabolism. Whereas antibodies of class IgM have a relatively short half-life of only four
to six days, IgG antibodies have a mean survival of approximately three weeks. Unless
repeated booster injections with the immunogen are given, the serum antibody level
will decrease after this period.
Figure 1.3. Diagram showing (A) the five subunits of mouse IgM linked by disulfide bridges (|—•—|) and the J chain
to form a pentameric ring structure. Each subunit (B) comprises two mu heavy (H) chains and two light (L) chains each
composed of constant (C) and variable (V) domains.
Antibody formation on the molecular level is a complex process, and a detailed account
of it is beyond the scope of this guidebook. The interested reader is referred to the
textbook Molecular Immunology by Atassi et al (1).

Antibodies
Polyclonal Antibodies
Polyclonal antibodies are produced by different cells, and in consequence, are
immunochemically dissimilar. They react with various epitopes on the antigen against
which they are raised (Figure 1.4). By far, the most frequently used animal for the
production of polyclonal antibodies is the rabbit, followed by goat, pig, sheep, horse,
guinea pig and others. The popularity of rabbits for the production of polyclonal
antibodies is attributed primarily to their easy maintenance. An additional advantage
is that human antibodies to rabbit proteins are much more rare than to proteins from
ruminants, such as goat. In addition, rabbit antibodies precipitate human proteins over
a wider range of either antigen or antibody excess, and pools of antibodies made
from many rabbits are less likely to result in major batch-to-batch variations than pools
made from only a few, larger animals. Many years of selective breeding for favorable
immunization response has made the New Zealand White rabbit the most frequently
used animal for the production of polyclonal antibodies (2).
Figure 1.4. Schematic diagram of polyclonal antibodies binding to various epitopes on an antigen.
Depending on the immunogenicity of the antigen, doses of from 10 µg to 200 µg are

traditionally administered to generate an immune response in animals. The antigen is
injected most often intradermally or subcutaneously, but injections into the footpad
muscle or peritoneal cavity are used also. In rabbits, volumes of 0.1–0.5 mL are given
usually intradermally and distributed over several sites; the antigen is suspended in an
equal volume of adjuvant, such as Complete or Incomplete Freund’s Adjuvant. Booster

shots, repeated once a month or when decreasing titers are noted, are intended to
maintain or increase antibody levels. Blood is collected most often from the ear (rabbits),
the jugular vein (larger animals) or from the heart, sometimes by sacrificing the animal.
After the removal of cells from the blood, polyclonal antibodies can be obtained either
in the form of stabilized antisera or as purified immunoglobulin fractions. For the latter,
precipitation by salts, followed by ion exchange chromatography, serves to remove the
bulk of other serum proteins. Affinity chromatography can be used to isolate the antigen-
specific antibodies and thereby free them of nonspecific antibodies.
Monoclonal Antibodies
Monoclonal antibodies are the product of an individual clone of plasma cells. Antibodies
from the same clone are immunochemically identical, and react with a specific epitope
on the antigen against which they are raised (Figure 1.5). Probably for reasons of
economy, mice are used most frequently for the production of monoclonal antibodies.
After an immune response has been achieved, B lymphocytes from spleen or lymph
nodes are harvested and fused with non-secreting mouse myeloma cells. While the B
lymphocytes convey the specific antibody, myeloma cells bestow upon the hybrid cells
(hybridoma) longevity in culture medium. Non-reactive B cells and myeloma cells are
discarded and the antibody-producing hybridoma is cultured and tested for desired
reactivity. Propagation can be carried out in culture medium or by transplantation of
the hybridoma into the peritoneal cavity of syngeneic mice from where the antibodies
are harvested in ascites fluid. Thus large and at least theoretically unlimited quantities
of monoclonal antibodies of specific and identical characteristics can be produced.
Figure 1.5. A given clone of monoclonal antibodies reacts with a specific epitope on an antigen.

Antibodies
In immunohistochemistry, monoclonal antibodies have certain advantages over their

polyclonal counterparts. These include high homogeneity, absence of nonspecific
antibodies, ease of characterization and minimal batch-to-batch or lot-to-lot variability.
Some pitfalls in the use of monoclonal antibodies should be noted. Test methods for
selection of useful clones and for quality control must be identical to the methods
for which they ultimately will be used. For example, monoclonal antibodies must be
characterized on formalin-fixed tissues and not on frozen tissue, if they ultimately are
intended for use on formalin-fixed specimens.
Similarly, results from testing reactivity of a new antibody on optimally fixed tissue must
not be relied upon to predict its reactivity on sub-optimally fixed tissue, such as tissue
fixed for a prolonged or inconsistent length of time. Also, as improved antigen retrieval
procedures are being published continuously, it is imperative that the screening of new
antibodies consider these additional variables (see Antigen Retrieval, Chapter 6).
Targeted epitopes also must be unique to a given antigen. Specificity, one of the
greatest benefits of monoclonal antibodies is lost if the antibody is directed against
an epitope shared by two or more different antigens (see Antibody Cross-Reactivity).
While cross-reactivity of a polyclonal antibody can be removed usually by absorption,
that is not possible with a monoclonal antibody.
Screening methods also should consider that monoclonal antibodies, unlike

polyclonal antibodies, depend more on environmental factors such as pH and solute
for optimum performance (3).
Antibody Affinity
Antibodies from hyperimmunized animals not only differ with regard to the determinants
they recognize on multivalent antigens, but also differ in their affinities for the same. The
term “affinity” has been used to describe both intrinsic and functional affinities (4).
The intrinsic affinity of an antibody resides in the HV region and is determined by the
same sequence of amino acids that determines specificity. Primarily ionic (electrostatic)
interactions, but also hydrogen bonding and van der Waals forces are the major
contributors to the intrinsic affinity between the paratope on the antibody and the
epitope on the antigen. Hydrophobicity forms last and has a stabilizing effect on the
cultivated immune complex, and, with soluble reactants, usually leads to its precipitation.
Covalent binding between antibody and antigen does not occur. The association
constant (Ka) of the binding between an antibody and its antigenic determinant is a
measure of the antibody’s affinity. It can range from 103 to 1010 liters per mole and is
the reciprocal of concentration in moles per liter. The higher the intrinsic affinity of the
antibody, the lower the concentration of the antigen needed for the available binding
sites of the antibody to become saturated (reach equilibrium). Just as the quantity (titer)
of an antibody increases with time during immunization, so does its quality (affinity).
This has been called “affinity maturation” (5). Lower doses of immunogen increase the
rate of affinity maturation, but may result in lower titers of antibody, and vice versa.

In immunohistochemistry, the functional affinity of an antibody or an antiserum can be

defined very loosely by the time required to reach equilibrium with the tissue antigen. If
equal aliquots of two antibodies or antisera of identical titer are incubated for increasing
periods of time with the antigen on the tissue, the antibody that reaches a plateau of
maximum staining intensity first is of a higher functional affinity. The term “avidity” has
been used synonymously to describe functional affinity (5), but also has been used to
denote the strength of the binding reached between antibody and its antigen (6). The
term avidity also has been used to describe the sum total of all intrinsic affinities found
in a polyclonal antibody population.
Because antigen-antibody reactions are reversible, the simple immune complexes

formed on tissue occasionally may dissociate during the washing cycles used in
immunohistochemistry. The ease and extent of this dissociation vary from antibody
to antibody, and low salt concentrations as well as low temperatures will reduce the
likelihood of weak staining due to dissociation of an already-formed immune complex.
Thus, high-affinity antibodies are desirable and have the advantage that dissociation
is less likely to occur than with low-affinity antibodies during washing. As mentioned
before, a polyclonal population of antibodies contains a more or less continuous
spectrum of low to high affinities against several epitopes on a given antigen. Therefore
after incubation with a primary antibody of this type, excessive washing is unlikely to
result in any appreciable loss of staining.
On the other hand, monoclonal antibodies are of uniform affinity and, if the same is
low, loss of staining may be due to the dissociation of the antibody from its epitope.
Therefore, if possible, monoclonal antibodies of high affinity should be selected. As
indicated above, factors that weaken the antigen-antibody bond such as high salt
concentrations, high temperature and very low pH during the washing of the specimens
should be avoided. Experience in the handling of antibodies in immunohistochemistry
has shown that the washing and incubation in buffer baths can be reduced safely and
that gentle agitation helps to reduce background staining (7).
Affinity of antibodies also is related to their capacity to form insoluble immune complexes.
Generally, the higher the affinity of an antibody, the greater its tendency to form a
precipitate. Precipitation proceeds through a rapid stage in which soluble antigen-
antibody complexes form, followed by slower aggregation and, eventually, precipitation.
Non-precipitating antibodies are mostly of lower affinity and are incapable of forming
the lattice required for precipitation to occur.
Monoclonal antibodies, regardless of whether they are of high or low affinity, do not
form a lattice with antigen, and, hence only rarely form insoluble precipitates. However,
in immunohistochemistry, the capability of a primary antibody to form precipitating
immune complexes is of little importance because reaction with immobilized tissue
antigen entails antibody capture onto tissue rather than precipitation.
Prozone is a property that was first noted in antibody-induced agglutinations. It is the

observation that some antibodies, when insufficiently diluted, fail to agglutinate cells

Antibodies
even though higher dilutions will do so. While prozone also can be observed in precipitin
reactions, in immunohistochemistry, it is a rare event (7).
As most antibodies carry a net positive electrostatic charge, the strength of the
antibody’s affinity for the targeted tissue antigen also depends on the availability and
abundance of the net negative electrostatic charges present on the latter. Excessive
formalin-fixation times of many tissues were held largely responsible for alteration of
these charges, and as a consequence, for the unpredictably erratic immune reactivity
with the primary antibody. Lost affinities, however, were restored largely by the routine
use of heat-induced retrieval for all antigens (8).
Antibody Cross-Reactivity
The term “cross-reactivity” denotes an immunochemical activity that can occur either
between an antibody and two or more antigens or vice versa, when an antigen reacts
with several different antibodies. Typical examples are when anti-λ (or -κ) chain
antibodies interact with all five Ig classes or when carcinoembryonic antigen (CEA)
reacts with antibodies against CEA, blood group antigens and normal tissue proteins,
respectively. The common denominator in each case is the sharing of at least one
common epitope between several antigens.
Another valid use of the term cross-reactivity denotes the experimentally-or accidentally-
induced changes within one or several epitopes, through antigen retrieval (9), leading to
a possible loss of specificity by a given monoclonal antibody for this antigen. The term
cross-reactivity also describes the interaction of an antibody with similar or dissimilar
epitopes on unrelated antigens. This latter phenomenon however is frequently a property
of low-affinity antibodies, and usually is subject to change because of affinity maturation
during immunization.
Cross-reactivity of antibodies to human antigens with identical or similar antigens of

other species, or “cross-species cross-reactivity,” can be of interest to the researcher
and veterinarian because of the scarcity of animal-specific antibodies. In an effort to
overcome this, two groups published reports on the results of cross-species reactivity
studies using commercially available antihuman polyclonal and monoclonal antibodies
(10, 11). It was demonstrated that the majority of animal antigens selected showed
strong reactivity with antihuman antibodies. However, for more technical detail on the
use of a given mouse primary antibody on animal tissues, the reader is referred to
animal research kit products.
The terminology of cross-reactivity however is misplaced when describing any observed

staining by the same antibody of different cells or tissue components, regardless
of whether or not they contain common antigens, as this would distort the strict
immunochemical definition of the term.

Antibody Reaction Rates

Although under ideal conditions antibodies react with their antigens very rapidly, in
immunohistochemistry the conditions are rarely ideal. Depending on length of tissue
fixation, antibody concentration, ambient temperature and other variables, primary
antibody incubation times of up to 48 hours may be required for maximum reactivity (12).
It is not surprising therefore, that as immunohistochemical procedures have become
increasingly useful in surgical pathology, the need for shortened processing times also
has been voiced. Very short incubation periods are made feasible by the relatively rapid
reaction rates that occur when higher concentrations of high-affinity primary and link
antibodies are used.
In these situations equilibrium between antigen-bound and free antibody rarely is

achieved. To achieve equilibrium, very long incubation periods with more dilute
antibody preparations are required. It is not known whether shorter incubations
with more concentrated antibody preparations would establish equilibrium sooner,
because as a rule nonspecific background staining may result under these conditions,
preventing unambiguous interpretation. Incubates of primary antibody have been
salvaged experimentally after their first use by aspiration from one section, and
transferred to additional sections (7). With some antibodies, up to seven identical tissue
specimens could be stained with equal quality when the primary antibody was used
in concentrations required for routine 10-minute incubations. This suggests that only
a very small fraction of the available antibody actually is utilized during these relatively
short incubation times. Needless to say, once an incubation time has been selected, it
must be maintained uniformly, or staining will not be consistently reproducible.
Generally, the size and shape of the antibody molecule and its conjugates or
complexes appear to be of little consequence in immunohistochemistry. Insufficient
tissue penetration, even when staining intranuclear or cytoplasmic antigens, has never
been observed, regardless of whether primary antibodies of class IgM (900 kD), large
complexes like PAP (400–430 kD) or APAAP (approximately 560 kD) or dextran-linked
reagents were used (see Immunohistochemistry Staining Methods, Chapter 7). However,
it is reasonable to assume that gross overfixation of tissue may make penetration more
difficult for antibodies and their complexes.
Antibody Stability
Polyclonal antibodies, when stored unfrozen and used subsequently in
immunohistochemistry, are somewhat less stable as immunoglobulin fraction compared
to whole antiserum (7). However, this reduced stability was found to depend largely
on the method of purification and storage as well as on the method of application.
Exposure of antibodies to extreme pH, as well as high or very low concentrations of salts
during purification tends to decrease their stability more than does exposure to mild
conditions such as ion exchange chromatography. Formation of soluble aggregates,
and subsequently precipitated polymers are the most frequent changes noted after
prolonged storage. These changes are probably the result of hydrophobic interaction
10
Antibodies
between the IgG molecules in solution. While the presence of soluble aggregates may
enhance their performance as precipitating antibodies, their increased hydrophobicity
has been shown to cause increased nonspecific binding in immunohistochemistry (see
Chapter 16, Background) (7). Removal of these aggregates and polymers from IgG
fractions is therefore prudent prior to their application for immunohistochemistry.
Just as storage of purified antibodies may augment their hydrophobicity due to

aggregation and polymerization, so may their conjugation to other molecules (13).
Conjugation with glutaraldehyde involves the epsilon-amino groups of lysine and alpha-
amino groups of the N-terminal amino acids resulting in their cross-linking. Because
there are many glutaraldehyde-reactive sites in IgG molecules, the hydrophobicity of
the conjugated antibodies may increase significantly, resulting in augmented attraction
to hydrophobic sites in the fixed tissue and increased background.
Monoclonal antibodies also have been shown to be influenced in their performance by
methods of purification and storage; 42 percent of monoclonal antibodies investigated
by Underwood and Bean showed changes in specificity, affinity and cross-reactivity
(14). Antibodies of class IgM and subclass IgG2b were especially sensitive.
It must be noted that actual-time testing of proteinaceous reagents is not feasible. While
commonly practiced in the pharmaceutical field (15, 16), high-temperature accelerated
degradation testing when applied to immunochemicals such as antisera and antibodies,
can be irrelevant or even misleading (17, 18).
Antibody stability in commercially produced reagents is determined best by real-time

and real-temperature testing by each manufacturer. Most manufacturers demonstrate
stability by testing during a pre-determined period of time, ie, the “shelf life.” While
many antibodies may retain activity longer, the only regulatory requirement for the
manufacturer is to certify the period of time that the antibody has been tested. There
is no requirement to continue testing until the antibody loses activity.
In addition, it is this writer’s experience that the conditions for the storage of reagents
in the user’s laboratory are frequently not identical to those that prevailed during the
manufacturer’s shelf-life studies. Because of the possibility of adverse storage conditions
after the purchase of the product, the manufacturer can offer only a limited liability
instead of predicting the actual demise of a reagent.
The only possible corollary to these requirements is to allow laboratories to document

the activity of the product until the loss of the same. Alternatively, laboratories may
aliquot and freeze undiluted antibody at –20 °C for later use. At this time, laboratories
must confirm activity prior to the use of the antibody in any test.
Finally, expiration dating as practiced today also serves the purpose of conforming to
regulatory requirements. Regulatory guidelines in place in the United States for clinical
laboratories have been mandated by the Clinical Laboratory Improvement Act of 1988
and by the College of American Pathologists. These regulations mandate that expired
reagents cannot be used in the clinical diagnostic laboratory on human tissue.
11
Handling of Antibodies
In order to achieve optimal performance from reagents used in immunohistochemistry, it
is imperative to observe basic rules for their handling and storage. If properly maintained,
most reagents will remain stable for months or even years. Recommendations given by
the manufacturer on specification sheets and on vial labels always should be heeded.
Receiving
Although many commercially produced immunochemicals are guaranteed to be
stable for up to several years, ready-to-use (RTU) antibodies have a shorter shelf life
(see Antibody Stability). Upon receipt, immunochemicals should be stored promptly
according to the manufacturer’s recommendations. Log reagents by entering the
manufacturer’s lot numbers, expiration date, date of receipt and invoice number. These
entries provide valuable information for the user, especially if later reclamations should
become necessary.
Storage
Perhaps the two most important considerations when storing antibodies are the storage
container and the temperature.
Storage Containers
Ideally, preferred materials for storage containers of protein solutions should have
negligible protein adsorptivity. Polypropylene, polycarbonate or borosilicate glass are
recommended and are used widely. Solutions containing very low concentrations of
protein (ie, less than 10–100 µg/ml), should receive an addition of immunochemically
inert protein. Generally, 0.1 percent to 1.0 percent bovine albumin is used to reduce loss
through polymerization and adsorption onto the container. Containers made of clear
and colorless materials are preferred, as these will allow ready inspection of contents.
Container labels also should allow access for inspection.
Storage Temperature
Probably more than any other factor, observe proper storage temperature as
recommended by the manufacturer. Monitor refrigerators and freezers used for storage
of immunochemicals for accurate and consistent temperatures. Store valuable or large
quantities of immunochemical reagents in equipment with temperature alarm and
emergency back-up power systems.
Store most RTU antibodies and their conjugates solutions at 2–8 °C, because freezing
and thawing is known to have a deleterious effect on their performance. This also applies
to entire kits that contain ready-to-use reagents, including monoclonal antibodies.
Store concentrated protein solutions such as antisera and immunoglobulin fractions in
aliquots and frozen at –20 °C or below, in order to prevent cycles of repeated freezing
12
Antibodies
and thawing. Bring frozen protein solutions to room temperature slowly, and avoid
temperatures above 25 °C.
Use and Care

Proper reagent care can reduce problems stemming from contamination, heat or
excessive light exposure. Reagent contamination can be avoided by the use of clean
pipet tips. Prompt return of reagents to proper storage conditions will prolong their
shelf life.
The appearance of immunochemical reagents, particularly undiluted antisera, is not

always indicative of their performance. Although beta-lipoproteins have a strong
hydrophobic property, neither lipemia nor lipolysis in antisera has been studied
systematically for interference with immunohistochemical staining. Where obvious
lipemia is encountered in an antiserum and thought to be the cause of interference with
successful staining, removal of the lipids by use of dextran sulfate and calcium (19),
or by extraction with organic solvents is recommended. Alternatively, the addition of 2
g Aerosil (Degussa, NY) to 100 mL antiserum followed by incubation for four hours at
37 °C has proven useful.
Mild to moderate hemolysis in antiserum resulting from suboptimal bleeding techniques

probably does not interfere with most immunohistochemical staining procedures,
but excessive hemolysis should be avoided. If excessive hemolysis or lipemia
is encountered, isolation of the immunoglobulin fraction from the antiserum may
be necessary. Such isolates usually will appear colorless and clear. Discard all
immunochemicals, including antisera and normal non-immune sera contaminated
with bacterial growth. Their use in immunohistochemical procedures most likely will
introduce artifacts and nonspecific staining.
Familiarity with the nature of antibodies, their capabilities and limitations, will allow
the user to better utilize these reagents and to more efficiently solve problems, if they
occur. The following chapters will further contribute to the understanding of antibodies
and also provide detailed information about the ancillary reagents and procedures
used in immunohistochemistry.
References
1. Atassi MZ et al. Molecular Immunology. Marcel Decker, Inc. New York, 1984.
2. Harboe NMG and Ingild A. Scand J Immunol 1983;17:345-51.
3. Boenisch T. Appl. Immunohistochem 1999;7(4):300-6.
4. Hornick CL and Karush F. Immunochemistry 1979;9:325-40.
5. Steward MW and Steensgaard J. Antibody Affinity: Thermodynamic Aspects and
Biological Significance. Boca Raton: CRC Press, 1983.
6. Herschowitz HID Immunophysiology: Cell function and cellular interactions in antibody
formation. In Bellanti JA. Immunology III. Philadelphia: Saunders, 1985.
7. Boenisch T. Appl Immunohistochem 2001;9(2):176-9.
13
9. Alexander J and Dayal Y. Appl Immunohistochem 1997;5(4):252-3.

10. Smith RA. J Histotech 1990;13(4):255-69.
11. Martin CA and Badrán AF. Appl Immunohistochem 1998;6(2):84-8.
13. Sternberger LA. Immunocytochemistry (2nd ed). New York: Wiley, 1979.
14. Underwood PA and Bean PA. J Immunol Meth 1985;80:89-97.
15. Kirkwood TBL et al. Biometrics 1977;3:38-48.
16. Tydeman MS and Kirkwood TBL. J Biol Standard 1984;12:195-206.
17. Jackson CM. IVD Technology 1997;3:38-48.
18. van Erp R et al. J Biotech 1991;20:249-62.
19. Kim YC and Nishida TJ. Biol Chem 1979;254:9621-26.
Footnote
*It should be understood that the term “immunohistochemistry,” as used in this chapter,
denotes and includes the term “immunocytochemistry.”
14
Chapter 2 ° Basic Immunochemistry
Thomas Boenisch
Introduction
In immunohistochemistry (IHC), antibody titer and dilutions as well as incubation time
and temperature are tightly interwoven in their effect on staining quality. These factors
can be changed independently, or as is more often the case, in complementary fashion
to bring about positive differences. Generally, when making changes the overriding goal
should be to achieve optimal specific staining accompanied by minimal interference
from background staining. This chapter will highlight these variables.
Antibody Titer
Optimum antibody titer may be defined as the highest dilution of an antiserum (or
monoclonal antibody) that results in maximum specific staining with the least amount of
background under specific test conditions. This highest dilution is determined primarily
by the absolute amount of specific antibodies present.
With polyclonal antisera, antibody titers have been expressed traditionally as

micrograms of antigen precipitated per milliliter of antiserum. While this is of interest,
it is not necessary information to the immunohistochemist. Augmenting polyclonal
antisera titers by isolating and enriching immunoglobulin fractions produces little benefit
for immunohistochemical applications, because nonspecific antibodies and soluble
aggregates - frequent sources of nonspecific background ‑ also become enriched
(see Background, Chapter 16). For monoclonal antibody preparations, the absolute
concentration of specific antibodies can be determined readily, and frequently forms
the basis for making required dilutions.
An optimal antibody dilution also is governed by the intrinsic affinity of an antibody. If

the titer is held constant, a high-affinity antibody is likely to react faster with the tissue
antigen and give more intense staining within the same incubation period than an
antibody of low affinity.
In more practical terms, titers may vary from 1:100 to 1:2000 for polyclonal antisera,
from 1:10 to 1:1,000 for monoclonal antibodies in cell culture supernatants, and up to
1:1,000,000 for monoclonal antibodies in ascites fluid. These dilutions may be exceeded
in the future due to ever-increasing sensitivities of newer detection methods, including
the use of an appropriate antigen retrieval procedure.
Antibody Dilution
Correct dilutions will contribute to the quality of staining if they are prepared accurately
and consistently. Often a manufacturer offers ready-to-use (RTU) reagents, or
15
recommends dilution ranges compatible with other variables such as method, incubation
time and temperature. If this information is not provided, optimal working dilutions
of immunochemical reagents must be determined by titration. Correct dilutions are
determined best by first selecting a fixed incubation time and then by making small
volumes of a series of experimental dilutions. Depending on specimen size, applications
of 0.1‑0.4 mL of solution per section is generally adequate. It should be noted that at
least on paraffin sections optimal dilutions of primary antibodies are not only signaled by
a peak in staining intensity, but also by the presence of minimal background (maximal
signal‑to‑noise ratios). Once the optimal working dilution has been found, larger volumes
can be prepared according to need and stability.
The extent to which monoclonal antibodies can be diluted is subject to additional criteria.
Because of their restricted molecular conformation and well-defined pI, monoclonal
antibodies are more sensitive to the pH and ions of the diluent buffer (1). Indeed, it
has been demonstrated that with the exception of the relatively rare IgG3 isotype,
all monoclonal antibodies could be diluted higher and stained more intensely at pH
6.0, especially after the use of heat-induced epitope retrieval (HIER) (2). IgG3 isotype
antibodies retained a preference for a more alkaline pH both before and after HIER.
Almost all monoclonal antibodies stained more intensely in the absence of NaCl. Of
several diluents used in this investigation, phosphate buffered saline (PBS), although
still widely used as a diluent for primary antibodies, was found to suppress the reactivity
of all monoclonal antibodies tested (2). Differences in the net negative electrostatic
charges of the target antigen are likely the explanation for these pH- and ion-related
observations (3).
Dilutions usually are expressed as the ratio of the more concentrated stock solution to
the total volume of the desired dilution. For example, a 1:10 dilution is made by mixing
one part of stock solution with nine parts diluent. Two‑fold serial dilutions are made by
successive 1:2 dilutions of the previous dilution. In order to make a very small volume
of a highly diluted solution, it may be necessary to make it in two steps. For example,
to prepare 1.0 mL of a 1:1000 dilution, first make 100 µl of a 1:10 dilution (10 µl +
90 µl), and then 1000 µl of a 1:100 dilution using 10 µl of the intermediate dilution
(10 µl + 990 µl).
The use of adjustable pipets for preparing dilutions allows for greater flexibility and more
accurate delivery. To measure volumes in excess of 1.0 mL, serological or volumetric
pipets can be used. Table 2.1 indicates the volumes of stock reagents and diluents
necessary to obtain dilutions ranging from 1:50 to 1:200. Checkerboard titrations are
used to determine the optimal dilution of more than one reagent simultaneously. In the
following example of a checkerboard titration, the optimal dilutions of the primary antibody
and the streptavidin-HRP reagent are found, while the dilution of the biotinylated link
antibody is held constant. Nine tissue sections are required for testing three dilutions.
16
Basic Immunochemistry
Table 2.1. Volumes of stock reagents and diluents.
Streptavidin-Peroxidase Primary Antibody Dilutions

1:50 1:50 1:100 1:200
1:100 1:50 1:100 1:200
1:200 1:50 1:100 1:200
If results achieved by use of several different dilutions are identical or similar, reagent
costs may become an additional factor in selecting optimal dilutions.
Precise definition of the optimal signal-to‑noise ratio as a function of the primary

antibody dilution is likely to be more critical with some methods. For example, it has been
found to be more restricted with the use of unlabeled enzyme‑antienzyme complexes
(PAP, APAAP), than with methods utilizing the streptavidin‑biotin technology (4). This
is probably consistent with the observation that as opposed to the PAP method, the
avidin-biotin method cannot distinguish between high and low concentrations of tissue
antigens (5). For additional information on immunohistochemistry staining methods the
reader is referred to Immunohistochemistry Staining Methods, Chapter 7.
Antibody Incubation
As mentioned above, incubation time, temperature and antibody titers are interdependent.
A change in one factor will affect the others.
Incubation Time
There is an inverse relationship between incubation time and antibody titer: The higher
the antibody titer, the shorter the incubation time required for optimal results. In practice
however, it is expedient to first set a suitable incubation time before determining the
optimal antibody dilution.
Incubation times for the primary antibody may vary within up to 24 hours, with 10‑30
minutes probably being the most widely used incubation time. For an antibody to
react sufficiently strongly with the bound antigen in a short period of time, it must be
of high affinity and concentration, as well as have the optimal reaction milieu (pH and
diluent ions). Variables believed to contribute to increased nonspecific background
staining should be kept to a minimum (see Background, Chapter 16). Primary antibody
incubations with a 24-hour duration allow for greater economy, because higher dilutions
of the same may be used. Low affinity and/or low titer antibodies must be incubated for
long periods in order to reach equilibrium*. But nothing can be gained by prolonging
primary antibody incubation beyond the time at which the tissue antigen is saturated
with antibody.
Equilibrium is usually not reached during primary antibody incubations of less than 20
minutes. Consistent timing of this step is therefore important. Inconsistent incubation
17
times can cause variations in overall stain quality and intensity, and may lead to incorrect
interpretation of results. These criteria are particularly essential in efforts that attempt
to assess the degree of tumor differentiation.
Incubation Temperature
Because antigen‑antibody reactions reach equilibrium more quickly at 37 °C compared
to room temperature, some workers prefer to incubate at the higher temperature.
However, while increases in incubation temperature allow for greater dilution of the
antibody and/or a shortened incubation time, consistency in incubation time becomes
even more critical. It is not known whether an increased temperature promotes the
antigen‑antibody reaction selectively, rather than the various reactions that give rise
to background.
A temperature of 4 °C is used frequently in combination with overnight or longer
incubations. Slides incubated for extended periods, or at 37 °C should be placed in a
humidity chamber to prevent evaporation and drying of tissue sections. Similarly, tissue
incubated at room temperature in a very dry or drafty environment will require the use
of a humidity chamber.
References
1. Larsson L-I. Immunocytochemistry: Theory and Practice. CRC Press, Inc.

Boca Raton, FL.
2. Boenisch T. Appl Immunohistochem & Mol Morph 1999;7(4):300-6.
3. Boenisch T. Appl Immunohistochem & Mol Morph 2002;10(4):363-7.
4. Boenisch T. Personal observations.
5. Sternberger LA and Sternberger NH. J Histochem Cytochem 1986;34:599‑605.
Footnote
*The term “equilibrium” here denotes saturation of antigen with antibody.
18
Chapter 3 ° Basic Enzymology
Thomas Boenisch
Introduction
Immunoenzymatic staining methods utilize enzyme‑substrate reactions to convert
colorless chromogens into colored end products. Of the enzymes used in these
applications, only horseradish peroxidase and calf intestine alkaline phosphatase will
be considered in some detail. Because of its low sensitivity, glucose oxidase (Aspergillus
niger) is used only rarely today.
This chapter also will discuss the various chromogens and substrates that can be used
in conjunction with peroxidase and phosphatase, together with suggested procedures
for the preparation of some substrate solutions.
Enzymes
Enzymes are proteinaceous catalysts peculiar to living matter. Hundreds have been
obtained in purified and crystalline form. Their catalytic efficiency is extremely high –
one mole of a pure enzyme may catalyze the transformation of as many as 10,000
to 1,000,000 moles of substrate per minute. While some enzymes are highly specific
for only one substrate, others can attack many related substrates. A very broad
classification of enzymes would include hydrolytic enzymes (esterases, proteases),
phosphorylases, oxidoreductive enzymes (dehydrogenases, oxidases, peroxidases),
transferring enzymes, decarboxylases and others.
Enzymatic activity is dependent upon several variables, such as enzyme and substrate
concentrations, pH, salt concentration of the buffer milieu, temperature and light. Many
enzymes also possess non‑proteinaceous chemical portions termed prosthetic groups.
Typical prosthetic groups are the iron‑protoporphyrin of peroxidase, and biotin of C02
transferases. In addition, many enzymes require the presence of metal ions such as
Mg++, Mn++, and Zn++, which function as electrophilic (electron‑attracting) agents.
The general formula, which describes the reactions of an enzyme with its substrate,
may be written as follows:
1. Enzyme (E) + Substrate (S) = ES complex
2. ES ‡ E + Products (P)
Thus before formation of the product, a transient enzyme-substrate complex is formed

at the “active site” (prosthetic group) of the enzyme.
Substances that interfere with the specific binding of the substrate to the prosthetic
group are “specific inhibitors,” and differ significantly from agents, which cause
nonspecific denaturation of an enzyme (or any protein). Two basic types of inhibitions
19
are recognized: Competitive inhibition and noncompetitive inhibition. Competitive

inhibition is the result of a reversible formation of an enzyme‑inhibitor complex (EI):
E + Inhibitor (1) + S = EI + S
The formation of the complex EI can be reversed by a change in the concentration of

either the substrate or the inhibitor, unless the affinity of I for E is greater than of S for E.
The action of carbon monoxide or azides on the heavy metals of respiratory enzymes
is a typical example of competitive inhibition.
In noncompetitive inhibition, the inhibition depends solely on the concentration of the

inhibitor and generally is not reversible. Noncompetitive inhibition may or may not involve
the prosthetic group of the enzyme, and manifests itself by slowing down or halting the
velocity of the enzyme’s reaction upon the substrate:
E+I+S‡EIS
Selecting the enzyme most suitable for a particular immunohistochemical application

depends on a number of criteria:
1. The enzyme should be available in highly purified form and be relatively
inexpensive.
2. Conjugation (covalent binding to antibody or avidin, for example) or noncovalent
binding should not abolish enzyme activity, although it may diminish it.
3. The bound enzyme should be stable in solution.
4. Endogenous enzyme activity should interfere only minimally with specific
antigen‑related staining.
5. Products of the enzyme reactions should be readily detectable and stable.
Horseradish peroxidase and calf intestine alkaline phosphatase meet most of these
criteria, and the following will list their properties in more detail.
Horseradish Peroxidase (HRP)

This enzyme (molecular weight 40 kD) is isolated from the root of the horseradish
plant (Cochlearia armoracia). HRP has an iron‑containing heme group (hematin) as its
active site, and in solution is colored brown. The hematin of HRP first forms a complex
with hydrogen peroxide (H202), and then causes it to decompose, resulting in water
and atomic oxygen. HRP oxidizes several substances, two of which are polyphenols
and nitrates. It should be noted that similar to many other enzymes, HRP and some
HRP‑like activities can be inhibited by excess substrate. The complex formed between
HRP and excess hydrogen peroxide is catalytically inactive, and in the absence of an
electron donor (eg, chromogenic substance), is reversibly inhibited. It is the excess
hydrogen peroxide and the absence of an electron donor that brings about quenching
of endogenous peroxidase activities. Cyanide and azide are two other strong (reversible)
inhibitors of peroxidase.
20
Basic Enzymology
HRP can be attached to other proteins either covalently or noncovalently. Covalent

binding of HRP to other proteins can be performed using either one‑step or two‑step
procedures and glutaraldehyde. The chemical 4,4’‑difluoro‑3,3’‑dinitrophenyI sulfone
(FNPS) is used less commonly for this purpose. In all cases, the epsilon‑amino
groups of lysine and N‑terminal amino groups of both proteins are involved in this
reaction. The two‑step conjugation procedure is preferred, because relative to
the antibody molecule the HRP molecule has a paucity of reactive groups. As a
consequence, adding glutaraldehyde to a solution containing an admixture of HRP and
antibody will result in more antibody molecules being conjugated to each other, than
to the enzyme. In the two‑step procedure, HRP reacts with the bifunctional reagents
first. In the second stage, only activated HRP is admixed with the antibody, resulting in
much more efficient labeling and no polymerization. The subsequent conjugates are
predominantly of 200,000 - 240,000 kD.
HRP also is conjugated to (strept)avidin using the two‑step glutaraldehyde procedure

and is used in this form in the Labeled Streptavidin Biotin (LSAB) procedure for example.
Conjugation with biotin also involves two steps, as biotin must first be derivatized to the
biotinyl‑N‑hydroxysuccinimide ester or to biotin hydrazide before it can be reacted with
the epsilonamino groups of the enzyme.
Noncovalent binding of HRP to antibody, also known as unlabeled antibody binding, is

described in great detail by Sternberger (1). Instead of the use of bifunctional reagents,
IgG‑class antibodies to HRP are used to form a soluble semicyclic immune complex
consisting of two antibody and three enzyme molecules. The molecular weight of the
peroxidase‑antiperoxidase, “PAP” complex is 400 ‑ 430 kD.
Calf Intestine Alkaline Phosphatase (AP)

Calf intestine alkaline phosphatase (molecular weight 100 kD) removes (by hydrolysis)
and transfers phosphate groups from organic esters by breaking the P‑0 bond; an
intermediate enzyme-substrate bond is formed briefly. The chief metal activators for
AP are Mg++, Mn++ and Ca++.
AP had not been used extensively in immunohistochemistry until publication of the
unlabeled alkaline phosphatase-antialkaline phosphatase (APAAP) procedure (2, 3).
The soluble immune complexes utilized in this procedure have molecular weights of
approximately 560 kD. The major advantage of the APAAP procedure compared to
the earlier peroxidase techniques was the lack of interference posed by endogenous
peroxidase activity. Because of the potential distraction of endogenous peroxidase
activity, the alkaline phosphatase techniques were recommended particularly for use on
blood and bone marrow smears. Endogenous alkaline phosphatase activity from bone,
kidney, liver and some white cells can be inhibited by the addition of one mM levamisole
to the substrate solution (4), although five mM has been found to be more effective (5).
Intestinal alkaline phosphatases are not adequately inhibited by levamisole.
21
Substrates and Chromogens
Peroxidase
As described above, HRP activity in the presence of an electron donor first results in
the formation of an enzyme‑substrate complex, and then in the oxidation of the electron
donor. The electron donor provides the driving force in the continuing catalysis of H202,
while its absence effectively stops the reaction.
There are several electron donors, which upon being oxidized, become colored products
and therefore are called chromogens. This along with the property of becoming insoluble
upon oxidation, make such electron donors useful in immunohistochemistry.
3,3’‑diaminobenzidinetrahydrochloride (DAB)
This produces a brown end product that is highly insoluble in alcohol and other organic
solvents. Oxidation of DAB also causes polymerization, resulting in the ability to react
with osmium tetroxide, and thus increasing its staining intensity and electron density.
Of the several metals and methods used to intensify the optical density of polymerized
DAB, gold chloride in combination with silver sulfide appears to be the most successful
(6). DAB has been classified as a potential carcinogen and therefore should be handled
and disposed of with appropriate care.
3‑amino-9-ethylcarbazole (AEC)
Upon oxidation, AEC forms a rose‑red end product, which is alcohol soluble. Therefore,
specimens processed with AEC must not be immersed in alcohol or alcoholic solutions
(for example, Harris’ hematoxylin). Instead, an aqueous counterstain and mounting
medium should be used. AEC is unfortunately susceptible to further oxidation
and, when exposed to excessive light, will fade in intensity. Storage in the dark therefore
is recommended.
4‑chloro‑11 ‑naphthol (CN)
CN precipitates as a blue end product. Because it is soluble in alcohol and other organic
solvents, the specimen must not be dehydrated, exposed to alcoholic counterstains, or
coverslipped with mounting media containing organic solvents. Unlike DAB, CN tends
to diffuse from the site of precipitation.
p‑phenylenediamine dihydrochloride/pyrocatechol (Hanker‑Yates reagent)
This gives a blue‑black reaction product, which is insoluble in alcohol and other organic
solvents. Like polymerized DAB, this reaction product can be osmicated. Varying results
have been achieved with Hanker‑Yates reagent in immunoperoxidase techniques.
22
Basic Enzymology
Alkaline Phosphatase
In the immunoalkaline phosphatase staining method, the enzyme hydrolyzes naphthol
phosphate esters (substrate) to phenolic compounds and phosphates.
The phenols couple to colorless diazonium salts (chromogen) to produce insoluble,

colored azo dyes. Several different combinations of substrates and chromogens have
been used successfully.
Naphthol AS-MX Phosphate
This can be used in its acid form or as the sodium salt. The chromogens Fast Red TR
and Fast Blue BB produce a bright red or blue end product, respectively. Both are
soluble in alcoholic and other organic solvents, so aqueous mounting media must be
used. Fast Red TR is preferred when staining cell smears.
New Fuchsin
This also gives a red end product. Unlike Fast Red TR and Fast Blue BB, the color
produced by New Fuchsin is insoluble in alcohol and other organic solvents, allowing for
the specimens to be dehydrated before coverslipping. The staining intensity obtained by
use of New Fuchsin is greater than that obtained with Fast Red TR or Fast Blue BB.
Additional substrates include naphthol AS-BI phosphate, naphthol AS-TR phsophate

and 5-bromo-4-chloro-3-indoxyl phosphate (BCIP). Other possible chromogens include
Fast Red LB, Fast Garnet GBC, Nitro Blue Tetrazolium (NBT) and iodonitrotertrazolium
Violet (INT).
Detailed descriptions and information for the preparation of the most commonly used
substrate-chromogen mixtures for HRP (7) and AP (8), as well as their appropriate use
and advantages or disadvantages are available (9-12).
Suggested Procedures for Substrate-Chromogen Reagents
Peroxidase
AEC Substrate Solution (recommended for cell smears)

1. Dissolve 4 mg AEC in 1 mL N,N‑dimethylformamide.
2. Add 14 mL 0.1 M acetate buffer, pH 5.2 and 0.15 mL 3% hydrogen peroxide.
3. Mix, and filter if precipitate forms.
4. Add solution to tissue and incubate for five to 15 minutes at room temperature.
5. Rinse with distilled water.
6. Counterstain and coverslip with aqueous‑based medium.
23
DAB Substrate Solution

1. Dissolve 6 mg DAB in 10 mL 0.05 M Tris buffer, pH 7.6.
2. Add 0.1 mL 3% hydrogen peroxide. Mix, and filter if precipitate forms. (Solution
is stable for one hour at room temperature.)
3. Add solution to tissue and incubate for three to 10 minutes at room temperature.
5. Counterstain and coverslip with either organic‑ or aqueous-based medium.
Alkaline Phosphatase
Fast Red Substrate Solution (recommended for cell smears)

1. Dissolve 2 mg naphthol AS‑MX phosphate, free acid (Sigma N 4875) in 0.2 mL
N,N‑dimethylformamide in a glass tube.
2. Add 9.8 mL 0.1 M Tris buffer, pH 8.2.
3. Add 0.01 mL of 1 M levamisole (Sigma L 9756) to block endogenous alkaline
phosphatase. (Solution can be stored at 4° C for several weeks, or longer
at ‑20’C.)
4. Immediately before staining, dissolve 10 mg Fast Red TR salt (Sigma F 1500) in
above solution and filter onto slides.
5. Incubate for 10‑20 minutes at room temperature.
7. Counterstain and coverslip with aqueous‑based medium.
New Fuchsin Substrate Solution (recommended for tissue sections)

1. Solution A: Mix 18 mL of 0.2 M 2‑amino‑2‑methyl‑1, 3 propanediol (Merck 801464)
with 50 mL 0.05 M Tris buffer, pH 9.7 and 600 mg sodium chloride. Add 28 mg
levamisole (Sigma L 9756).
2. Solution B: Dissolve 35 mg naphthol AS‑BI phosphate (Sigma N 2250) in 0.42
mL N,N‑dimethylformamide.
3. Solution C: Under fume hood, mix 0.14 mL 5% New Fuchsin (Sigma N 0638, 5 g
in 100 mL 2 N HCI) with 0.35 mL of freshly prepared 4% sodium nitrite (Sigma S
2252, 40 mg in 1 mL distilled water). Stir for 60 seconds.
4. Mix Solutions A and B, then add Solution C; adjust to pH 8.7 with HCI. Mix well
and filter onto slides.
24
Basic Enzymology
New Fuchsin Substrate Solution (alternative procedure)

1. Solution A: In fume hood add 0.2 mL of 5% New Fuchsin (Merck 4041, in 2 N HCI)
to 0.5 mL of fresh 4% sodium nitrite. Agitate for 30‑60 seconds. Add 100 mL of
0.05 M Tris buffer, pH 8.7, and 100 ~Ll of 1 M levamisole to block endogenous
alkaline phosphatase
2. Solution B: Dissolve 50 mg naphthol AS‑BI phosphate (Sigma N 2250) in 0.6 mL
N,N‑dimethylformamide.
3. Add Solution B to Solution A and mix well. Filter directly onto slides.
References
1. Stemberger LA. Immunocytochemistry (2nd ed). New York: Wiley, 1979.

2. Mason DY et al. J Cancer Res Clin Oncol 1981;101:13‑22.
3. Cordell JL et al. J Histochem Cytochem 1984;32:219‑29.
4. Ponder BA and Wilkinson MM J. Histochem Cytochem 1981;29:981-4.
5. Gown AM In DeLellis RA (ed) Advances in Immunohistochemistry. New York: Raven
Press, 1988, pp 31‑45.
6. Newman GR et al. J Microscopy 1983;132:RPl‑2.
7. Dako Specifications, numbers K0597, K0598, K0599, K0624 and K0698.
8. Dako Specifications numbers K3461, K3465 and K3467.
9. Newman GR et al. J Microscopy 1983;132:RP1-2.
10. Clark CA et al. J. J Histochem Cytochem 1982;30:27-34.
11. Gay et al. J Histochem Cytochem 1984;32:447-51.
12. Bondi A et al. Histochemistry 1982;76:153-8.
25
26
Chapter 4 ° Fixation and Processing
A. J. Farmilo and Ronald H. Stead, Revised by A. J. Farmilo
Introduction
Immunohistochemistry (IHC) has advanced considerably since the first edition of this
handbook was published in 1983 (1), and the driving force behind that change has been
the need for standardization. If tissue staining is to provide consistent, reproducible
diagnostic information, it must continue to evolve from an “art form” to a science. That
evolution demands quantitation and reproducibility of methodology and, extending
from that, consistency of results.
One of the last of these IHC “art forms” is tissue fixation and processing. Laboratory
professionals are little closer to uniformity in this part of the process, and achieving that
uniformity, or “standardization,” remains one of the true unknowns in diagnostic interpretation.
Fixation
Part of the challenge is the finite amount of antigen in each tissue sample, and the
fact that most steps in the IHC process destroy some of this antigen. This is especially
problematic at the critical step of tissue fixation, because it is at this step that we
intentionally try to change protein structure in order to preserve them from elution,
degradation, or other modifications that occur in normal, unfixed tissue samples.
In addition to preventing antigen elution or degradation, fixation also should preserve

the position of the antigen, whether nuclear, cytoplasmic or membrane-bound, and
preserve as much antigenic secondary and tertiary structure as possible, to provide a
target for antibodies that will be used to detect the antigen.
As a result of poor or inadequate fixation, many examples exist of situations that have
led to incorrect interpretation of staining patterns. One example is elution of estrogen
receptor protein from nucleus to cytoplasm. In this situation, the antigen is detected in
the cytoplasm and therefore the cell stains “positive.” But in fact the antigen should be
primarily localized in the nucleus, and therefore diagnostically the stain is useless.
The same antigen can be used to demonstrate the importance of fixation and antibody-
antigen reactions. Fixation in neutral buffered formalin will result in the destruction of
an epitope against which some monoclonal antibodies react. Use of those antibodies
would indicate a “negative” reaction for estrogen receptor, while the use of antibodies
for a different epitope, one that is not destroyed by the fixation, would indicate a
“positive” reaction.
What is the solution to this complex issue? Standardization of fixative and fixation
protocols would be an ideal start. Many fixatives have been developed over the years
and at least two fairly recent ones have been promoted as possible “standards.” But
27
so far no single fixative has proven ideal for all markers, antibodies and applications.
Therefore standardization and validation will have to focus on particular antibodies and
their corresponding staining protocols.
The acceptance of a common procedure for fixation is also extremely important and
essential to achieving reproducible results. This means that reagent preparation must
be done exactly the same way each time a particular staining protocol is performed.
Reagents and protocols need validation, which would include determining the limits
of the reagent’s shelf life, optimal fixation time and conditions such as temperature
and humidity. Many fixation reagents are concoctions of reactive and moderately toxic
chemicals, and often little is known about the exact reactions that occur within them.
For example, formalin preparations vary greatly, and concentrations of aldehydes,
acids, and other by-products in each preparation may change with time and storage,
and those changes will vary from product to product.
Validation is an initial step for two reasons: First, to ensure that a certain standardized
procedure will give consistent and diagnostically useful results. Second, to test the limits
of changes in the procedure that will continue to provide those results. For example,
users can validate fixation time by running a series of tests using fixation times of zero,
four, eight, 12, 24 and 36 hours; plus times of five, 15 and 30 days. For a given antigen
and antibody combination, users might find that the zero-, four- and eight-hour fixations
gave sub-optimal results, perhaps because the antigen was not fixed completely, and
diffused through the cell or tissue. They then might determine that a range of 12 hours
to five days is optimal, and that the 15- and 30-day results are sub-optimal due to over-
fixation. They therefore have validated their procedure with respect to fixation time,
and now know that the tissue requires a minimum fixation of 12 hours and a maximum
fixation of five days. Practically speaking, that would mean that overnight fixation would
be required, that weekend fixation would be OK, but a longer fixation time would not be
useful. With this information, users would be able to evaluate the results obtained from
tissues received from outside sources by comparing fixation procedures.
For smaller laboratories, the work involved in validation is often difficult, but there are
two alternatives. Users can choose a system with an existing standardized and validated
protocol and validated interpretation system. Commercially available kits generally
provide these, and when utilized exactly as described in the kit insert, are guaranteed to
provide diagnostically useful results. A second option would be to use one of the more
common “standard” systems of fixatives with known antibodies, in which publication
data has provided some evidence of functionality. As an example, a laboratory could
use a 10 percent neutral buffered formalin fixation with a standard protocol, followed by
a biotin-streptavidin HRP system, using a monoclonal antibody combination called AE1/
AE3. This has been proven to be a reliable measure of cytokeratin in tissue sections.
28
Fixation and Processing
Tissue Handling
The computer-related adage, “garbage-in, garbage-out” can apply to IHC as well,
because the first steps of tissue handling arguably dictate the quality of results, more
than do any steps that follow. Therefore a good foundation is to remember that the
“first steps” start the very moment that tissue becomes a sample. Necrotic degradation
begins immediately once the tissue is separated from its source of nutrients, so the time
to processing is quite often critical.
For most IHC procedures, it is imperative that tissue not dry out. Collection from the
surgical arena should be onto moist absorbent paper, in a covered container, followed
by rapid delivery to the pathology lab for processing.
Tissue then should be trimmed and cut for fixation. The area of interest should be cut
into blocks no more than two cm square by four mm thick. Thickness is important. The
fixative must penetrate tissue in order to be effective. Fast penetration is desirable –
the thinner the tissue, the faster fixation can begin. The most common formalin fixatives
penetrate quickly, then fix tissue slowly.
The most frequently used fixative is a solution of 10 percent neutral buffered formalin.
Due to its cross-linking characteristic, it is an especially good fixative for small molecules
such as hormones (2). Optimum fixation time is critical and will vary from one antigen-
antibody combination to another. Generally, six to 12 hours is acceptable, but longer
fixation is needed occasionally. Over-fixation can pose problems, in that the cross-linking
can mask epitopes needed to react with the antibody. A frequently used method of
repairing this damage involves heating the fixed tissue in distilled water to a temperature
of 95 degrees for 15 to 20 minutes. This will be discussed later in this chapter as part
of the overall staining procedure.
Many other fixatives are available and a considerable body of literature exists that
describes situations in which one of these performs better than others. Some of these
fixatives will be discussed later in this chapter. Other specific applications exist in which
tissue is frozen and cut, rather than fixed.
Formalin always should be fresh (see above reference to formaldehyde and formic
acid formation with time), and buffered to a pH of 7.0-7.6. As this is a slow reacting
fixative, acidic mixtures may induce structural or antigenic changes resulting in poor
morphology and low detection.
Table 4.1. Ten percent neutral buffered formalin, pH 7 (10 percent NBF).
Formalin (40 percent formaldehyde) 100 mL
Dibasic sodium phosphate, anhydrous 6.5 g
Monobasic sodium phosphate, monohydrate 4.0 g
Distilled water 900 mL
29
There are other aldehyde-based fixatives, such as those using glutaraldehyde as a

base, but they all act similarly to 10 percent NBF and are used much less frequently.
Another class of fixatives used significantly in the past is mercuric-chloride fixatives.

These do not initiate aldehyde linkages, but react with a number of amino acid residues
such as thiols, amino groups, imidazole, phosphate and hydroxyl groups. On the
positive side, fixation times are short, in the order of five to eight hours. On the negative
side, it should be noted that mercuric chloride is highly toxic, and special disposal
procedures are required. For these reasons and because of the prevalence of viable
alternatives, these fixatives are used less and less in laboratories today.
Table 4.2. B5 Fixative
Mercuric chloride 60 g
Reagent A: Sodium acetate 12.5 g
Reagent B: 10 percent neutral buffered formalin
Working solution is 90 mL of Reagent A with 10 mL of Reagent B
Table 4.3. Zenker’s Fixative
Potassium dichromate 25 g
Mercuric chloride 50 g
Glacial acetic acid 50 g
NOTE: Fixation times are four to 24 hours, with an overnight wash or removal of mercuric chloride crystals required. This
can be accomplished by one wash in 0.5 percent iodine in 70 percent ethanol, and a second wash in five percent sodium
thiosuphate in water.
Alcoholic Fixatives
This class includes Carnoy’s, Methacarn and others. They have been used for IHC
purposes primarily to avoid the loss of antigenicity caused by excessive formalin fixation,
or for monoclonal antibodies that reacted against an epitope destroyed by formalin.
These fixatives typically found most of the application in looking at lymphocytes using
CD-specific markers, and in looking for immunoglobulins such as IgG, A, and M.
Specialty fixatives, such as Osmium tetroxide, which is used primarily in electron

micrography and acetone, is used in fixation of frozen sections. Others used for research
30
purposes on specific tissue, organs or even whole organisms are not discussed in
this publication.
The final fixative class that is becoming more significant is the “combination fixative.”
These often combine alcohol with formalin, calcium or other heavy metals, and also
with some kind of buffering mixture. Many are commercial, and as such their exact
formulations are typically not disclosed by their manufacturers. Most are designed to
address the search for a universal fixative that can standardize this element of IHC.
To be truly universal, most of these fixatives also address RNA and DNA fixation, for
genetic studies in fixed tissue (3, 4, 5).
Many of these fixatives are used widely, including Omnifix (AnCon Genetics, Melville,
New York, USA), Tissufix #2 (Chaptec, Montreal, Quebec, Canada), UMFIX (Sakura
Finetek USA Inc., Torrance, California, USA) and HistoChoice (AMRESCO, Solon, Ohio,
USA). So far none have become accepted universally as the standard fixative.
Specialized Tissue Preparations

No discussion of fixation would be complete without mentioning a few specialized tissue
preparations that have been popular in the past. Frozen sections used to be required
for some studies, particularly for lymph node. Their use was due primarily to antigen
destruction caused by formalin fixation, or for example, to the need to examine a thicker
(10 micron) section to study axons in nerve tissue. The introduction of antigen unmasking
methods using heated water has reduced the need for frozen sections.
The primary remaining motive for using frozen sections in routine practice is the need
for a quick examination that eliminates the time required for fixation, processing and de-
waxing. Frozen tissue sections also are used when direct or indirect immunofluorescence
is the detection method, in which case formalin fixation can produce weaker results.
Frozen sections should be fixed with acetone (room temperature, five seconds)
before storing. They are then re-processed in acetone (4 °C, 10 minutes) and then
re-hydrated in buffer for five minutes before immunostaining.
Blood smears, tissue imprints, cell cultures and purified cells may be examined as
fresh tissue or as fixed tissue. These cells can be centrifuged to make a pellet that is
then fixed just as in tissue fixation. Alternatively, a fresh smear may be made on the
slide, and the cells fixed either with acetone or 10 percent NBF for 10 minutes. It is
important to incubate the slide with an endogenous peroxidase blocking solution prior
to staining if there are a large number of erythrocytes present, as these will stain due
to endogenous peroxidase.
Finally, many of the newer fixation methods incorporate microwave treatments, either
for the fixation itself or to speed fixation of other reagents (6). Direct microwave fixation
is probably fixation due to heat, and is primarily a coagulation of the proteins. In
conjunction with fixatives, microwaving probably speeds the reaction by heating the
solution. It also perhaps speeds the penetration of the solution due to the relaxing of
the cell structure.
31
Tissue and Slide Processing

Once the tissue is well-fixed, subsequent steps seem to have little effect on antigen
detection. Variations in xylol processing, alcohol re-hydration, wax temperature, time
or formulation, instrumentation used etc., provide satisfactory results in most cases.
Some basic processing principles are:
° No processes should raise tissue temperature to higher than 60 °C, as this will
cause severe loss of antigenicity that may not be recoverable.
° Tissue fixation medium must be replaced by wax, generally done through a series
of incubations in increasing alcohol concentrations to 100 percent, followed by
xylene and then hot wax. This is to provide stability of the tissue (wax) in order
to make cutting the sections easier.
° The tissue sections should be cut at three or four microns or so in thickness, and
certainly no thicker than five microns. Thick sections have multiple layers of cells,
and make interpretation extremely difficult.
° When cut, sections are floated on water and picked up on slides that are coated
with some adherent material. Some commercially available slides come with a
positive charge that attracts the negative charges of tissue proteins. Slides can
also be bought or prepared with a coating of albumin or lysine, either of which
will provide a sticky surface for creating flat, adherent sections. Sections that are
not flat and that have non-adherent ridges likely will be digested or torn off of the
slide during immunostaining.
° Once on the slide, wax must be removed completely, in order that the
aqueous antibody solution can adhere properly to and penetrate the tissue.
This usually is done by heating the slides to about 60 °C to soften the wax,
and then reversing the procedure described in Detailed De-Waxing Protocol,
A, below. The slide is immersed in xylene, 100 percent alcohol and then
diminishing concentrations of alcohol until the final buffer is fully aqueous.
Note that 50 slides per 250 mL of xylene is the limit before the xylene
is no longer effective, and residual wax begins causing artifacts in the final
stained tissue.
Detailed De-Waxing Protocol

A. Circle and label the specimen with a diamond pencil.
B. Place in 60 °C oven for 30 minutes.
C. Transfer immediately to a fresh xylene bath for three minutes.
D. Repeat step C above with a second xylene bath.
E. Place in a fresh bath of absolute alcohol for three minutes.
F. Repeat step E above with a second bath of absolute alcohol.
32
G. Place in a bath with 95 percent ethanol for three minutes.

H. Repeat step G with a second 95 percent ethanol bath.
I. Rinse under gently running water.
J. Do not let dry; store in buffer; begin required antigen treatment (see previous
section) or immunostaining.
References
1. Immunochemical Staining Methods, 3rd Edition, Boenisch, T. editor, Dako Corporation,

Carpinteria, 2001.
2. Mies C, Molecular biological analysis of paraffin-embedded tissues; Hum Pathol.
1994;25:555-60.
3. Gillespie JW, et al. Evaluation of Non-Formalin Tissue Fixation for Molecular Profiling
Studies, Am J. Pathol. 2002;60:449-57.
4. Herman GE, Chlipala E, Bochenski G, Sabin L, Elfont E. Zinc formalin fixative for
automated tissue processing. J Histotechnol 1988;11:85-9.
5. Morales AR, et al. Continuous-specimen-flow, high-throughput, 1-hour tissue processing.
A system for rapid diagnostic tissue preparation. Arch Pathol lab Med 2002;126(5):583-90.
6. Ni C, Chang TC, Searl SS, Coughlin-Wilkinson E, Albert DM. Rapid paraffin fixation for
use in histological examination. Ophthalmology (Rochester) 1981;88:1372-4.
Bibliography
Pearse AGE. Histochemistry. Theory and applied. 4th ed. Edinburgh: Churchill Livingstone, 1980.
Leong A. Extract from Woods and Ellis, Laboratory Histopathology: A Complete Reference,
1994, Churchill Livingstone.
33
34
Chapter 5 ° Molecular-Friendly Tissue Processing
Mehrdad Nadji, MD
Why Molecular Histopathology?

Most pathology laboratories use fixation and processing technologies that are more than
100 years old. These traditional methods continue to be used widely because of their
excellent qualities for routine morphological examination and their cost-effectiveness
(1). However, at the molecular level their impact on biomolecule preservation is variable
and unpredictable. Because of the rapidly advancing era of molecular medicine, it is not
unreasonable to predict that molecular methods eventually will either replace existing
morphologic approaches, or more likely will be used in conjunction with them. Most
of today’s diagnostic and therapeutic decisions are based on the evaluation of small
tissue biopsies, and laboratories are expected to use the same precious small volume of
tissues for histology and molecular tests. Pathology laboratories therefore should devise
molecular-friendly tissue handling systems that allow for morphological diagnosis while
rendering the same archival tissue suitable for advanced molecular testing (2).
What Is a Complete Molecular-Friendly Histology Platform?

A complete molecular-friendly histopathology platform requires that specimens are
properly handled from the moment they are removed from a patient to the time they are
archived. With the introduction of fixatives and processing systems that protect molecular
properties of tissue, two major steps toward this goal have been taken. It should be
remembered, however, that a molecular-friendly fixative alone or a simple formalin-free
processing system by itself does not guarantee that the final product is suitable for
advanced molecular studies. Molecularly compatible fixatives and tissue processing
are merely two components of a complete molecular histopathology platform. No matter
how efficient the fixation and processing systems, if the time interval between surgical
excision and fixation is long, there will be considerable degradation of biomolecules.
Therefore, an overall “molecularly conscious” laboratory philosophy with provisions for
proper pre-fixation and post-processing handling of tissue is sometimes more important
than the fixative or the processor alone.
Fixation
It has been suggested that the best fixative for preservation of tissue macromolecules
is “no” fixative. This is because past experiences have shown that all chemical fixatives,
in one way or another, modify, degrade or destroy nucleic acids and proteins. For this
reason fresh or fresh-frozen tissues have been used for most molecular studies. But
these have limited value for assessment of histomorphology or for the performance
of routine ancillary tests such as histochemistry (HC) and immunohistochemistry
35
(IHC). In addition, transportation and long-term storage of frozen tissue creates

logistical problems that renders it impractical for routine use in most diagnostic
histopathology laboratories.
Formalin-fixed, paraffin-embedded histologic sections, however, are quite suitable for

most HC and IHC tests, although they yield degraded nucleic acids suitable only for
slide-based in situ hybridization as well as PCR amplification of short amplicons. An
example is less than 500 bp for DNA and less than 100 for RNA. The material therefore
is of limited value for performing molecular assays that require intact molecules, such
as high-molecular-weight RNA and biologically viable proteins. For this reason a search
for alternative non-formaldehyde molecular fixatives has been ongoing the past several
years (3, 4).
Chemical solutions that potentially can protect macromolecules in tissue can be grouped
into two general classes. One class protects nucleic acids well, but the same tissue
is unsuitable for histomorphologic evaluation. These “molecular preservatives” are
therefore excellent alternatives to freezing the tissue, but of limited value as practical
histology fixatives. In other words they must be used in addition to formalin, and that
limits their utilization for small biopsies.
The second class could be regarded as true “molecular fixatives,” because they not
only protect macromolecules but preserve acceptable histomorphology. They therefore
can be used as a single universal reagent to fix tissue and to preserve its molecular
properties at the same time. Such complete molecular fixatives have not been available
until recently.
In addition to protecting intact biomolecules and preserving microanatomy, an ideal

molecular fixative preferably should be non-toxic, non-volatile, active at ambient
temperatures, economically priced and cost-effective. A molecular fixative recently
introduced by Vincek et al for the most part meets these requirements (5). That fixative
- a mixture of methanol and polyethylene glycol - is non-volatile and active at room
temperature. It protects tissue DNA, RNA and proteins along with histomorphology. In
addition, long exposure of tissue to the fixative, up to six months at room temperature,
does not significantly alter its molecular properties or histomorphology.
Processing
The value of harvesting microwave energy for histopathology in general and for tissue
processing in particular, has been well established (6, 7). In most published works
conventional microwave ovens are used, including some that are adapted for histology
purposes. In 2002, Morales and coworkers reported the development of a microwave-
assisted, continuous-specimen-flow, one-hour tissue-processing method (8). This
manual rapid-tissue-processing (RTP) system utilized microwave energy along with
vacuum and a combination of common histologic reagents – minus formalin and xylene.
It permitted preparation of paraffin blocks from either fresh or prefixed tissue in about
one hour. The system utilized a specially designed cylindrical, low-energy microwave
36
Molecular-Friendly Tissue Processing
that distributed energy uniformly throughout the chamber, thus avoiding the creation
of hot-cold spots commonly observed in conventional microwave processing. The
manual procedure is automated now into a rapid-tissue-processing system, complete
with robotics, internal reagent containers, and user-friendly operating software. As a
corollary, it has been observed that tissue samples processed by this methodology
show improved RNA preservation, particularly when they are not prefixed in formalin.
This unexpected but highly desirable “molecular-friendliness” led to a search for a
fixative that similarly could protect tissue biomolecules. The result was development of
the molecular fixative by Vincek et al, referred to above.
Validation
Molecular fixative and the RTP system must be used together to preserve
macromolecules. Use of molecular fixative with conventional processing, or the use
of RTP without a molecular fixative, will result in degradation of tissue nucleic acids
and proteins. Since the complete system was intended for use as a molecular-friendly
alternative to formalin fixation and conventional processing, a detail morphologic,
immunohistochemical and molecular biologic evaluation of processed tissue was carried
out as summarized in the following:
The Processing System

The histologic quality of the RTP system for formalin-fixed tissues was validated through
comprehensive parallel studies, including a blinded review of slides by an expert
external panel (9). In addition to integrity of histomorphology, quality of histochemical
and immunohistochemical properties of processed tissues was established through
extensive testing and reviewing. Altogether results confirmed that when formalin-fixed
tissues were processed in the RTP system, no modification of protocols was necessary
for Hematoxylin and Eosin (H&E) staining, histochemistry, immunohistochemistry, and
in situ hybridization.
Combined Molecular Fixation and Processing Platform (MP)

When molecular fixative was used as an alternative to formalin, the RTP-processed
tissues were subjected to new sets of validation studies. These experiments used
parallel slices from surgically removed specimens. One slice was fixed in formalin and
the other in molecular fixative; they both then were processed by the RTP system.
Summary of Results
Histomorphology
As safe alternatives to formalin, alcohol-containing fixatives have been in use for many
years and most pathologists are familiar with their histologic properties. As with other
alcohol-based fixatives, the molecular fixative produces a histomorphology that is
37
similar, but not identical to formalin. For example, the molecular fixative-exposed tissues
show an overall brighter, shiny appearance in hematoxylin and eosin-stained slides.
The minor morphologic differences, however, in no way interfere with establishing the
correct diagnosis.
Immunohistochemistry
IHC of MP specimens is different from that of formalin-exposed tissue, and therefore
modification of staining protocols may be necessary. A comparative study showed that
for most routinely-used antibodies the sensitivity of immunohistochemistry performed on
molecular-fixed tissue is either comparable or superior to formalin-fixed specimens. This
is not surprising, because the superiority of alcohol-containing fixative for preservation
of certain tissue antigens in general and intermediate filaments in particular has
been observed before. A word of caution, however: Since a number of stand-alone
immunohistochemical tests are designed solely for use on formalin-fixed tissue, one
must adjust the antibody concentration or remove the antigen retrieval step to achieve
comparable sensitivity in MP specimens.
Molecular Properties
As a general rule, any molecular test that can be performed on formalin-fixed tissue
could be done on specimens processed in the molecular system. This includes PCR
amplification of small segments of DNA and RNA, as well as in situ hybridization. The
latter requires shorter predigestion time, usually about one-third of the time required to
digest formalin-fixed tissues. This is because the formalin-induced cross-linking of tissue
proteins is not a problem in a formalin-free system. Tests that require intact biomolecules
cannot be performed on formalin-fixed paraffin-embedded specimens. The same tests,
however, are feasible on archival tissue prepared by the molecular platform.
The following summarizes validation of some of these tests as they apply to the
preservation of intact RNA and proteins.
RNA Preservation
Tissues processed by the molecular platform yield an intact RNA comparable to that
of fresh tissue, whereas in formalin-fixed specimens, RNA is degraded significantly as
evidenced by the absence of 28S and 18S ribosomal bands. Similarly, in quantitative
real-time PCR, the copy number of templates of molecular system is similar to fresh
tissue, and significantly higher than that of formalin-fixed samples. In addition, extracted
RNA from molecular and fresh tissue yields similar cDNA microarray profiles. Finally, it
has been demonstrated that high–molecular-weight RNA can be extracted successfully
by laser capture microdissection from H&E sections of paraffin blocks processed by
the molecular platform (10). It should be remembered, however, that validation of tissue
RNA integrity has to be carried out under well-controlled RNase-free conditions. This
includes maintenance of an RNase-free laboratory environment, meaning RNase-free
38
Molecular-Friendly Tissue Processing
instruments, glassware and reagents. Even more important is to ensure that endogenous
RNase activity of tissue is blocked immediately and efficiently. To that end one has to
establish strict operating room protocols that require immediate fixation of small biopsies,
and timely delivery of larger specimens to the laboratory for proper handling.
Protein Preservation
Protein extracts from MP blocks show distinct spot patterns on 2D-gel electrophoresis
similar to that of fresh tissue. This is in contrast to formalin-fixed specimens that
produce a small number of distinguishable spots. On Western blots, MP samples also
reveal distinct bands with most antibodies tested, including some antibodies against
phosphorylated proteins. Only a few antibodies react with protein extracts of formalin-
fixed tissues, and the intensity of bands is usually weaker and less distinct. Recent
studies also have shown that proteins isolated from MP blocks are suitable for surface
enhanced laser desorption and ionization spectrometry (SELDI-TOF), yielding high-
resolution protein-profile patterns. No such pattern is observed with formalin-fixed
specimens.
Conclusion
At this writing, several molecular preservatives/fixatives and formalin-free, tissue-
processing systems are available. While an all-inclusive, combined system similar
to MP has yet to be marketed and validated, such systems hopefully one day will be
commonplace. The most formidable obstacle to this might be existing mind-sets, but
the benefits of establishing a complete molecular histopathology laboratory as a key
component of “personalized” diagnosis and treatment outweigh all challenges.
References
1. Grizzle WE. The use of fixative in diagnostic pathology. J Histotechnol 2001;24:151-2.

2. Morales AR, Essenfeld H, Essenfeld E, Duboue MC, Vincek V, Nadji M. Continuous-
specimen-flow, high-throughput,1-hour tissue processing. A system for rapid diagnostic
tissue preparation. Arch Pathol Lab Med 2002;126:583-90.
3. Bostwick DC, Al Anneuf N, Choi C. Establishment of the formalin-free surgical pathology
laboratory. Utility of an alcohol-based fixative. Arch Pathol Lab Med 1994;118:298-302.
4. Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P. Unlocking the archive gene expression
in paraffin-embedded tissue. J Pathol 2001;195:66-71.
5. Vincek V, Nassiri M. Nadji M, Morales AR. A tissue fixative that protects macromolecules
(DNA, RNA, and protein) and histomorphology in clinical samples. Lab Invest
2003;83:1427-35.
6. Kok LP, Boon ME. Ultrarapid vacuum-microwave histoprocessing. Histochem J
1995;27:412-9.
7. Leong AS-Y. Microwave irradiation in histopathology. Pathol Annu 1998;2:213-33.
8. Morales AR, Nassiri M, Kanhoush R, Vincek V, Nadji M. Experience with an automated
microwave-assisted rapid tissue processing method. Validation of histologic quality and
impact on the timeliness of diagnostic surgical pathology. Am J Clin Pathol 2004;121:528-36.
39
9. Nadji M, Nassiri M, Vincek V, Kanhoush R, Morales AR. Immunohistochemistry of tissue

prepared by a molecular-friendly fixation and processing system. Appl Immunohistochem
Mol Morphol 2005;13:277-82.
10. Vincek V, Nassiri M, Block N, Welsh CF, Nadji M, Morales AR. Methodology for
preservation of high molecular-weight RNA in paraffin-embedded tissue. Application for
laser-capture microdissection. Diag Mol Pathol 2005;14:127-33.
40
Chapter 6 ° Antigen Retrieval
Marc Key and Tom Boenisch
Introduction
Because of the superior preservation of morphology, formalin-fixed paraffin-embedded
(FFPE) tissue remains the medium of choice for most clinical and research studies.
However, the loss of immunoreactivity by many antigens as a result of fixation in formalin
has introduced challenges. To more fully appreciate the chemical complexity of fixing
tissue in formalin, the reader is encouraged to consult two reviews on this topic (1, 2).
Inconsistent use of formalin fixation between laboratories, especially as it pertains to the
variables of concentration, pH and exposure time, has contributed to this complexity,
as these factors influence immunohistochemistry (IHC) stain results. Physiological and
pathological changes in tissue composition, including the juxtaposition of tissue proteins
and their antigenic sites (epitopes), make fixation outcomes unpredictable. Each antigen
may contain from one to many epitopes, and each may be composed of five or more
amino acids. These in turn may be linked continuously in sequence, or be spatially
arranged in three-dimensional proximity as a result of intermolecular folding. Formalin
fixation will allow some epitopes to emerge unchanged. Those are considered “formalin-
resistant” epitopes. Others that undergo substantial changes are considered “formalin-
sensitive” epitopes. In this process, cross-linking unrelated proteins to target antigens
is also possible, resulting in the antigen’s partial or complete loss of immunoreactivity.
Such loss of immunoreactivity may be irreversible or reversible. If it is reversible, the
epitope frequently is referred to as “masked.”
A Short History of Antigen Retrieval*

The first attempt to improve formalin-fixed tissue antigens’ immunoreactivity used tryptic
digestion prior to immunofluorescent staining (3). Proteolytic digestion compensates
for the impermeable nature of non-coagulant fixatives by “etching” tissue, and
exposing hidden determinants. Today other proteolytic enzymes, including bromelain,
chymotrypsin, ficin, pepsin, pronase and other proteases have been reported to restore
immunoreactivity to tissue antigens with varying success. Enzyme use may, however,
also entail the risk of destroying some epitopes. Formalin fixation in conjunction with
digestion procedures needs to be optimized and then adhered to firmly (4).
An entirely new approach for immunoreactivity restoration in FFPE tissue sections
was reported by Shi et al 1991 (5). This technology used solutions containing various
metals and microwave heating for restoration, and applied the term “antigen retrieval”
(AR) for the first time.
The concept of recovering lost immunoreactivity through exposure to heat near water’s
boiling point was met at first with skepticism, because it went against the tenet of
41
protecting proteins from the denaturing effect of heat. However, Cattoretti et al developed
another major step forward in the use of heat by employing a citrate buffer of pH 6.0
instead of the original metal solution for the first successful demonstration in FFPE tissue
of the proliferation marker Ki-67 (6). Shortly thereafter, Gown (7) and Leong (8) were
able to apply their modifications of AR methods to a wide variety of additional markers.
Their modifications improved staining of many tissue markers, but more importantly they
showed that a whole new class of antigens, previously found to be non-reactive in FFPE
tissue, could be demonstrated successfully for the first time. These included additional
proliferation markers, hormone receptors (ER and PR), growth factor receptors (HER2/
neu), CD markers and others. Antigen retrieval is now a widely accepted method for
heat-assisted retrieval of antigens in FFPE tissues prior to IHC staining (9, 10).
More recently, combinations of enzymatic digestion and heat-induced antigen retrieval

have been reported. Iczkowski et al (11) combined steam heat with protease digestion,
an EDTA buffer of pH 8.0, and obtained staining with monoclonal anti-keratin antibody
34ßE12. This staining was found to be superior to that obtained when only one of these
measures was applied. Detailed information on optimal methods of antigen retrieval are
usually available in the manufacturer’s product specification sheet.
Principle and Technique

Antigen retrieval relies on application of heat to FFPE tissue sections in an aqueous
medium. After deparaffinizing and rehydrating tissue sections, slides are immersed
in an aqueous solution commonly referred to as a “retrieval solution.” Although many
different chemicals have been proposed, most retrieval solutions share a pH near two,
seven or 10. Recent systematic comparisons of several retrieval solutions showed that
0.01 M TRIS-HCl, pH 1 or 10, was slightly superior to citrate buffer of pH 6.0 and gave
the best overall results (12).
Following immersion in the preheated retrieval solution, containers holding the slides are
exposed to heat. This step is critical and the degree to which immunoreactivity can be
restored is related directly to the duration of incubation and the attained temperature.
The most commonly used heating methods include microwave ovens, autoclaves,
steamers, pressure cookers and water baths (7, 8, 13-16). Their advantages and
disadvantages, however, are subject to ongoing experimentations whose preliminary
results have been summarized by Battifora et al (17). Although an optimal temperature
has not been established, most AR methods apply temperatures near the boiling point
of water. Optimal length of exposure to heat may vary from 10 minutes to 60 minutes
and depends, to some extent, on the length of formalin fixation. Twenty minutes appears
to be the most satisfactory for most antigens and fixation protocols. Cooling usually is
allowed to take place slowly, requiring another 20 minutes to 30 minutes.
At higher elevations (above 4,500 feet or 1,200 meters), boiling of the AR solution
may occur prior to achieving the desired optimal temperature. In such situations, a
recommended alternative procedure is to heat the slides at the maximum achievable
temperature and to extend the incubation time of the slides in the AR solution until
42
Antigen Retrieval
the desired staining intensity is achieved (18). An additional possible solution is to

use a closed pressure system, such as a pressure cooker or autoclave to achieve
temperatures of at least 95 °C. However, each laboratory must determine the best
method and antigen retrieval time for their particular circumstances.
Several studies have now confirmed that pressurized systems supporting higher
temperatures (up to about 120 °C) have yielded superior results in terms of intensity
and number of sites stained, compared to non-pressurized systems operating at lower
temperatures (19-22).
Mechanism of Action
The precise mechanism of action of AR has long fascinated researchers and fueled
numerous investigations into this mystery (23-27). However, in spite of these efforts
the exact mechanism still remains largely unknown today. In view of the complexity
of antigens, this observation is not surprising. Heat is obviously of great importance
in reversing the damage caused by fixation with formalin and embedding in paraffin.
Whatever the mechanism, some of the cross-linking induced by formalin must remain
intact, as without this stabilizing structure, proteins would be denatured irreversibly by
the heat used during AR. This seemingly contradictory observation can be explained
only by the fact that some cross-links are reversible (Schiff bases), thus restoring the
immunochemical integrity of the protein, while others are not (methylene bridges).
Although much remains to be learned, our primary concern is that AR works. Future
studies almost certainly will provide new insights and help us to understand what we
can presently only accept.
Cytology
Methods of AR also have been used successfully for some cytology specimens. It has
been shown that by certain modifications, AR procedures can be used successfully for
the recovery of estrogen receptor, Ki-67, LCA, HER2/neu and cytokeratin. In contrast
to FFPE material, the success of this method is not so much related to the mode of
fixation, as it is readily applicable to aldehyde- and alcohol-based fixatives as well. It
was proposed that immunoreactivity was facilitated by an increase in cell membranes’
permeability, thus providing access to previously masked cell and nuclear antigens. The
modification includes the incorporation into the retrieval solution of a small amount of
detergent. For alcohol-fixed specimens it was also necessary to reduce the temperature
to 37 °C in order to maintain morphology. However by including formalin in the fixative,
no modifications were necessary, and standard high-temperature AR yielded optimal
results without compromising morphology (see Methods of Immunocytology for Slide-
Based Cellular Analysis, Chapter 12, for further details).
43
Target Retrieval for In Situ Hybridization

Soon after the discovery of AR for immunohistochemistry, investigators applied similar
approaches for the recovery of nucleic acid targets in FFPE. Today many retrieval
methods optimized for nucleic acids combine proteolytic digestion with high-temperature
target retrieval. This combined protocol provides better overall results than either method
alone. For greater detail, see In Situ Hybridization, Chapter 11.
Antigen Retrieval and Its Use in Doublestaining

One of the prerequisites for the successful sequential staining of several antigens in
the same tissue section is the removal of all reactants prior to applying the subsequent
primary antibody. Dako’s EnVision™ Doublestain System accomplishes this using of
an acid-elution step, leaving behind only the converted chromogen of the first cycle.
However, depending on the affinity of the first antibody, this method occasionally left
some primary antibody still bound to the tissue. An alternative method that we have
found to be superior is the intervening use of antigen retrieval prior to the application
of the subsequent primary antibody. Apparently high temperature results in nearly
complete “removal” of bound antibodies, because these proteins have not been fixed,
while the fixed proteins of the tissue remain intact.
The action of the antigen retrieval reagent is to either physically remove the reactants
and/or to alter them sufficiently so they are no longer immunoreactive. This basic method
can be extended to accommodate multiple staining within the same tissue specimen,
provided different chromogens are employed. The following chromogens were used for
simultaneous staining: DAB (brown), Fuchsin (red), Fast Red (red), BCIP/NBT (purple)
and nickel-DAB (gray).
Conclusion
As immunohistochemical techniques continue to be refined, their application in routine
and research pathology is becoming increasingly useful. Antigen retrieval has made a
significant contribution in this endeavor, as many markers previously believed to be lost
to the process of FFPE now can be demonstrated routinely. The benefits are especially
obvious with such important diagnostic markers as estrogen and progesterone receptors,
Ki-67 and HER2/neu. The greater sensitivity in their demonstration gained through AR
may, however, require reevaluating staining results and clinical interpretation (12).
As many recent publications have born out, heat-induced AR has been decidedly more
successful than the use of proteolytic enzymes, and therefore has profoundly affected
the practice of immunohistochemistry. However, because of the ongoing proliferation
of alternative AR methods, including new and better retrieval solutions for different
antigens, some bewilderment exists today among pathologists and histologists. In
the future therefore, greater attention will have to be directed to the standardization of
fixation in conjunction with, antigen retrieval (4, 12), and very likely optimized for each
separate antigen (28).
44
Antigen Retrieval
References
1. Fox CH et al. J Histochem Cytochem 1985;33:845-53.

2. Puchtler H and Meloan SN. Histochem 1985;82:201-4.
3. Huang SN et al. Lab Invest 1976;35:383-90.
4. Taylor CR et al. Appl Immunohistochem 1996;4:144-66
5. Shi S-R et al. J Histotech Cytochem 1991;39:741-8.
6. Cattoretti G and Suurmeijer AJH. Adv Anatomic Pathol 1994;2:2-9.
7. Gown AM et al. Appl Immunohistochem 1993;1:256-66.
8. Leong AS-Y and Milios J Appl Immunohistochem 1993;1:267-74.
9. Kim SH, Kook MC, Shin YK, Park SH, Song HGJ. Mol Histol 2004;35:409-16.
10. Gown AM. Am J Clin Pathol 2004;121:172-4.
11. Iczkowski et al. Mod Pathol 1999;12(1):1-4.
12. Shi S-R et al. Appl Immunohistochem 1998;6:89-96.
13. Shi S-R et al. J Histochem Cytochem 1995;43:193-201.
14. Bankfalvi A et al. J Pathol 1994;174:223-8.
15. Miller RT and Estran C. Appl Immunohistochem 1995;3:190-3.
16. Portiansky EL and Gimeno J Appl Immunohistochem 196;4:208-14.
17. Battifora H et al. Adv Pathol Lab Med 2000;8:2-19.
18. Koopal SA, Coma MI, Tiebosch ATMG, and Suurmeijer AJH. Appl Immunohistochem
1998;6:228-33.
19. Bankalvi A, Navabi H, Bier B, et al. J Pathol 1994;174:223-8.
20. Miller K, Auld J, Jessup E, et al. Adv Anat Pathol 1995;2:60-4.
21. Miller RT, Estran C. Appl Immunohistochem 1995;3:190-3.
22. Leong AS, Lee ES, Yin H, et al. Appl Immunohistochem 2002;10:263-8.
23. Rait, VK, O’Leary TJ, Mason JT. Laboratory Investigation 2004;84:292-9.
24. Rait, VK, Xu L, O’Leary TJ, Mason JT. Laboratory Investigation 2004;84:300-6.
25. Sompuram SR, Vani K, Messana E, Bogen SA. Am J Clin Pathol 2004;121:190-9.
26. Sompouram SR, Vani K, Bogen SA. Anatomic Pathology 2006;135:91-8.
27. Sompouram SR, Vani K, Hafer LJ, Bogen SA. Anatomic Pathology 2006;125:82-90.
Footnote
*Alternate terminology for “antigen retrieval” includes epitope retrieval, heat-induced epitope
retrieval (HIER), target retrieval and target unmasking. The latter two versions have a more
generic appeal and also have been applied to the retrieval of nucleic acid targets for in
situ hybridization.
45
46
Dextran Ba
Dextran Backbone
2° Antibody
1° Antibody
Chapter 7 ° Immunohistochemistry Staining Methods

Antigen
Marc Key
Step One Step Two
Introduction
Immunohistochemistry has emerged as a powerful investigative tool that can provide
supplemental information to the routine morphological assessment of tissues. The use
of immunohistochemistry to study cellular markers that define specific phenotypes
has provided important diagnostic, prognostic, and predictive information relative to
disease status and biology. The application of antibodies to the molecular study of tissue
pathology has required adaptation and refinement of immunohistochemical techniques,
particularly for use in fixed tissues. In contrast to solution-based immunoassays that
detect relatively abundant native proteins, in fixed tissues the preservation of antigen
is variable and unpredictable. Thus, the history of immunohistochemistry has been a
constant effort to improve sensitivity for detection of rare surviving antigenic targets with
the ultimate goal of integrating tissue-based analysis with proteomic information.
Immunohistochemistry: In the Beginning

Because of the superior morphology provided by formalin-fixed paraffin-embedded
tissues, this has become the medium of choice for most clinical and research studies.
The peroxidase-labeled antibody method, introduced in 1968, was the first practical
application of antibodies to paraffin-embedded tissues and overcame some of the
limitations of earlier fluorescence antibody methods (1). These pioneering studies
using enzyme labels instead of fluorescent dyes opened the door to the development
of modern methods of immuohistochemistry.
The successful application of immunohistochemical methods to formalin-fixed surgical

pathology specimens stimulated rapid progress in this newly emerging field, and in
quick succession came the introduction of the immunoperoxidase bridge method (2)
and the peroxidase anti-peroxidase (PAP) complex method (3).
47
Peroxidase
Anti-Peroxidase Complex
Secondary Antibody
Primary Antibody
Tissue Antigen
Figure 7.1. Peroxidase Anti-Peroxidase (PAP) Complex Method
Avidin-Biotin Immunohistochemistry
In 1981 a new generation of immunohistochemical methods emerged with the advent of
the avidin-biotin methods, which remains widely used today (4). All avidin-biotin methods
rely on the strong affinity of avidin or streptavidin for the vitamin biotin.
Streptavidin (from Streptomyces avidinii) and avidin (from chicken egg) both possess
four binding sites for biotin. The biotin molecule is conjugated easily to antibodies
and enzymes. In the avidin-biotin complex (ABC) method secondary antibodies are
conjugated to biotin and function as links between tissue-bound primary antibodies
and an avidin-biotin-peroxidase complex (5).
48
Dextran Ba
Dextran Backbone
2° Antibody
Immunohistochemistry Staining Methods
1° Antibody
Antigen
Avidin-Biotin
StepComplex
One Step Two
Must be prepared 30
minutes prior to use
Biotinylated
Secondary
Antibody
Primary
Antibody
Tissue Antigen
Figure 7.2. Avidin-Biotin Complex (ABC) Method
In a similar method, the labeled streptavidin-biotin (LSAB) method also utilizes a

biotinylated secondary antibody that links primary antibodies to a streptavidin-
peroxidase conjugate (6). In both methods a single primary antibody subsequently is
associated with multiple peroxidase molecules, and because of the large enzyme-to-
antibody ratio, a considerable increase in sensitivity is achieved compared to direct
peroxidase-conjugate methods.
Streptavidin
Enzyme Complex
Biotinylated
Secondary
Antibody
Mouse/Rabbit
Primary
Antibody
Tissue Antigen
Figure 7.3. Labeled Streptavidin-Biotin (LSAB) Method
49
Because avidin is a glycoprotein and has an isoelectric point (pI) of 10, it has a propensity
to bind non-specifically to lectin-like and negatively charged tissue components
at physiological pH. In contrast to avidin, streptavidin has a more neutral isoelectric
point and lacks the carbohydrate moieties. These differences result in less nonspecific
tissue binding.
Polymer-Based Immunohistochemistry
Although many of these (strept) avidin-biotin methods are still in widespread use, there
are certain limitations characteristic of these methods. The presence of endogenous
biotin in tissues can lead to significant background staining in certain circumstances.
Formalin fixation and paraffin embedding has been shown to significantly reduce the
expression of endogenous biotin, but residual activity can still be observed in tissues
such as liver and kidney. Furthermore, with the advent of heat-induced antigen retrieval,
the recovery of endogenous biotin can appear as an unwanted side effect. Methods to
block endogenous biotin are partially effective, but add another layer of complexity to
an already complex procedure. These limitations are further exacerbated by the use
of frozen tissue sections, in which levels of endogenous biotin are usually even higher
than those encountered in paraffin-embedded specimens.
Because of these limitations, polymer-based immunohistochemical methods that do not

rely on biotin have been introduced and are gaining popularity (5). These methods utilize
a unique technology based on a polymer backbone to which multiple antibodies and
enzyme molecules are conjugated. In the EPOS (Enhanced Polymer One Step)* system,
as many as 70 enzyme molecules and about 10 primary antibodies are conjugated to
a dextran backbone. This allows the entire immunohistochemical staining procedure,
from primary antibody to enzyme, to be accomplished in a single step (6). On the
other hand, one limitation of this method is that it is restricted to a select group of
primary antibodies provided by the manufacturer, and not suitable for user-supplied
primary antibodies.
To overcome this limitation a new type of dextran polymer, EnVision™ +*, was introduced.
This polymer system contained a dextran backbone to which multiple enzyme molecules
were attached. However, unlike EPOS, which contained primary antibodies, the
EnVision™ system contained secondary antibodies with anti-mouse Ig and anti-rabbit
Ig specificity. This universal reagent could be used to detect any tissue-bound primary
antibody of mouse or rabbit origin. The utility of this method opened the door to a
new family of polymer-based immunohistochemical methods. The sensitivity of these
methods compared to LSAB and ABC methods was comparable or even slightly
greater in most cases (7). However, because of the large molecular size of the polymer
conjugates, accessibility to certain epitopes was restricted, presumably due to steric
hindrance, in a minority of cases.
50
Dextran Ba
Dextran Backbone
2° Antibody
1° Antibody
Antigen
Antigen Enzymes
Step One Step Two
1° Antibody
2° Antibody
Enzyme (HRP or AP)
Dextran Backbone
Dextran Backbone
2° Antibody
1° Antibody
Antigen
Step One Step Two
Figure 7.4. Two-Step Polymer Method (EnvisionTM)
Tyramide Amplification
The tyramide amplification technique is based on the ability of phenolic compounds to
become oxidized to highly reactive and unstable intermediates (8). When biotinyl tyramide
is oxidized, dimerization with electron-rich aromatic compounds, such as those found in
protein molecules, occurs (9). This reaction can be harnessed in immunohistochemistry
to generate highly reactive biotinyl-tyramide intermediates that bind rapidly to protein
molecules in the immediate vicinity of peroxidase enzymes. This reaction results in the
deposition of numerous biotin signals. In a typical immunohistochemistry procedure,
peroxidase enzymes are associated first with primary antibodies by any of the standard
immunohistochemical methods, for example by the ABC or LSAB methods. Biotinyl
tyramide and hydrogen peroxide are applied as a substrate to generate numerous
biotin (biotinyl tyramide) signals. These biotin molecules then can be used to capture
subsequent streptavidin-peroxidase enzymes that are converted to a chromogenic
endpoint via diaminobenzidine or similar chromogenic substrates (10).
51
Cycled Tyramide Amplification

The sequence of streptavidin-peroxidase and biotinyl-tyraminde can be applied
alternately to perform a cycled tyramide amplification procedure. In practicality, however,
cycling usually cannot exceed two or three cycles before background staining limits
the utility of this approach. Commercial tyramide amplification products are available
and include Tyramide Signal Amplification (TSA, DuPont NEN Life Sciences, Boston,
MA) and Catalyzed Signal Amplification (CSA)*.
Fluorescyl-Tyramide Amplification
In keeping with current trends in immunohistochemistry to develop alternatives to
biotin-streptavidin detection methods, a fluorescyl-tyramide amplification system has
been introduced recently (FT-CSA)*. In this procedure peroxidase is associated with a
tissue-bound primary antibody by application of a secondary anti-mouse Ig antibody to
which peroxidase has been conjugated. The peroxidase catalyzes the conversion and
deposition of fluorescyl-tyramide onto the tissue section. At this point the reaction can
be terminated and viewed by fluorescence microscopy, or the signal can be converted
to a colorimetric reaction by the sequential application of an anti-fluorsecein antibody
conjugated to peroxidase followed by a diaminobenzidine-hydrogen peroxide substrate.
In comparison to standard IHC methods, tyramide amplification methods typically

have increased sensitivity by at least 50 fold or greater (11). As with any amplification
method, background tends to increase along with signal. Therefore it is essential to run
appropriate positive and negative controls and interpret any positive staining within the
context of the negative control.
Rolling Circle Amplification

Rolling Circle Amplification (RCA) is a novel signal amplification system that generates
a local signal via extension and amplification of an oligonucleotide tail. Although
initially developed for nucleic acid detection, this method also can be applied to
immunohistochemistry. RCA-mediated immunohistochemistry has been applied
successfully to the detection of a variety of cell surface and intracellular molecules (12).
The method utilizes a short oligonucleotide sequence coupled to a primary or secondary
antibody molecule. After binding to the tissue, a circularized nucleic acid probe with
a complementary sequence is hybridized to the oligonucleotide. The oligonucleotide
then acts as a primer and is extended linearly using a DNA polymerase and the rolling
circle. Then the extended DNA is hybridized with labeled oligonucleotide probes. These
labels may include, for example, biotin, which then can be visualized by any one of
the many avidin-biotin detection methods. RCA derives its specificity from an antigen-
antibody reaction and its sensitivity from nucleic acid synthesis. RCA has been reported
to generate a 105 -fold increase in signal (13).
52
Dextran Ba
Dextran Backbone
2° Antibody
1° Antibody
Conclusion
Antigen
As immunohistochemical techniques continue to evolve, their application to surgical and
research pathology is becoming increasingly valuable. Various amplification methods
Step One Step Two
have made significant improvements to this technology such that many antigens,
previously believed to have been lost to the process of fixation and embedding, now
can be demonstrated routinely. However, as the sensitivity of immunohistochemistry
continues to increase, accepted staining criteria and clinical interpretation may
require re-evaluation.
New signal amplification methods continue to be developed, each with their own unique
strengths and weaknesses, and this can present a bewildering assortment of choices
that profoundly influence the practice of immunohistochemistry to the investigator or
clinician. As technology marches forward, new arrays of tissue markers are emerging
that are providing the tools to generate important new discoveries. As new markers are
added to this list, our knowledge of the underlying biology and pathogenesis of disease
is increased. The full impact is still many years away.
References
1. Nakene PK. Simultaneous localization of multiple tissue antigens using the peroxidase
labeled antibody method: A study of pituitary glands of the rat. J Histochem Cytochem
1968;16:557-60.
2. Mason TE, Phifer RF, Spicer SS. An immunoglobulin-enzyme bridge method for
localizing tissue antigens. J Histochem Cytochem 1969;17:563-9.
3. Sternberger LA, Hardy PH Jr., Cuculis JJ, Meyer HG. The unlabeled antibody-enzyme
method of immunohistochemistry. Preparation and properties of soluble antigen-
antibody complex (horseradish peroxidase-antihorse-radish peroxidase) and its use in
identification of spirochetes. J Histochem Cytochem 1970;18:315.
4. Hsu SM, Raine L, and Fanger H. Use of avidin-biotin peroxidase complex (ABC) in
immunoperoxidase techniques: A comparison between ABC and unlabeled antibody
(PAP) procedures. J Histochem Cytochem 1981;29:577-80.
5. Heras A, Roach CM, Key ME. Enhanced polymer detection system for
immunohistochemistry. Lab Invest 1995;72:165 (Abstract).
6. Chilosi M, Lestani M, Pedron S, Montagna L, Benedetti A, Pizzolo G, Menestrina F. A
rapid immunostaining method for frozen sections. Biotech Histochem 1994;69:235.
7. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C. The EnVision™
system: a new immunohistochemical method for diagnostics and research. Critical
comparison with the APAAP, ChemMateTM, CSA, LABC, and SABC techniques. J Clin
Pathol 1998;51:506-11.
8. Gross AJ, Sizer IW. The oxidation of tyramine, tyrosine, and related compounds by
peroxidase. J Biol Chem 1959;234:1622-14.
9. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a
novel method of signal amplification. Application to immunoassays. J Immunol Methods
1989;125:279-85.
10. Adams JC. Biotin amplification of biotin and horseradish peroxidase signals in
histochemical stains. J Histochem Cytochem 1992;40:1457-63.
53
11. Merz H, Malisius R, Mann-Weiler S, Zhjow R, Hartmann W, Orscheschek K,

Moubayed P, Feller AC. Methods in laboratory investigation immunoMax. A maximized
immunohistochemical method for the retrieval and enhancement of hidden antigens. Lab
Invest 1995;73:149-56.
12. Gusev Y, Sparkowski J, Raghunathan J, Ferguson H, Montano J, Bogdan N, Schweitzer
B, Wiltshire S, Kingsmore SF, Maltzman W. Weeler V. Rolling circle amplification. A new
approach to increase sensitivity for immunohistochemistry and flow cytometry. Am J
Pathol 1002;159:63-75.
13. Wiltshire S, O’Malley S, Lambert J, Kukanshis K, Edgar D, Kikngsmore S, Schweitzer B.
Detection of multiple allergen-specific IgE on microarrays by immunoassay with rolling
circle amplification. Clin Chem 2000;46:1990-3.
Footnote
* A proprietary methodology developed by Dako.
54
Chapter 8 ° Immunofluorescence
W. Roy Overton, Revised by Jim Hudson and Karen Atwood
Introduction
Fluorescent dyes were developed first in the late 19th century. But it wasn’t until 1950
that antibodies conjugated with fluorescein isothiocyanate were utilized to produce
specific biological staining to generate fluorescence in a specimen. These stained
tissues and cells could be examined readily by fluorescence microscopy. Today,
attaching fluorescent compounds, or “fluorochromes,” to antibodies enables scientists
and clinicians to gain tremendous information about the biology and pathology of
cells from humans, animals, plants and microbes. The following is a discussion of
these compounds.
Among the properties of many compounds is the ability to absorb one color of light and
then emit a different color of light. This causes the compound to appear to be glowing,
or fluorescing, and the compound is referred to as a fluorochrome. A “fluorophore” is a
component of a molecule that causes a molecule to fluoresce. It is a functional group
in a molecule that absorbs energy of a specific wavelength and re-emits energy at a
different wavelength. Fluorescein isothiocyanate is an example of a fluorophore that
can be attached chemically to a different, non-fluorescent molecule to create a new
and fluorescent molecule.
To better understand how a fluorochrome works, it is necessary to examine this process

at the subatomic level. Electrons normally spin around the nucleus of an atom at a
distance that is referred to as the electron’s “ground state” or “ground level.” If the
atom is hit by photons of light that can excite the electron, such as ultraviolet radiation,
then the electron will move up to a higher energy state that is farther from the nucleus.
The electron is unable to maintain that distance from the nucleus due to the electron’s
magnetic attraction to the protons in the nucleus, so quickly drops to a slightly closer
distance, called the “lowest singlet excited state.” Moving to the lowest singlet excited
state causes the electron to release a little of the energy that it got from the light, but it
releases energy as heat. The electron then returns to its original ground state, releasing
the rest of the energy that it absorbed from the light. This energy is released as light,
but since some energy was released as heat into the lattice of the molecule, there is
less energy in that light. Thus, the emitted light appears to be a different color than the
light that excited the atom.
Light travels in waves that determine the color of the light. If the light has a lot of energy,
its waves are shorter than a wave of light with less energy. The wavelength of the light
determines the color of the light. Very high-energy light such as ultraviolet (UV) light
has very short wavelengths. The wavelength of UV light is less than 400 nm. Because
the wavelength is so short, the human eye is unable to see UV light, but electronic
55
photodetectors are able to detect and measure this invisible light. Visible light has
wavelengths from 400 nm to 700 nm, that produce the colors violet, blue, green, yellow,
orange and red. Above 700 nm is the infrared range, which is also invisible to the human
eye, but can be felt as heat or detected by electronic photodetectors.
In immunofluorescent staining, mercury-vapor, xenon or halogen lamps in the fluorescent

microscope usually are used to excite the fluorochromes. The chemical properties of
the fluorochrome determine whether its electrons can be excited to the higher energy
state by a specific wavelength. If the electrons can be excited to the higher energy state,
the chemical properties of the fluorochrome also will determine the amount of energy
lost as heat when the electrons drop back down to the lowest singlet excited state and
the wavelength of light produced when the electrons return to their ground state. The
difference in the wavelength of the light that excites the electrons and the light that is
emitted is called the “Stokes shift,” and is determined by the amount of energy lost as
heat. The emitted wavelength is always longer (if single photons are absorbed) or equal
to the incident wavelength, due to energy conservation.
Some fluorochromes have a small Stokes shift, and the excitation and emission
wavelengths have almost the same wavelengths. But other fluorescent compounds
have large Stokes shifts. For example, the fluorochrome, fluorescein, can be excited
by blue-green light, and its Stokes shift is only about 25 nm, which means that the light
emitted is green. This contrasts with another fluorochrome, phycoerythrin, which also
can be excited by blue-green light, but has a large Stokes shift. Thus, the light emitted
is yellow-orange. In immunofluorescence, a single wavelength can be used to excite
several fluorochromes with different Stokes shifts and, thereby, produce a variety of
fluorescent colors.
The electrons of a fluorochrome can be excited by a range of wavelengths of light. For

example, the fluorochrome, fluorescein, will fluoresce when hit by light with a wavelength
between 430 nm and 520 nm. However, the closer the excitation wavelength is to
495 nm, the more fluorescence will be produced. This optimal wavelength is called
the excitation peak. Similarly, the light produced by fluorochromes has a range of
wavelengths. The emission of light from fluorescein ranges from 490 nm to 630 nm,
and the emission peak is approximately 520 nm.
Knowing the excitation and emission properties of fluorescent compounds makes it

possible to select combinations of fluorochromes that will work together. However, for a
fluorochrome to be useful in a biological application, it must attach to or be contained
within a particle of biological significance. Many fluorochromes can be attached to
antibodies, which then will bind to specific chemical structures on or inside of cells.
There are many other chemical and physical properties of fluorochromes that determine
where and when these dyes are useful in various biological assays. For example,
some of the fluorochromes that bind to DNA, such as Hoechst 3342, can get into
living cells, but most DNA-binding fluorochromes cannot get past the cell membrane.
The fluorescent dyes that cannot get past a viable cell membrane, such as propidium
iodide, often are used to distinguish live from dead or dying cells.
56
Immunofluorescience
Fading, Quenching and Photobleaching

Fluorescence detection can be affected adversely by “fading.” This is a reduction of
fluorescent emission intensity caused by photobleaching or quenching.
Photobleaching is an irreversible degradation of the activated or excited fluorochrome

as a result of its interaction with molecular oxygen (1). Illumination of the fluorochromes
by light of the appropriate wavelength can result in an excited state that renders it
more chemically reactive. It then may react irreversibly with any available oxygen
molecules. This interaction may result in decomposition, polymerization, or oxidation
and subsequent reaction with another molecule.
Photobleaching can be minimized by using the lowest illumination possible. To minimize

the effects of photobleaching, fluorescence microscopy can be combined with other
techniques that are non-destructive to fluorochromes, such as differential interference
contrast (DIC), Hoffman modulation contrast (HMC), and phase contrast. The operator
locates the area of interest on the slide using a non-destructive low level light before
switching on the fluorescence excitation light.
Quenching of an excited fluorochrome may occur due to a non-radiative or radiative

energy loss and is mediated through compounds in the micro-environment.
Non-radiative energy loss and reduction in fluorescence intensity can be caused
by the presence of oxidizing agents, salts, heavy metals or halogen compounds. In
some cases, quenching results from radiative energy loss or the transfer of energy
from the fluorochrome (donor molecule) to another molecule (acceptor) that resides
physically close to the excited fluorochrome. This is called fluorescence resonance
energy transfer (FRET).
There are several commercially available anti-fading mounting media available that
significantly reduce this phenomenon (2).
Fluorescein
Purified antibodies are conjugated with fluorescein isothiocyanate isomer (FITC). After
conjugation, unreacted FITC is removed completely by gel filtration on Sephadex G-
25. Further purification is carried out by ion exchange chromatography. This process
removes unconjugated antibody molecules and antibody molecules to which more than
four molecules of FITC are attached. These conjugates consist of optimally labeled
antibody molecules for immunofluorescent use. Then fluorescein/protein ratio measured
as the absorbance ratio measured as the absorbance ration A495nm/A278nm is 0.65,
corresponding to a molar FITC/protein ratio of 2.3-2.5. FITC conjugates with a higher
F/P value, such as those prepared for flow cytometric analysis, are not suitable for
immunofluorescence, as they will produce high background, false positive staining and
possible self-quenching of the FITC molecule.
57
The FITC-labeled immunofluorescent stain does not require strong ultra-violet radiation
for excitation. With a peak absorption of 495, light generated by a quartz-halogen or
xenon lamp is sufficient.
Procedure for Formalin-Fixed Paraffin-Embedded Tissue

° Cut four micron sections onto charged or silanized slides.
° Allow sections to dry at 37 °C for four hours.
° De-wax and hydrate tissue sections.
° Rinse in deionized (DI) water.
° Wash in PBS for 10 minutes at 4 °C.
° Enzyme digest tissue sections if proteolytic treatment is required.
° Stop enzyme digestion by incubation in TBS for 60 minutes at 4 °C.
° Wash in PBS for 10 minutes at 4 °C.
° An optional serum block may be used at this point to block Fc receptors. Tap
off excess.
° Incubate with FITC conjugated antibodies, diluted in PBS and one percent bovine
serum albumin, in a moist chamber for 20 minutes at room temperature.
° Rinse slides in PBS to remove excess antiserum.
° Wash in PBS for 10 minutes at 4 °C (2x).
° Mount with fluorescent mounting medium .
° Seal coverslip edges with clear nail polish and store at 2-8 °C in the dark.
Procedure for Frozen Sections

° Cut four micron cryostat sections.
° Fixation:
ß Fix in acetone for 10 minutes at 4 °C, air dry for 30 minutes, post fix in acetone
for 90 seconds at 4 °C;
ß Air dry for 1-12 hours, fix in acetone for 10 minutes at 4 °C.
° Wash in PBS for one to five minutes at 4 °C.
° An optional serum block may be used at this point to block Fc receptors
° Tap off excess.
° Incubate with FITC conjugated antibodies, diluted in PBS and one percent bovine
serum albumin, in a moist chamber for 20 minutes at room temperature.
° Rinse slides in PBS to remove excess antiserum.
° Wash in PBS for 10 minutes at 4 °C (2x).
° Mount with fluorescent mounting medium.
° Seal coverslip edges with clear nail polish and store at 2-8 °C in the dark.
58
Immunofluorescience
Buffers:
° Phosphate buffered saline: pH 7.2:
ß 33.99 g NaCl;
ß 9.258 g Na2HP42H2O;
ß 2.15 g KH2OPO4.
ß Bring to five liters with DI water.
° Phosphate buffered saline: pH 7.0;

ß Dako Code S3024.
° Tris-Buffered Saline:
ß Dako Code S1968 or S3001.
° Pronase:
ß Dako Code S2013.
Table 8.1. Antibody dilution chart for direct immunofluorescence on frozen sections.
Code Dako FITC Conjugated Antibody Dilution in PBS
F0117 Albumin 1:20-1:40
F0254 C1q Complement 1:10-1:20
F0201 C3c Complement 1:75-1:100
F0111 Fibrinogen 1:50-1:70
F0204 IgA 1:20-1:40
F0202 IgG 1:20-1:40
F0203 IgM 1:20-1:40
F0198 Kappa Light Chains 1:20-1:40
F0199 Lambda Light Chains 1:20-1:40
X0929 Negative Reagent Control See NOTE
NOTE: The negative reagent control is used on an additional tissue section. To determine the dilution factor, calculate
the total protein (TP) of each antibody to be used in the test run (TP of primary antibody/optimized dilution factor).
Select the highest calculated TP and divide it into the TP of the negative reagent control (TP negative reagent control/
highest calculated TP). This is the dilution factor of the negative reagent control for the run.
59
Positive and negative controls are required now by the Clinical Laboratory Improvement
Amendments of 1988 (CLIA) for each staining run. Positive and negative tissues are
stained with the antibody.
An unstained control slide may be used to determine if autofluorescence is present.

Primary or autofluorescence is seen when a specimen has not been labeled with a
fluorescing dye, but still manifests fluorescence during exposure to short wavelength
energy. Tissue autofluorescing substances include: Elastic fibers, lipofuscins, collagen,
porphyrins, vitamin A, cartilage, keratin, cardiac muscle, fat, waxes, hormones, calcium
and powdered crude drugs. Autofluorescence also may be caused by free aldehydes
from fixation.
A number of “home-brew” procedures have been shown to quench autofluorescence.

Those include pronase digestion; 100 mM glycine in PBS (pH 7.4) for 10-20 minutes; 50
mM ammonium chloride in PBS for 10 minutes; and one percent sodium borohydride
in PBS for 10-20 minutes.
Other factors that can contribute to unexpected or undesired staining include heat-
induced epitope retrieval (HIER) lipofusion artifacts; reagent contamination; sub-optimal
temperature and duration at which the reagents are incubated; dead or necrotic cells
and Tween 20 added to the wash buffer.
In addition, due to the size of some fluorochromes such as RPE, some conjugated
antibodies may become trapped in an intact cell during analysis for intracellular antigens.
References
1. Song L, Hennink EJ, Young IT, Tanke HJ. Photobleaching kinetics of fluorescein in
quantitative fluorescence microscopy. Biophys J 1995;68:2588-600, PN19816.
2. Ono M, Murakami T, Kudo A, Isshiki M, Sawada H, and Segawa A. Quantitative
Comparison of Anti-Fading Mounting Media for Confocal Laser Scanning Microscopy. J
Histochem Cytochem 2001;49:305-12.
60
Chapter 9 ° Multi-Staining Immunohistochemistry
Nanna K. Christensen and Lars Winther
Introduction
Immunohistochemistry (IHC) has become established as an important tool for both
research and diagnostic purposes. However, in some cases there is a need for
knowledge about the relative localizations of targets, which can be obtained only by
visualizing all relevant targets on one slide. This chapter describes the advantages
of multiple staining, as well as the considerations that have to be made to ensure
successful staining. This article will discuss the choice of appropriate protocols as well
as the choice of visualization systems.
Advantages of Multiple Staining

Multiple staining can be defined as the detection of two or more targets on one slide,
thus increasing the information obtained from each slide. Hands-on time per slide
depends on the method used. Sequential staining does not reduce hands-on time
compared to combining single staining; whereas simultaneous staining does reduce
turn-around time (see below). With increasing demand for reduced turn-around-time,
multiple staining may offer at least part of the solution. Furthermore, there is a demand
for less invasive sampling techniques giving smaller and fewer specimens and available
slides. In such cases multiple staining also may be a great advantage.
Equally important, multiple staining makes it possible to assess the topographic

relationship of the targets, for example, to determine whether targets are present in
different cells, in the same cell or even in the same cellular compartment. Information
also can be obtained on possible cell-to-cell spatial contacts of different cell types.
Some of this information also can be obtained using single staining on serial sections.
However, this is laborious and time consuming and the sections must be very thin to
ensure all structures or cells are present in the entire series of sections. Multiple staining
allows the combination of in situ hybridization (ISH) and IHC, giving information about
a particular target both at protein level and DNA/mRNA level.
The diagnosis of prostatic epithelial neoplasia (PIN) is just one example of the clinical
importance of multiple staining. Prostatic needle biopsy is the preferred method for
diagnosing early prostate cancer. But in some cases an ambiguous diagnosis is made
due to the fact that the biopsy has identified only a few malignant glands or several
histological benign mimics of cancer (1). Since basal cells are present in the benign
cancer mimics but absent in the malignant glands, these cells can be used to distinguish
between the two cases. Basal cells are labeled using high-molecular-weight cytokeratin,
cytokeratin 5/6 or p63 immunostaining. In addition, the gene product of p504s, alpha-
methylacyl-CoA-racemase is expressed in a high percentage of prostate carcinomas,
but is negative or only weakly expressed in benign prostate tissue. Thus it is used as
61
a positive cancer marker. In cases of small foci, ambiguous lesions may disappear
when using serial sections, causing suspected malignancies to remain undiagnosed.
A multiple staining protocol reduces the percentage of residual ambiguous lesions and
the need for additional biopsies.
Multiple staining is well known from flow cytometry, where staining of three to four
different targets on the same cell is routine. A single sample elicits considerable
information, allowing unambiguous separation of different cell-types and identification
of abnormalities. ISH routinely uses multiple staining on slides to determine
gene amplification from the ratio of the signals from the gene probe of interest to a
reference probe.
ISH also can be used in multiple staining to detect chromosome translocations using split-
signal FISH. Probes directed towards stretches immediately upstream and downstream
of the breakpoint are labeled green and red, respectively. Thus when probes are
co-localized, the mixture of green and red results in a yellow signal, but when the
chromosome breaks, the signals separate and individual green and red signals can be
seen. In this case, single-target staining would not give the desired information. Multiple
staining is well established in ISH, and there are obvious advantages to extending this
to an IHC format to gain the benefit of the additional information.
Technical Challenges
Users experienced with the challenges of single-target staining will find the demands
for multiple staining are similar but more complex.
Before embarking on a multi-staining project, some important issues should be

considered:
° To avoid target or species cross-reactivity, complex protocols may be necessary.
° Spectral differentiation of stain colors may be difficult, especially if the targets
are co-localized. Rare targets that are co-localized with more abundant targets
may not show, and if colors are mixed, results may be difficult to separate from
single colors.
° Even if targets are not co-localized it is difficult to balance signals enabling rare
targets to be visible in the same slide as highly abundant targets. This is due to
the narrow dynamic range of IHC. An adjustment in concentration of the primary
antibodies may solve this problem.
° If different targets are viewed under different magnifications, it may not be possible
to get the topographic information desired.
Pretreatment
Multiple staining, like single staining, can be performed on both formalin-fixed, paraffin-
embedded tissue, cryosections, cell smears and cytospin preparations. Multiple staining
is constrained by the fact that it may not be possible to find one tissue pre-treatment
62
Multi-Staining Immunohistochemistry
protocol that is optimal for all targets. Often protocols optimized for individual staining
differ from one target to the other; for example, different target retrieval methods are
used. If that is the case, it is necessary to determine a method that allows all targets to
be stained, although the method may be sub-optimal for some targets.
In cases where targets of different abundances are to be stained, a method must be

selected that gives the best balancing of the signals. Combining ISH and IHC on one
slide is challenging, particularly because targets require very different pre-treatment
protocols. Since ISH processes such as DNA denaturing are not compatible with the
presence of the antibodies for IHC, the ISH protocol normally is performed first.
Staining Method Selection

To ensure success, IHC staining must be planned carefully. This is even more important
with multi staining. If primary antibodies are commercially available both directly labeled
and unlabeled and from different host-species, there are several different staining
methods to choose from; however, very often the choice is limited by the available
reagents (2). Care must be taken to avoid cross-reactivity between reagents. A flow
chart or similar aid might prove useful in selecting the best method.
In general, staining methods can be divided in the following classes:
Sequential Staining
An indirect technique using unlabeled primary antibodies where the staining of one
target is completed including the application of the chromogenic dye, before the
application of the next.
The primary and secondary antibodies from the first staining are eluted before
staining the next target (for an example, see Figure 9.1). This avoids cross-reactivity-
related problems; however, elution may be difficult with some high-affinity primary
antibodies, leading to spurious double stained structures. This technique therefore is not
recommended for evaluation of mixed colors at sites of co-localization. Elution also risks
denaturing epitopes of antigens that are to be subsequently visualized. Furthermore,
for some chromogens there is a risk that the first chromogen (DAB in particular) shields
other targets. Not all reaction products are capable of surviving the rigorous washing
required to remove the antibodies. Thus in order to avoid blurry staining results the most
robust dyes should be applied first.
Simultaneous Staining
A direct method with directly labeled primary antibodies, or an indirect method based
on unlabeled primary antibodies raised in different host species, or of different Ig
isotype or IgG subclass (3).
A simple example of this method is when the primary antibodies are fluorescently or
enzyme labeled to allow direct visualization. This avoids cross-reactivity but is rarely
63
practical since some form of amplification is necessary to get sufficient signal. In that
case, primary antibodies are conjugated directly with enzymes, biotin, haptens or
fluorochromes, subsequently employing the corresponding antibody or streptavidin
reagent as the second layer. This is less time-consuming than the sequential method,
since primary and secondary antibodies can be mixed together in two incubation steps.
However, it requires avoiding all cross-reactivity.
With the indirect method it is also possible to apply timesaving antibody cocktails.
Generally it is advantageous to use secondary antibodies raised in the same host in
order to prevent any unexpected inter-species cross-reactivity.
Multi-Step Technique
An indirect/direct method combining unlabeled primary antibodies with antibodies
that are directly conjugated. The method starts with the staining of the unlabeled
antibody/antibodies.
Sequential staining avoids the problem of cross-reactivity but cannot be used for
co-localized targets. The technique often leads to a long staining protocol and carries
an inherent risk of incorrect double staining due to insufficient elution of one set of
reagents before application of the next. Simultaneous staining is less time-consuming
since the reagents of each layer can be mixed together. However, the technique can be
used only if suitable primary antibodies are available. Multi-step staining can be used
when the selection of primary antibodies is limited. However, when using this method,
it is not possible to mix reagents.
Users often will find that the choice of staining method is limited by the availability of
the primary antibodies with respect to species origin or label.
When targets are known or suspected to be co-localized and the only available primary
antibodies are unlabeled monoclonal mouse antibodies of the same IgG subclass, none
of the techniques described above are applicable.
One solution is the Dako Animal Research Kit (ARKTM) Peroxidase, which contains
reagents for labeling mouse primary antibodies with a biotinylated anti-mouse Fab
fragment, followed by blocking of the remaining reagent with normal mouse serum. This
can be applied to the tissue as part of the multi-step technique (4). The kit gives a non-
covalently labeled antibody, thus avoiding the risk of reducing the affinity. In addition,
only small amounts of primary antibody are needed and the kit does not require time-
consuming purification steps.
Another solution is Zenon Technology (Invitrogen) developed for flow cytometry. It

uses essentially the same technique, and offers labeling kits for mouse primary
antibodies available as enzyme conjugates or conjugated to one of a wide variety of
fluorescent dyes.
Visualization systems with dual recognition such as the EnVisionTM+ Dual Link system do
not discriminate between species, and are thus only suitable for multiple staining when
64
using the sequential method. Visualization kits with amplification layers that are not well
specified should be avoided, since possible cross-reactivity cannot be predicted.
Selection of Dyes
The primary choice to make when deciding how to make the targets visible is whether
to use immunoenzyme staining or fluorescence. Both have advantages and
disadvantages and in the end, decisions should be made based on conditions of the
individual experiment.
Chromogenic Dyes
When selecting color combinations for multiple staining with chromogenic dyes, it
is advisable to choose opposing colors in the color spectrum, to facilitate spectral
differentiation. If using a counterstain, this also must be included in the considerations.
When working with co-localized targets, dyes must be chosen so that it is possible to
distinguish the mixed color from the individual colors. Double staining using chromogenic
dyes is well established, but it is demanding if the targets are co-localized. For triple
staining, it is more difficult to get colors that can be unambiguously differentiated and
it is very difficult if targets are co-localized.
A narrow dynamic range is a handicap for immunoenzymatic staining. The precipitation

process, which is crucial for this method, is only triggered at a certain threshold
concentration of substrate/product. On the other hand, at high concentrations the
precipitated product may inhibit further reaction. Therefore it is difficult to visualize rare
targets and highly abundant targets in the same slide. To reduce this problem using the
strongest dye to stain the most rarely expressed target is advantageous. Or if possible
use extra amplification like the Catalyzed Signal Amplification (CSA) System to bring
rare targets within the same dynamic range as highly expressed targets.
There is a limited range of chromogenic dyes to choose from. These are examples of
enzyme/chromogen pairs suitable for triple staining:
° GAL/XGAL/Turquoise, AP/Fast blue, HRP/AEC/Red;
° HRP/DAP/Brown, GAL/XGAL/Turquoise, AP/Fast red;
° HRP/DAP/Brown, AP/New Fucsin/Red, HRP/TMB/Green.
In conclusion, chromogenic dyes can be used successfully for double staining; however,
identifying co-localized targets may be a problem. Triple staining is also possible, but
great care must be used in selecting dyes.
65
Fluorescent Dyes
Double immunofluorescence labeling is also quite well established (5). Some of the same
considerations as with chromogenic dyes apply when working with immunofluorescence.
It is equally necessary to select dyes with distinguishable spectral properties. However,
there are more colors available and the emissions spectra of the fluorescent molecules
are narrower than the spectra of the chromogenic dyes. DAB in particular has a very
broad spectrum. The use of multiple fluorescent colors is also already well established
in FISH and flow cytometry, where dichroic filters and bandpass filters are employed to
separate different fluorescent signals. The spectral separation can be aided by digital
compensation for overlapping emission spectra.
When staining targets that are co-localized fluorescent dyes, allow separate
identification of targets. This makes it possible to discern targets even in widely
different concentrations, whereas subtly mixed colors may pass unnoticed easily with
immunoenzyme staining.
Immunofluorescence potentially has a wider dynamic range than immunoenzyme

staining. Using this method, there is no enzymatic amplification involved and thus the
dynamic range is determined solely by the sensitivity of the detectors.
On the other hand, there are some inherent problems with the use of immunofluorescence:
° Fluorescence signal is quenched when the fluorochromes are in close proximity.
° Dyes undergo photo bleaching when subjected to light and will thus only fluoresce
for a limited time unless stored in the dark.
° Even when stored protected from light, some fluorochromes will deteriorate slowly
at room temperature.
° The morphology viewed in slides is different from what is observed in
immunoenzyme staining with counterstains.
° Increased background due to autofluorescence can pose a problem when
working with some formalin-fixed tissues.
° Leaching of stored antibody conjugates may pose a problem.
In spite of these drawbacks, immunofluorescence gives clear, sharp localization

of targets and has advantages over chromogenic dyes when working with co-
localized targets.
Some chromogenic dyes fluoresce as well, such as Fast Red, an AP-substrate that is
brighter in fluorescence microscopy than in bright field microscopy.
66
Other Labels
Colloidal gold-labeled antibodies were developed originally for electron microscopy,
but with silver-enhancement they are visible with normal light microscopy.
Another example of inorganic stains is Quantum dots (Q-dots). These are fluorescent
nanoparticles with varying emission wavelengths, depending on the size of the particle.
They can be linked to antibodies or streptavidin as an alternative to fluorochromes (6).
However, the size of their conjugates may pose diffusion problems.
Automated Image Acquisition and Analysis

Digital image analysis will increase the number of usable dyes since it does not rely on
the human eye for detection and differentiation. A digital image is acquired at excitation
wavelengths relevant for the dyes applied, and separate detectors record individual
colors. So, for example, digital image analysis will allow the combination fluorescent
and immunoenzyme dyes.
Detectors, however, have biased color vision. They amplify colors differently than does
the human eye. Therefore dyes used on image analysis should be optimized for the
best possible fit with the detector’s filter properties.
Image analysis systems contain algorithms that allow compensation for overlapping
emission spectra comparable to flow cytometry. They also allow signal gating within an
interesting range of wavelengths, enabling users to see only signals within the desired
range. Visualizing a combination of several gates with color selected independently of
the dyes used for staining may clarify pictures and make conclusions easier to reach.
This also makes it possible to set a threshold on signal intensity to exclude unspecific
staining or background from final images.
Another advantage of digital image analysis is that it allows signal quantitation. Through
software manipulation users, can count how many signal clusters exceed a certain level
of intensity, and, potentially, calculate the ratio of different cell-types. For example, an
image analysis algorithm can calculate the percentage of cells that stain positive for a
certain target, combine that percentage with information of other stained targets and,
based on this, highlight diagnosis.
Conclusion
Multiple-target staining will one day be as routine as single-target staining is today.
Use of the technique will expand, since it offers reduced turn-around time and
information not obtainable from single-target staining. Availability of labeled primary
antibodies, antibodies raised in different host species and multiple staining kits also is
likely to increase.
Software for automated image acquisition and analysis will play a key role in this
evolution since the limit to how many colors the human eye can distinguish will be
67
reached soon. Analysis algorithms will never entirely replace a skilled pathologist, but
algorithms will improve gradually as the amount of information loaded into underlying
databases increases. Eventually algorithms will become sufficiently “experienced” to
be able in many cases to suggest a diagnosis, and only the final decision will be left
for the pathologist.
Figure 9.1. Sequential doublestaining method performed with the EnVisionTM G|2 Doublestain Kit * using polyclonal
anti-kappa (red) and polyclonal anti-lambda (brown) as primary antibodies. Formalin-fixed paraffin-embedded section
from tonsil.
68
Figure 2. Sequential doublestaining method performed with the EnVisionTM G|2 Doublestain Kit * using monoclonal
anti-CD3 (red) and monoclonal anti-CD20 (brown) as primary antibodies. Formalin-fixed paraffin-embedded sections
from tonsils.
References
1. Mol Molinié V et al. Modern Pathology 2004;17:180-90.

2. Van der Loos CM Immunoenzyme Multiple Staining Methods, BIOS Scientific Publishers
Ltd 1999.
3. Chaubert P et al. Modern Pathology 1997;10(6):585-91.
4. Van der Loos CM and Göbel H J Histochem Cytochem 2000;48(10):1431-7.
5. Mason DY et al. J Pathol 2000;191:452-61.
6. Wu X et al. Nat Biotechnol 2003;21(1):41-6.
Footnote
* A proprietary methodology developed by Dako.
69
70
Chapter 10 ° Ancillary Methods in Immunohistochemistry
Gale E. Pace
Introduction
Ancillary reagents in immunohistochemistry are supplemental components –
peripheral elements that maximize quality and reliability. This chapter covers these
components, overlapping topics from other chapters, but addressing them from a
different perspective.
These reagents are subordinate to the main reaction of an antibody with its target
epitope. They include some of the following components: Protein blocks, endogenous
enzyme blocks, avidin/biotin reducing agents, chromogen enhancers, antibody diluents,
enzymatic epitope retrieval solutions, wash buffers and water. Understanding the effects
of each type of reagent when used independently or in conjunction with other ancillary
reagents is crucial to obtaining the desired results.
Enzymatic epitope retrieval is defined as a method used to relax the rigidity of the protein
structure that results from the cross linkages of formalin fixation. Proteolytic enzymes are
used in an attempt to restore the immunodominant structure in the epitope of interest.
This method makes an epitope available to associate with its antibody. As noted in the
antigen retrieval chapter, the retrievable epitopes may be associated with Schiff bases,
while the methylene bridges are considered irreversible to maintain structural integrity.
Proteolytic enzymes are thought to cleave proteins at specific locations depending on
the specificity of the enzyme. If cleavage points are in proximity to a cross-link, then the
resulting effect is a relaxation of the rigid protein structure facilitating contact between
the primary antibody and the corresponding antigenic determinant.
71
&QJUPQFDBQQFECZGPSNBMJO
&QJUPQFCMPDLFECZGPSNBMJO
XJUI4DIJGGCBTFSFBDUJPO
NFUIZMFOFCSJEHF
)
/ $ )
$
)
) "OUJHFO
"OUJHFO 1FQUJEF
1FQUJEF
1IPTQPMJQJET
Figure 10.1. Chemical illustration of a cell membrane, demonstrating the differences between a methelyne bridge and an epitope that has been fixed with a Schiff base.
72
Ancillary Methods in Immunohistochemistry
Several enzymatic solutions contribute to IHC, as illustrated in the chart below. Each
enzyme responds to a specific amino acid sequence. Since the specific cleavage sites
are usually unpredictable, the procedure is not always successful and sometimes results
in the loss of certain epitopes. Typically enzymatic digestion doesn’t affect epitopes
with high carbohydrate content. However, it can be appropriate for glycoprotein-rich
targets, such as the epitope for glucagon immunoreactivity in certain tumors (1).
Theoretically, conditions and enzymes used for unmasking could be different for
each antigen. For example, proteinase K may be required to unmask an epitope for
primary antibody cytokeratin AE1/AE3 but it may alter a CD20 epitope. Proteinase K
is an effective proteolytic enzyme, however, it has proven to be less selective than
protease XXIV for retrieving certain epitopes. Analysis through preliminary experiments
should be done to determine incubation times, temperatures, morphological effect and
concentrations of enzymes for proper optimization.
The optimal temperature for most proteolytic enzymes used for IHC is about 37 °C.
However, lower temperatures are possible and in some cases are preferable because
they allow a greater degree of control over the digestive process.
Table 10.1 shows several enzymatic reagents and their incubation conditions that have
been used successfully in IHC.
Table 10.1. Enzymatic reagents and their incubation conditions.
Enzyme Approximate activation temperature Incubation time in minutes

or range in ° Celsius
Proteinase K 25-37 5
Trypsin 37 10
Pepsin 37 5–20
Protease XXIV 37 5–10
Pronase 25-37 30
NOTE: Formalin does not preserve tissue proteins by coagulation but it is thought to form cross links with basic
amino acids. Ethanol and mercuric chloride-based fixatives are based on coagulation. With few exceptions retrieval
should not be performed on ethanol fixed tissues. It should only be conducted with limited controlled protocols in
mercuric–chloride-based fixatives.
73
Endogenous Enzyme Blocks

This block is an inhibitor that prevents an enzyme that originates within a cell or tissue
from causing a reaction with another substance (substrate).
The development of immunohistochemistry detection systems was founded on the

principle of enzyme-substrate reactions. Specifically, this is done to convert colorless
chromogens into colored end products for visualization. However, certain types of
cells have endogenous enzymes that can convert colorless chromogens to colored
end products, independent from detecting the antigen antibody complexes producing
false-positive results.
There are two common enzymes that effect most IHC clinical applications: Horseradish
peroxidase and alkaline phosphatase.
Table 10.2. Endogenous enzymes found in a variety of cells and tissue types.
Enzyme: Peroxidase Enzyme: Alkaline Phosphatase*

Placenta
Red Blood Cells
Intestine - situated between cellular components of mucosa
Granulocytes Proximal tubules of kidney
Eosinophils Osteoblast in bone
Hepatocytes Arterial & capillary endothelial cell surfaces
Muscle Stromal reticulum cells
Kidney Neutrophils
Monocytes Follicle and mantle zones in most lymphoid tissue
*Alkaline Phosphatase is destroyed by routine fixation and paraffin-embedding procedures.

4
4
4
4
4
4
4 4
4 4 4
4 4 4 4 4
4 4 $FMM 4 4
4 4 4 4 4
4 4 4
4
4
4
4
4
4
4
4
Cell with Endogenous Enzyme Enzyme Substrate Complex
Figure 10.2. Illustration of a cell with endogenous enzyme and enzyme substrate complex. Enzymes inhibited by excess
substrate are rendered inactive and are unable to respond to chromogens. These enzymes are considered “blocked,”
meaning that the substrate has become an inhibitor.
74
Table 10.3. Common endogenous enzyme blocking reagents for horseradish perioxidase and alkaline
phosphatase systems.
Dual endogenous enzyme block, Dako code S2003 HrP and AP Labels
Hydrogen peroxide Horseradish peroxidase label

Levamisole + chromogen except intestinal alkaline
Alkaline phosphatase label
phosphatase
Weak acid (0.3 N HCl), including Alkaline phosphatase label
intestinal alkaline phosphatase
Figure 10.3. Figures 10.3a and 10.3b: Endogenous peroxidase reaction.
E E E E E E E E E E E
Figure 10.3a. A typical IHC HrP detection reaction, showing a primary antibody (green) binding to its target
antigen (blue) without an endogenous enzyme block or DAB substrate.
$ISPNPHFO
$ISPNPHFO
$ISPNPHFO
$ISPNPHFO
$ISPNPHFO
$ISPNPHFO $ISPNPHFO $ISPNPHFO

$ISPNPHFO $ISPNPHFO $ISPNPHFO $ISPNPHFO $ISPNPHFO $ISPNPHFO $ISPNPHFO
& & & & & & & & & & &
Figure 10.3b. A typical IHC HrP detection reaction with added DAB (brown) in the presence of peroxidase.
75
Figure 10.4. Figures 10.4a, 10.4b, and 10.4c: An example of a teaction using an endogenous enzyme block.
4
Figure 10.4a. Substrate (gray) responding to enzyme in an endogenous peroxidase reaction.

4
4
Figure 10.4b. Substrate (gray) responding to enzyme in an endogenous peroxidase reaction, with the addition of a
primary antibody and detection.
$ISPNPHFO
$ISPNPHFO $ISPNPHFO
r
$ISPNPHFO
$ISPNPHFO
4
Figure 10.4c. Substrate (gray with red blocked circles) responding to enzyme in an endogenous peroxidase reaction,
with the addition of a primary antibody, detection and chromogen (brown). Red blocked circles indicate that chromogen
only reacts to uninhibited enzymes on the detection system.
76
Figure 10.5. Example of endogenous peroxidase in RBC of Kidney with DAB.
Figure 10.6. Example of endogenous alkaline phosphatase in ileum with Permanent Red.
77
In rare instances, the enzyme-blocking reagent may alter a specific epitope. It then
may be appropriate to apply the primary antibody prior to the enzymatic block to
insure its reaction. In such cases the blocking reagent can be applied at any point after
the primary and before the enzyme-labeled components. Endogenous peroxidase,
pseudo-peroxidase and alkaline phosphatase activity should be quenched
when enzyme conjugated detection systems are utilized for visualization methods
with chromogens. Omitting this vital protocol step may result in unwanted
chromogenic reactions.
Protein Blocks
These are reagents used to reduce the chances of nonspecific reactions of an antibody
with components other than its target antigen.
Figure 10.7. Figures 10.7a, 10.7b, and 10.7c: Example of a protein block
&OEPHFOPVT *SSFMFWBOU1SPUFJOT
1SPUFJO
&O[ZNF 5BSHFU"OUJHFO
E E E E E E
Figure 10.7a. Tissue prior to protein block application, showing endogenous enzyme and irrelevant proteins (black) and
target antigen (blue).
4
4
4
1SPUFJO#MPDLJOH3FBHFOU
E E E E E E
Figure 10.7b. Endogenous enzyme block has been added, followed by protein block. Protein block should not be rinsed off.

4
4
4
1SPUFJO#MPDLJOH3FBHFOU
E E E E E E
Ag
Figure 10.7c. Primary antibody has been added. Its high affinity for the antigen overpowers the attraction of the protein
block. The protein block masks irrelevant sites with less affinity.
78
A primary antibody’s high affinity for the antigen will displace the low affinity of the protein
block. Within any given tissue, highly charged molecules exist as normal components.
These molecules may not be the target antigen of a given immunohistochemical protocol.
When applying a primary antibody, if the target antigen is present, the primary antibody
will bind to it, resulting in an immunospecific reaction. However, in circumstances where
the tissue has not been adequately blocked the primary antibody also may combine
with non-target sites, resulting in a non-immunospecific reaction. If this happens, the
secondary antibody also will bind, leading to background staining.
Antibody Diluents
These are inert fluids or reagents used in immunohistochemistry to dilute a particular
antibody stock solution for the purpose of preparing a working antibody reagent.
Ionic interactions are one of the primary forces controlling immunochemical interactions
between antigens and antibodies. Buffers near physiological pH (pH = 7.0-7.2) are
normally utilized for dilution of primary antibodies. Diluents can have different isoelectric
points. The isoelectric point (pI) is the pH value at which the net electric charge of a
molecule in a solution is zero. The pI for immunoglobulins can range from 5.8 to 8.5 so
diluents can cause a net negative or positive charge on antibodies resulting in specific
and nonspecific reaction (2).
"OUJCPEZ "OUJHFO
0
$) 0) $$)$) )ZESPHFOCPOET

/)
0
$)$)$)$)/) $ $) *POJDJOUFSBDUJPOT
0
$)
$)
$)$) $) $) )ZESPQIPCJDJOUFSBDUJPOT
$) $)
$)
$) $) $) $) $) 7BOEFS8BBMTGPSDFT
$) $)
Figure 10.8. Antibodies are attracted to antigens initially through electrostatic, and subsequently Van Der Waals
and hydrophobic interactions. The illustration below shows the importance of pi and how it influences spatial
complementarities. If the pH of the environment is close to pi, the immunoreactivity can be impaired.
79
0 0
0 0 )
*GUIFEJMVFOUQ) -$ -
$ +
JTMPXFSPSIJHIFS +
+
- -+ UIBOUIFQMUIF - -
DBOIBWFB
+ OFUQPTJUJWFPS
OFHBUJWFDIBSHF
) ) / /
/ / ) )
) ) )
) ) )
- + -
+
-
+ -
Figure 10.9. If the overall ionic strength of the environment is varied, it can alter the 1° conformation and/or the ionic
interactions, allowing nonspecific binding of the primary to charged components, as well as no reaction with the intended
epitope with negative results.
Antibody diluents purchased from manufacturers can provide stability to the working
primary antibody solution.
Some of the choices available include:

° Antibody diluent with standard Tris HCl, detergent and stabilizers.
° Antibody diluent with background reducing components (bovine serum albumen,or
normal serum, or other proteins).
Beware of diluents with normal serum components:

° Can nonspecifically bind with secondary antibodies resulting in false positive results.
° Can cause a reduction in sensitivity of the primary antibody.
Because of numerous unknown factors influencing the overall stability of diluted
antibodies there is little room for a general and safe recommendation for how long a
diluted antibody is stable.
Technicians are advised to follow proper quality control procedures for validation if
diluted primaries are utilized for extended periods of time.
An advantage to using commercially diluted primary antibodies is the built-in customer

protection provided by regulatory mandates. Manufacturers must demonstrate stability in
commercially produced reagents for a set period of time, with the antibodies subjected
to real-time shelf-life quality control and accelerated shelf-life studies through controlled
heating processes. However, manufacturers are required only to certify the time period,
and antibodies actually may retain immunoreactivity for a longer period of time. There
80
is no requirement for manufacturers to continue testing until the antibody looses

activity. For some commercial reagents, manufacturers add sufficient preservatives to
maintain viability of concentrated or ready-to-use antibodies for 12 to 18 months. CLIA
88 and CAP regulations in the United States allow laboratories to document antibody
activity until an antibody has entirely lost its immunoreactivity based on good quality
control practices.
Other Important Points about Diluents

° Antibody diluents’ effectiveness can be a direct function of its pH.
° High concentrations of sodium chloride or azides are used frequently as
preservatives, but can reduce antibody reactivity.
° Phosphate diluents can add to ionic strength, causing decrease in specific and
nonspecific staining.
° Stability of a diluted antibody can vary over time depending upon the dilution.
° Generally speaking, over time the more dilute the antibody, the less stable the
working solution.
° Refrigeration can cause changes in pH.
° Reagents must come to room temperature before use.
° Phosphate buffered saline (PBS) should not be used as a diluent unless
recommended by the manufacturer.
Table 10.4. Diluent factors that may affect antibody/antigen reaction.
Reagent Added component Subtracted component
Bovine Serum Albumin (BSA) Decreases nonspecific staining Increases nonspecific staining
NaCl May cause negative results Increases nonspecific staining
PO4 ions
If Tris HCl is used then specific
Phosphate Buffered Saline Increases nonspecific staining
staining
Tween 20 or Berol Decreases nonspecific staining Increases nonspecific staining
1% Normal Serum Decreases nonspecific staining Increases nonspecific staining
81
Wash Buffers
These are useful in immunohistochemistry for removing excess or unwanted reagents
or complexes formed during each step. Common wash buffers commercially available
include Tris Buffered Saline (TBS) and Phosphate Buffered Saline (PBS). Both have
their benefits and pitfalls depending on the conditions encountered.
Tris Buffered Saline

Tris(hydroxymethyl)aminomethane is utilized in IHC to help reduce the effects of
nonspecific staining, because of its stability and chemical properties when combined
with sodium chloride (NaCl), Tween 20, and 0.01% sodium azide.
Pure Tris, and the crystalline hydrochloride salt of Tris, have little if any buffering
capacity when in solution independently. But mixing the two compounds together will
produce a range of pH’s with buffering capacity ranging from a pH of 7.0-9.0. The
pH values of all buffers are temperature and concentration interdependent. As the
solution decreases in temperature, pH increases at a rate of approximately 0.03 units
per degree centigrade.
When conditions require a higher specificity due to a selection of more sensitive

detection methods, the saline and detergent content can be increased to minimize
the potential of non-specific binding of reagents. A dilution of 0.05% Tween 20 can
be used to reduce the effects of nonspecific labeled polymer attachments. As an
example, Table 10.5 describes the differences between two Dako wash buffers, S3006
(recommended for general IHC procedures) and S3306 (recommended for high-
sensitivity IHC procedures).
Table 10.5. Wash buffer comparison.
Standard Tris Buffered Saline, Dako Code S3006 High Salt Tris Buffered Saline, Dako Code S3306
150mM NaCl 300mM NaCl
0.05% Tween 20 0.1% Tween 20
pH 7.6 at 25 °C pH 7.6 at 25 °C
82
Chapter 10, Figures 10.10a and 10.10b. Human prostate tissue with Cytokeratin 34BE12, Dako Code M0630,
demonstrating differences in nonspecific staining results when standard or high-salt rinse buffers are used.
Figure 10.10a. Cytokeratin 34BE12, Dako Code M0630, on human prostate tissue, rinsed with 150mM NaCl 0.05%
Tween 20 Tris Buffered Saline, Dako Code S3006, pH 7.6 at 25 °C.
Figure 10.10b. Cytokeratin 34BE12, Dako Code M0630, on human prostate tissue, rinsed with 300mM NaCl 0.05%
Tween 20 Tris Buffered Saline, Dako Code S3306, pH 7.6 at 25 °C. 83
Table 10.6. Effects of temperature on pH of Tris buffered saline.
Temperature in °C pH
5 °C 8.18
25 °C 7.6
37 °C 7.30
Phosphate Buffer Saline (PBS)

This has a long history in IHC and still is used in certain applications where specified
by protocol (kidney biopsies, direct skins, Aspergillus). PBS is better at reducing auto
fluorescence in immunofluorescent assays than Tris buffer, and is inexpensive to make.
However, it can cause a higher incidence of nonspecific staining, producing primary
antibody shielding, and subsequently reducing specific binding capacity to the targeted
epitopes with certain monoclonal antibodies (CD30, for example).
Buffer Storage
Working solutions of Tris buffers generally are stable when stored at 25 °C for four
days. Commercially available wash solutions that come in concentrated configurations
generally can be stored at 2 °C to reduce bacterial growth and should be discarded
per expiration date to maintain reagent viability. However, highly concentrated buffers
may form crystals due to lower solubility at cold temperatures. Therefore the stock buffer
solutions stored in the cold should be inspected carefully before use. Crystals forming
in stock solutions generally will re-dissolve upon warming to room temperature.
Measuring pH of Buffers
When measuring pH of Tris buffer, the electrode used should be of appropriate type
such as Glass-Calomel (mercurous chloride). Silver/silver chloride reference electrodes
with Tris buffers containing protein may cause spurious results. Strict guidelines should
be enforced to insure proper utilization of laboratory reagents, thereby giving more
consistent and reliable results.
NOTE: Technologist should be mindful to keep accurate records of pH values prior to using a wash
buffer. These records should be observed for trends of increasing or decreasing pH values. Use
appropriate pH probe for the respective buffers. pH should be recorded at room temperature 25 °C.
84
Twenty-Day Validation Protocol

During a 20-day validation period of a primary antibody and staining system, measure
and record the pH of buffers used in the protocol. Retain those values where acceptable
staining is observed.
NOTE: If using a pre-set Tris buffer, such as commercial Tris buffered saline (TBS), these values should
remain constant (at 25 °C). At the end of 20 days, calculate the standard deviation or dispersion of a set
of values from the mean (3).
The following is a suggested method for measuring pH:

° Calculate the mean of the 20 values.
° Subtract each sample value from the sample mean and square the product.
° Total the squares.
° The square root of the summed squares gives a standardized value or standard
deviation (SD).
° Multiply the standard deviation by two.
° Subtract 2SD and add the initial mean. This will produce a range of acceptable
values.
Table 10.7. The Levy Jennings Chart. May be useful in recording pH values.
The Levy Jennings Chart may be useful in recording the pH values:
2SD___________________________________________
1 SD_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Mean__________________________________________
1 SD_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
2SD__________________________________________
NOTE: Two standard deviations from the mean is sufficient for acceptable ranges in pH.
85
Suggestions for Making Wash Buffer Solutions

° Do not add old wash buffer to new wash buffer.
° Make fresh buffer according to manufacturer’s specifications.
° Do not dilute reagents beyond the recommended dilution.
° Place a label on all solution containers when they are opened.
° Write your initials and the date that the solution was opened on the label.
° Do not mix different types of buffers.
° Make buffer with either distilled, organically filtered deionized, or reagent grade
water. Do not use tap water.
Antimicrobials such as chloramines, in tap water as well as unfiltered deionized water can
remove buffering effects of Tris buffer in particular, contributing to nonspecific staining
and creating harmful byproducts such as methane, hydrazine, and formaldehyde.
Chromogen Enhancers
These are considered a color modification process, and should be considered as a
separate chromogen in the grading system.
Technically, DAB enhancers contain compounds that continue the DAB reaction,
allowing for further enhancement. Enhancers should be applied immediately after
rinsing slides with reagent grade or filtered, deionized water.
Incubation times are determined by the individual laboratory, based on the desired hue
of the chromogen. The end product will be deeper chocolate-brown color. Enhancers
require the presence of the original reaction and should not turn a non-reactive stain
result into a positive result – it only works with what already is deposited.
Enhancers are usually heavy metals, which continue the reduction process with
elements such as copper, silver, nickel, gold, or cobalt. Some studies show that if the
diaminobenzadine reaction is stopped with tap water instead of reagent-grade water,
a gold color develops.
86
Figure 10.11. Examples for various DAB enhancements.
Figure 10.11a. Figure 10.11b. Figure 10.11c.

No enhancement (Di water) Tap water enhancement Enhanced with Dako DAB Enhancer
References
1. Yokoo H, Nakazato Y. A monoclonal antibody that recognizes a carbohydrate epitope of
human protoplasmic astrocytes. Acta Neuropathol 1996;91:23-30.
2. Boenisch T. Article of Applied Immunohistochemistry and Molecular morphology
1999;7:(4).
3. Henry JB, M.D. Clinical Diagnosis & Management by Laboratory Methods; 18th Edition,
WB Saunders Company, Philadelphia, PA 991;1:89-91.
87
88
Chapter 11 ° In Situ Hybridization
Richard Harvey, Updated by Andreas Schønau
Introduction
In situ hybridization is a powerful technique for detection of nucleic acid sequences. It
allows the user to detect the presence of specific targets inside individual cells while
preserving cell and tissue morphology. This allows for simultaneous assessment of the
morphological alterations associated with the lesion and highly detailed information on
the genetic composition of the cells.
The technique has developed significantly over the last decades. Different kinds of
probes and labeling have been developed to accommodate the very different needs
of the relevant targets and patient samples. The following section addresses some of
the most relevant probes and labels, and provides a few clinically relevant examples of
how in situ hybridization is being used to answer important clinical questions.
Types of Probes
DNA
DNA probes are still the most frequently used type of probes both in clinical and
research laboratories. This is true for a variety of reasons. First, they are relatively
easy to make in large quantities, either by synthesis or growth in a vector. Secondly,
they are the best characterized. The kinetics and properties of DNA probes are better
understood than RNA or Peptide Nucleic Acid (PNA) probes (see below). Thirdly, the
advent of nucleic acid amplification techniques such as Polymerase Chain Reaction
(PCR) has increased their availability greatly. Finally, DNA probes can come in all sizes
(from short oligonucleotides to megabase constructs).
RNA
RNA probes are not used quite as frequently as DNA probes, although they do have
their own niche applications. Often referred to as “riboprobes,” these are single-stranded
materials that typically are synthesized from a vector via an RNA polymerase. Some
of their advantages are that they are already single stranded (for example, need no
initial denaturation) and they hybridize slightly better to DNA targets than their DNA
counterparts. Their sizes range from short oligonucleotides to several kilobases.
Riboprobes larger than a couple of kilobases are uncommon. One of the principal
disadvantages to RNA probes is their inherent instability due to the ubiquitous presence
of RNAses. RNAses are quite abundant in the environment and are extremely difficult
to inactivate.
89
PNA
PNA probes are the newest members of this category (1). PNAs can have the
same bases as DNA and RNA probes; however they are joined by a backbone of
amide linkages (like proteins) instead of the sugars and phosphates of DNA and
RNA. The end result of this modified structure is that, while the bases still conform
to Watson-Crick base bonding rules, the kinetic properties are much different.
PNAs tend to hybridize much more rapidly than their DNA counterparts do and they
are also quite effective at discriminating single-base mismatches. PNAs are also very
useful in hybridizing to regions that are involved in extensive secondary structure.
The primary disadvantages of PNA probes are that their properties are not yet as
well understood as DNA oligonucleotides and their solubility is much lower than a
corresponding DNA. They are typically quite short (usually less than 30 bases) and
presently must be made synthetically.
Probe Length
The length of a probe is highly dependent upon the application for which it is intended.
Consider both the high and low extremes of probe size. An oligonucleotide of just 16
bases is statistically large enough to be unique in the human genome if the 3.2 x 109
bases of the human genome can be assumed to be comprised of random sequences.
While the genome is most certainly not made up of completely random sequences, this
is still a useful number for starting probe design. Sequences of less than 16 bases are
quite likely to occur multiple times, whereas those larger than 16 bases have a better
chance of being unique.
On the opposite end of the spectrum, large probes also have limits. Because of the
repetitive elements found throughout the genome, the larger a probe becomes, the
more likely that it contains some form of repeat. Additionally, for ISH experiments it is
important that the probe be sufficiently small to make it through the cellular scaffolding
and reach its target. Although this size limit is debatable, generally an upper limit of
approximately 500 bases is considered acceptable for ISH. Probes larger than this are
typically fragmented (sonication or enzymatically) down to this size.
Types of Labels
The purpose of introducing a label on the probe is to allow for subsequent detection
of the probe, thereby retrieving relevant information on target localization and target
abundance. Direct fluorescence in situ hybridization (FISH) requires the use of probes
labeled directly with fluorescent molecules, while other in situ hybridization techniques
normally make use of secondary molecules to translate the primary label into a
visual signal.
Directly labeled FISH probes can be detected immediately after hybridization and
stringent wash. The fluorescent labels are instantly detectable and are normally
compatible with standard fluorescence microscopes. Labels typically include red
90
In Situ Hybridization
and green fluorochromes, but others are also available. The number of different
fluorochromes that can be used in the same assay depends on the configuration of
the fluorescence microscope including the filters. As the method does not include any
amplification steps, directly labeled FISH probes are normally fairly large (> 100,000
bp) or target repetitive regions.
Probes for ISH applications usually are detected by use of secondary molecules. The
primary label, which could be any hapten (including fluorescent molecules), is attached
to the probe and recognized by a secondary molecule – normally an antibody or
streptavidin. The secondary molecule can be either directly detectable, for example, a
fluorescent label; be conjugated to an enzyme for chromogenic detection; or form the
basis for further amplification steps, depending on the required level of sensitivity.
Types of Samples
The term in situ means “in the normal place.” This means that in situ hybridization takes
place in the cell where the target DNA or RNA is normally present. Cells normally are
handled by placing them on a glass slide, and basically any collected cell sample that
can be applied as a mono-layer on a glass slide also can be hybridized.
Cytology samples are intact cells from a liquid sample that are spread on a slide.
Fixation is usually fairly mild, and the hybridization procedure includes steps like fixing
cells to the slide, applying the probe mix, denaturing probe and specimen, hybridizing
and conducting a stringent wash to remove excess probe. Cytology samples include
hematological samples, lavage samples, cervix smears, etc. DNA and RNA are usually
well-preserved in these kinds of samples, provided that fixation has occurred shortly
after extraction of the sample
Tissue samples are typically either frozen or embedded in paraffin, and both can
be used for hybridization assays. Formalin-fixed and paraffin-embedded tissue is
very suitable for both DNA and RNA analyses, although the stability of RNA is very
dependent on the time span between extraction of the sample and fixation. Fixed and
embedded tissue requires pre-treatment similar to that for IHC methods, to allow for
efficient hybridization. As a consequence, the procedure typically includes steps such
as heat-induced target retrieval and/or enzymatic digestion of the tissue, prior to the step
mentioned for cytology samples above. Evaluation of a tissue sample is also different
from that of a cytology sample. This is mainly due to the high density of the material
and the fact that preparation of tissue samples includes cutting of cells, resulting in
fragments of cells and nuclei on the slide. This affects the scoring algorithms that can
be applied, especially when enumerating nuclear targets.
91
Examples
Split-Signal FISH Probes for Detection of BCR-ABL Translocation in Acute

Lymphoblastic Leukemia (ALL)
A hematological sample is spread on a glass slide and fixed. A probe mix containing
a red probe and a green probe located on either side of the BCR breakpoint region on
chromosome 22 is applied. Sample and probe are denatured and the probe is allowed
to hybridize overnight before a stringent wash is conducted to remove excess probe. The
slide is dried and mounted using fluorescence mounting media containing an anti-fade
agent such as diamidino phenylindole dihydrochloride (DAPI). Results are evaluated
using a fluorescence microscope. A normal cell will have two sets of co-localized signals
corresponding to the normal situation in which no translocation has occurred, and the
red and the green probe will bind in close proximity on the intact chromosome. When
viewed microscopically the two probes appear to co-localize, which produces a yellow
color. Translocated cells will have one set of co-localized signals corresponding to the
normal allele, and one set of split signals. A split signal indicates that the two probes
have been separated physically as part of the translocation process. For this reason
the probes are no longer co-localized, and the resulting split can be identified easily
as individual green and red signals by means of a fluorescence microscope.
Assessment of HER2 Gene Amplification Status in Breast Cancer

A formalin-fixed, paraffin-embedded tissue is cut into sections of four to six µm and
placed on a glass slide. After deparaffinization and rehydration, specimens are heated in
pre-treatment solution for 10 minutes. The next step involves a proteolytic digestion using
ready-to-use pepsin at room temperature for five to 15 minutes. Following the heating
and proteolytic pre-treatment steps, a probe mix including a Texas Red-labeled DNA
probe covering the HER2 gene on chromosome 17, and a mixture of fluorescein-labeled
PNA probes targeted at the centromeric region of chromosome 17 (CEN-17) is applied.
Sample and probe are denatured and the probe is allowed to hybridize overnight. After
a stringent wash the specimens are mounted with fluorescence mounting medium
containing DAPI, and coverslipped.
Results are evaluated using a fluorescence microscope and the number of HER2 (red)
and CEN-17 (green) signals in 20 nuclei are counted. Finally the ratio of HER2 to CEN-17
signals is calculated and compared with the cut-off for amplification. A value of greater
than 2.0 is indicative of amplification.
Amplification of the HER2 gene and/or overexpression of its protein have been
demonstrated in 25 to 30 percent of breast cancers. This up-regulation is associated
with poor prognosis, increased risk of recurrence, and shortened survival. Several
studies have shown that HER2 status correlates with sensitivity or resistance to certain
chemotherapy regimens (2).
92
In Situ Hybridization
Demonstration of high HER2 protein overexpression or HER2 gene amplification

is essential for initiating therapy with Herceptin™, a monoclonal antibody to HER2
protein. Clinical studies have shown that patients whose tumors have high HER2 protein
overexpression and/or amplification of the HER2 gene benefit most from Herceptin™ (1).
Detection of High-Risk HPV Infections in a Cervical Smear

A cervical smear is spread on a glass slide and fixed. A cocktail of biotin-labeled DNA
probes targeting 13 different HPV genotypes associated with poor prognosis is applied.
Sample and probe are denatured and the probe is allowed to hybridize. Following
a stringent wash, the probe is detected by use of the GenPoint™ Tyramide Signal
Amplification System, resulting in clear and distinct precipitation of DAB chromogen at
the localization of the probe. Results are visualized using a light microscope.
Presence of a signal indicates the presence of either episomal or integrated viral
DNA. The appearance of the signal (allows the microscopist to distinguish between
the episomal (confluent) and integrated (punctuate) forms of the viral target DNA. The
intensity of the signal may reflect the copy number of the viral target.
HPV DNA testing may reduce health care costs by triaging patients into appropriate
management strategies such as replacing some unnecessary colposcopies with regular
screening in low-risk patients. The clearest role for HPV DNA testing is to improve
diagnostic accuracy and to limit unnecessary colposcopies in patients with borderline
or mildly abnormal cytologic test results (4).
Conclusion
There are numerous probes, along with methods for their labeling. This leaves
opportunities for optimal design to a specific desired application. Regardless of
steps taken toward optimizing probe performance, specimen processing and sample
pretreatment remain two of the largest sources of variability in assay performance and
have to be standardized to ensure consistent results.
Compared to other nucleic acid detection techniques, in situ hybridization is a powerful
tool, allowing for low-level detection of specific nucleic acid targets inside individual cells
while preserving morphology. This technology undoubtedly will lead to the development
of new tests for genetic markers, provide an expanded role for ISH in clinical testing,
and improve patient management.
References
1. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim
SK, Norden B, Nielsen PE. PNA hybridizes to complementary oligonucleotides obeying
the Watson–Crick hydrogen-bonding rules. Nature1993;365:566-8.
2. Nichols DW, Wolff DJ, Self S, Metcalf JS, Jacobs D, Kneuper-Hall R, Cate JC. A Testing
Algorithm for Determination of HER2 Status in patients with Breast Cancer. Annals of
Clinical & Laboratory Science 2002;32 (1):3-11.
93
3. Bilous M et al. Current perspectives on HER2 Testing: A Review of National Testing

Guidelines. Mod Pathol 2003:16:173-182.
4. Burd EM. Human Papillomavirus and Cervical Cancer. Clin Microbiol Rev 2003
January;16(1):1–17.
94
Chapter 12 ° Methods of Immunocytology
for Slide-Based Cellular Analysis
Marc Key
Introduction
Cytological examination of single cells and small groups of cells provides a wealth
of diagnostic and prognostic information to laboratory professionals with specialized
training in deciphering complex morphological information (1, 2). These interpretations
usually are based on the characteristics of cells stained with a variety of organic
and inorganic dyes that can highlight differentially various cellular and subcellular
components. Immunocytology adds an additional dimension to cytology by further
providing the means for molecular analysis. By employing specific antibodies that target
well-characterized molecular targets, it is possible to combine molecular analysis with
subcellular analysis (3-6).
Many of the methods of immunocytology derive from the general methods of

immunohistology, where whole tissue samples are analyzed by specific antibody
probes. Despite these similarities there are critical distinctions between the analysis
of isolated cellular samples and whole tissue samples. An understanding of these
differences is crucial in achieving optimal immunocytochemical staining.
Procedures
Sample Collection
There are three primary methods of sample collection, 1) collecting the sample into
a transport or collection medium containing a fixative, 2) collecting the sample into a
container without fixative, or 3) collecting the sample directly onto the microscope slide
in the unfixed state. The latter two methods are similar in that the cells are not initially
exposed to a fixative before being placed on the microscope slide.
Sample Collection with Fixative

Cytology samples may be collected directly into a medium containing fixative. This is
particularly true when using an automated monolayer preparation instrument where
this method of collection is required by the manufacturer. Although these methods
have been optimized for ease of collection, transport, and morphological analysis,
only a few studies have tested their compatibility with immunocytology (7, 8). Because
the manufacturer’s transport medium is proprietary, little information is available on
its effects in preserving epitopes for subsequent antibody staining. Many of these
transport media contain mixtures of ethanol and polyethylene glycol. Such fixatives are
95
generally compatible with immunocytology procedures, whereas fixatives containing

high amounts of methanol, isopropanol, or formalin may cause denaturation of certain
antigens thus producing weak immunostaining.
In order to ensure optimal immunostaining, samples collected into fixatives should be

processed and stained as soon as possible. Samples held up to 48 hours are suitable
for immunocytochemical analysis.
Sample Collection without Fixative

Samples collected without fixative should be processed and stained as soon as
possible. The following table provides a preferred schedule for sample collection,
processing, and staining.
Table 12.1. Schedule for processing cytology specimens.
Procedure Time from initial sampling
Cell smears Prepare slide immediately after sample collection
Cell imprints Prepare slide immediately after sample collection
Red blood cell removal Perform within 24 hours
Cell wash and resuspension Perform within 24 hours
Cell enrichment methods Perform within 24 hours
Preparation of monolayer Perform within 24 hours
Slide storage Up to 48 hours (room temperature)
Stain slides Perform within 48 hours
The optimal schedule requires that all steps up through preparation of the microscope
slide should be completed within the first 24 hours. All subsequent staining steps should
be completed within 48 hours.
Comparison of Pre-Fixed to Unfixed Specimens

The process of fixation renders the cell membranes rigid. If cells are fixed in suspension,
as is the case when cells are collected into transport medium, the cells retain their
three-dimensional shapes as free-floating cells. For squamous epithelial cells this
shape generally is elongated and flattened, whereas most other cell types, particularly
white blood cells and many types of tumor cells, retain a spherical conformation. When
these fixed preparations are deposited onto the slide, they tend to retain a rounded
appearance with densely staining nuclei and scant cytoplasm. In contrast, when cells
are applied to a microscope slide in the unfixed state, they tend to flatten and spread,
providing more nuclear and cytoplasmic detail. Thus the morphology of the same cell
type can be vastly different depending on how the sample was processed (9).
96
Methods of Immunocytology for Slide-Based Cellular Analysis
The choice of whether to fix before or after application of the cells to the slide depends
on the sample type, and also on the manufacturer’s requirements when using an
automated monolayer device. Both methods are compatible with antibody staining.
However, fixation after application of cells to the slide frequently provides better
morphological detail.
Sample Preparation
Microscope Slides
In order to ensure adequate cellular adhesion, the slides must be treated chemically to
promote cell adhesion. Positively charged slides or silanized slides are available from
several commercial sources and are preferred for immunocytology applications.
Application of Specimens to Microscope Slides

Cells may be applied to slides manually, using cell smear methods, or with the aid of
an automated monolayer device or cytocentrifuge. For automated methods, follow the
manufacturer’s instructions. After applying samples to the slides, the slides should be
either dry or nearly dry without excess liquid. Complete the process by rapidly air drying
any slides containing residual liquid. If slides storage is required before staining, store
slides in the unfixed state.
Slide Storage
Stain slides as soon as possible after preparation. If it is necessary to delay staining:
° Store unfixed slides at room temperature in a sealed container for no more than
24 hours.
° If a longer storage period is necessary, slides may be stored for up to seven days
at –20 °C or up to 30 days at –70 °C.
ß Individually wrap slides with two layers of aluminum foil, securely sealing all
seams. Special care is required to avoid scratching or otherwise damaging
the area of cellular deposition.
ß Place wrapped slides in a plastic bag, expel excess air, and seal bag.
ß Store at –20 °C to –70 °C.
ß When slides are removed for staining, first equilibrate slides to room
temperature for 30 minutes prior to removal from the plastic bag. In order to
prevent condensation on the unfixed cells, it is important that the slides reach
room temperature before unwrapping the aluminum foil.
ß Unwrap slides and proceed immediately to fixation and staining.
97
Fixation
The method of fixation is perhaps the most critical step in achieving optimal results.
For optimal morphology, strong fixation is preferred in order to preserve cellular
detail. In contrast for antibody staining, weak fixation is preferred in order to retain
protein molecules in their native conformation. The precise balance between these
two opposing requirements is critical for optimal staining. Fixatives containing ethanol
and propylene glycol commonly are used for cytology and are generally compatible
with antibody staining. A further consideration is that immunocytology procedures are
generally more harsh than standard cytology methods, making the balance between
over- and under-fixation particularly challenging. While the goal for immunocytology
is to achieve both acceptable morphology and high-sensitivity immunostaining, in
general practice morphology frequently is compromised in order to achieve the high
sensitivity of the latter.
Fixatives are divided generally into two categories depending on their mode of action.
Agents that combine with proteins are called additive fixatives, and agents that
precipitate proteins are called coagulating fixatives. Because of the harsh nature of
immunocytology, strong fixation is required in order to achieve optimal morphology.
A fixative combining both the additive properties of formalin and the coagulating
properties of ethanol provides an ideal solution. A general fixative for immunocytology
is given below:
General Fixative for Immunocytology

° 50 mL of absolute (100 percent) ethanol;
° 5 mL of 40 percent (w/v) solution of polyethylene glycol in deionized water;
° 5 mL of formalin from 37 percent formaldehyde stock;
° 40 mL of deionized water.
Fixation Procedure
The following procedure is applicable for all samples, whether or not they have been
pre-fixed.
° Place slides in fixative for 10 minutes at room temperature.
° Rinse briefly in buffered saline (phosphate-buffered saline (PBS), or Tris-buffered
saline (TBS).
° Proceed to staining, without allowing slides to dry.
98
Immunostaining Methods
Permeabilization and Antigen Retrieval

Cells must be permeabilized to allow antibodies and visualization reagents to penetrate
the cell membranes. A suitable permeabilization reagent can be prepared from a buffer
containing detergent.
Formalin is a cross-linking fixative that can denature epitopes by forming methylene

bridges. These cross-links may be broken, restoring the epitopes to their native
configuration, by applying heat. A suitable antigen retrieval reagent can be prepared
from a buffer containing detergent. A combined method of performing permeabilization
and antigen retrieval is outlined below.
Permeabilization/Retrieval Reagent
° 1.92 g Citric acid, anhydrous.
° Dissolve in 900 mL deionized H20.
° 0.1% Nonidet P40 (NP40).
° pH to 6.0 with concentration NaOH.
° Bring up to 1000 mL with deionized H20.
Procedure
° Place permeabilization/retrieval reagent into a Coplin jar and heat to 95 °C;
° Add slides to Coplin jar and incubate for five minutes at 95 °C;
° Rinse slides with buffered saline.
Blocking endogenous enzymes

Peroxidase and alkaline phosphatase are the two enzymes most frequently employed
in immunocytology. However, both of these enzymes occur naturally in a variety
of cells and tissues. In order to avoid false-positive staining, these endogenous enzymes
must be blocked prior to immunocytochemical analysis. Depending on the visualization
method either endogenous peroxidase or endogenous alkaline phosphatase must
be blocked.
Blocking methods for peroxidase generally employ solutions of hydrogen peroxide up to

three percent. However, for cytology specimens three percent hydrogen peroxide can
severely damage cellular morphology. Therefore weaker concentrations of hydrogen
peroxide containing sodium azide are recommended. Commercial blocking reagents
are available. However, the blocking reagent should specify that it is intended for use
with cytology samples.
99
Endogenous peroxidase blocking reagent

° 0.03% hydrogen peroxide in deionized water.
° 0.2% (w/v) sodium azide.
Endogenous alkaline phosphatase blocking reagent

° 0.1 N HCl in deionized water.
Procedure for blocking endogenous enzymes

° Incubate slides with endogenous enzyme blocking reagent for five minutes at
room temperature.
Antibody Preparation and Staining Methods

The antibody preparation and staining methods for immunocytochemistry are
similar to those previously discussed for immunohistochemistry. For a review of
immunohistochemical staining methods the reader is referred to Immunohistochemistry
Staining Methods, Chapter 7.
Controls
Positive Control
In every staining procedure a positive control must be run in order to establish the
proper performance of the staining reagents and methods. The most appropriate
positive controls are cytology samples containing known positive cells of interest. Once
a positive sample is identified it is possible to make a repository of positive slides that
can serve as future positive controls for up to two months. Positive control cell slides
can be stored frozen at -20 °C, as previously described, and used for up to two months.
After prolonged storage, a decrease in staining intensity frequently is observed. If
staining becomes noticeably weaker the slides should be discarded even if they are
less than two months old.
In the absence of appropriate cytology material, a tissue section containing known
positive elements may be used to verify the performance of the reagents. However, the
procedural elements of the protocol cannot be verified with tissue sections.
Negative Control
An appropriate negative control is performed on a second identical cytology sample
collected and prepared at the same time as the patient test sample.
An isotype-matched negative control reagent, diluted to the same concentration as the

primary antibody, is used in place of the primary antibody.
100
References
1. Nasuti JF, Tam D, Gupta PK. Diagnostic value of liquid-based (ThinPrep) preparations in
nongynecologic cases. Diagn Cytopathol 2001;24:137-41.
2. Leung CS, Chiu B, Bell V. Comparison of ThinPrep and conventional preparations:
Nongynecologic cytology evaluation. Diagn Cytopathol 1997;16:368-71.
3. Bedard YC, Pollett AF, Leung SW, O’Malley FP. Assessment of thin-layer breast aspirates
for immunocytochemical evaluation of HER2 status. Acta Cytol 2003;7:979-84.
4. Chieng DC, Ko EC, Yee HT, Shultz JJ, Dorvault CC, Eltoum IA. Malignant pleural
effusions due to small-cell lung carcinoma: A cytologic and immunocytochemical study.
Diagn Cytopathol 2001;25:356-60.
5. Dabbs DJ, Abendroth CS, Grenko RT, Wang X, Radcliffe GE. Immunochytochemistry on
the ThinPrep Processor. Diagn Cytopathol 1997;17:388-92.
6. Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: A contemporary review.
Cancer (Cancer Cytopathol) 2001;93:293-308.
7. Kaplan MA, Segura AM, Wang HH, Schnit SJ, Upton MP. Evaluation of CytoLyt and
PreservCyt as preservatives for immunocytochemistry for cytokeratin in fine needle
aspiration. Applied Immuhohistochem 1998;6:23-9.
8. Leung SW, Bedard YC: Immunocytochemical staining on ThinPrep processed smears.
Mod Pathol 1996;9:301-6.
9. Fetsch PA, Simsir A, Brosky K, Abati A. Comparison of three commonly used cytologic
preparations in effusion immunocytochemistry. Diagn Cytopathol 2002;26:61-6.
101
102
Chapter 13 ° Automating Immunohistochemistry
Ron Zeheb
Introduction
In today’s busy histology lab, an instrument to automate immunohistochemical (IHC)
stains has become almost as essential as a Hematoxylin and Eosin (H&E) stainer or
an automated coverslipper. Skilled histotechnologist time is too valuable to be spent
on hand pipetting, egg timers and ensuring moist incubation chambers, when effective
alternatives are readily available. IHC automation leverages technologist time, by having
an instrument perform the many reagent additions, incubations and washes. While the
instrument is running, the histotech who would otherwise tend the IHC, could help keep
up with the day’s routine workload by embedding, sectioning, and labeling slides.
Choosing the Right IHC Stainer

So what exactly is automated IHC, and how do you know if it’s right for your lab? In
essence, an automated IHC stainer is simply a robot that follows pre-programmed
instructions that mirror the steps that a skilled histotech would use when staining a slide.
Like any other critical piece of equipment that’s brought into the lab, the automated IHC
stainer should: 1) produce consistent, high-quality slides, 2) be robust and reliable, 3)
be cost effective, 4) be easy to use and maintain and 5) fit in well with the lab’s workflow
and reporting requirements.
A properly functioning and maintained instrument will perform its pre-programmed

instructions exactly the same way again and again every time it is run. This is one of the
great advantages of an automated system, and the principal reason why an instrument’s
slide staining consistency is typically superior to manually stained slides. The operator
of the instrument and the reagent manufacturers share responsibility for ensuring that
the primary antibodies, detection (visualization) reagents, and any washes or buffers
are made correctly and positioned on the instrument; are contamination-free; and are
used within appropriate expiration dates.
Because tissue handling and processing may vary widely from institution to institution,
prior to the routine implementation of any new IHC stain for clinical diagnostic use, the
user of an automated IHC stainer should verify that the staining results are appropriate.
Antibody titer and reaction conditions should be adjusted to achieve the desired
staining results, and the instrument should lend itself to making such modifications
when needed. With these simple prerequisites, the user of an automated IHC stainer
can expect consistent, high-quality slides every time. Some instruments are designed
to permit the user considerable flexibility in choice of reagents and staining protocol
design. That is, the user can choose the reagents they want, and program the reagent
additions and wash steps to produce the stain of their choosing. This approach is well
103
suited for a lab that is knowledgeable and comfortable with the IHC staining procedure
and desires a high degree of flexibility. Other instruments permit a more limited degree
of user-modification to the staining protocol, and typically little or no flexibility (other than
choice of primary antibody) to use other than instrument-matched detection reagents.
This may suit labs that prefer a more hands-off approach.
Maintaining Your IHC Stainer

With proper maintenance, most automated instruments can be expected to provide
many years of reliable service. You probably will be running your IHC stainer at least
once every day and in many cases two or three times per day depending on case-
load and work shifts. Once installed and operating, it’s easy to develop a dependence
on the instrument. Any unexpected interruption in the ability to use the instrument
can throw the entire lab’s schedule into turmoil. The best way to keep your stainer
humming along is to read, understand and follow the directions in the manufacturer’s
user’s manual. Make sure you pay attention to and follow recommended cleaning
and maintenance schedules. If something doesn’t look right or sound right, call the
manufacturer’s customer service department. An active approach might make the
difference between a simple, rapid fix and a complex, lengthy one. When shopping
around for a new IHC stainer, one of the criteria you may wish to consider when making
your selection is the manufacturer’s proven history of instrument reliability as well as its
commitment to customer support and service.
Economics of IHC Stainers

The cost to acquire and operate an automated IHC stainer varies from manufacturer to
manufacturer. In addition to the outright purchase of a new instrument, most companies
make available numerous purchase options, including the purchase of a refurbished
instrument at a reduced price and various leases, rentals and reagent acquisition plans.
The options should be reviewed to determine which works best for your particular
needs, time of year, funding cycle, etc. Of course, once the instrument is acquired, you
still have the daily operating expenses incurred through the purchase of antibodies,
detection reagents, buffer solutions and other ancillaries. Estimating these operating
expenses can be done with the help of the instrument company’s representatives and
will help you plan your budget. In many cases the instrument’s operating expenses
may be offset partially by freeing histotechnologists’ time. The additional labor freed by
use of the instrument may help reduce the need for expensive overtime or increased
personnel. The consistent, high-quality staining that instruments provide can also help
save money by reducing the number of re-stains and by making it easier and faster for
a pathologist to render a diagnosis.
Flexibility and Ease of Use

In some respects, a more flexible platform is by necessity more complex. However,
well-designed software and a clean, intuitive user interface goes a long way toward
104
Automating Immunohistochemistry
making that platform easy to use as well as flexible. Not everyone feels comfortable and
competent operating computer-driven devices. An instrument that’s easy to use will be
accepted and embraced by more of the histology staff, thus easing entry of the (possibly)
new technology into the lab and making the scheduling of work rotations easier. The
instrument’s ease of use also will come in handy when the lab decides to branch out
into more complex but very useful home-brewed assays, such as multiplex IHCs that
utilize cocktails of several antibodies and potentially multi-colored detection.
Workflow and Data Management

Finally, any decision to make an investment in automation should take into account how
well the device fits into the natural workflow of the lab, as well as the data management
system of the institute.
Integrating the Modules of Work Flow
Tissue Patient
Sample Record
Data Management and Laboratory Workflow
Integration Information Technology
1 Tissue Preparation 3 IHC Staining

ß Patient ID on Slides ß Target Retrieval
ß Slicing Tissue ß Antibody Staining
ß Tissue onto Slides ß Image Analysis
2 H&E Staining
ß Deparaffinization
ß H&E Staining
Figure 13.1. Data management and workflow.
What is the lab’s cutoff time for new IHC orders? When does the pathologist expect
to receive the stained slides for review? What is the expected turn-around time for
Integrated Information Management
reporting the results, and will use of the instrument improve that? Just as an instrument
can provide flexibility in staining, it also can provide flexibility to the lab with respect
to scheduling
Tissue runs and reporting results. For example, most histology labs operate on
Patient
Sample Record
a single shift that may begin at 5:30 a.m. and end by 2:30 p.m. The day begins with
the removal of theData Management
previous night’sand
runLaboratory Workflow
of tissue from the processor and continues with
embedding, sectioning and staining with H&E. A pathologist examines these slides and
may order additional testing, including IHC and/or ISH (in situ hybridization testing).
Improve Tissue Sample to Patient Record:
ß Reduce Time Required from Days to Hours.
105
ß Move from Qualitative Observations to Qualitative Results.
ß Increase Success Rate.
ß Enhance Throughout with Continuous Flow Automation.
2 H&E Staining
ß Deparaffinization
ß H&E Staining
Integrated Information Management
Tissue Patient
Sample Record
Data Management and Laboratory Workflow
Improve Tissue Sample to Patient Record:

ß Reduce Time Required from Days to Hours.
ß Move from Qualitative Observations to Qualitative Results.
ß Increase Success Rate.
ß Enhance Throughout with Continuous Flow Automation.
Figure 13.2. Objectives of Integrated Information Management.
Additional slides are sectioned for the requested new procedures. There may be a cutoff
time by which the IHC tests must be ordered, in order for the slides to be sectioned that
day. By that time it’s getting late, and could almost be time for the histotechnologists to
wrap up for the day. The next day these slides are processed and IHC stained, and the
whole process repeated. In comparison, an automated IHC stainer capable of running
unattended overnight could allow those slides to be stained on the same day they are
sectioned, and ready for review by a pathologist first thing in the morning, instead of
mid-afternoon. In other words, automation provides options that could streamline lab
operations in addition to providing consistent, high-quality results. Exactly how an
instrument would benefit any given lab depends on the lab itself and the willingness of
the staff to consider and implement beneficial changes to their usual routine.
106
Chapter 14 ° Virtual Microscopy and Image Analysis
Kenneth J. Bloom
The History
Automating manual microscopy has been evolving since the first demonstration of
telepathology in 1968. The concept has evolved along two distinct pathways, one based
on technology, the other on need. The technology folks focused on adapting technology
developed for other disciplines in an effort to prove that automated microscopy was
possible. Improvements in digital camera resolution, speed and fidelity, the invention of
the robotic microscope and stage, the development of the internet and the exponential
advancements in computer technology including processor speed, memory and storage
have contributed to eliminating the hurdles that prevented a viable automated microscopy
system. The second group focused on resolving problems in anatomic pathology, such
as rapid second opinion, pathology staffing of remote frozen sections, cost reduction
for reference laboratories, medical student and resident teaching, continuing medical
education, and improved storage and retrieval of slides - to name just a few (1-7).
The concept of developing a functional robotic telepathology network, with the aim
of providing real-time expert opinions for frozen sections and difficult cases was put
forth by Ronald Weinstein in the mid 1980s (8). I spent a large part of my residency
developing the software and system integration necessary to build a prototype so
that human performance data could be generated (9). All of the performance studies
supported the feasibility of telepathology, and a demonstration project for the U.S.
Department of Defense showed how slides prepared in El Paso, Texas could be read
remotely via satellite, at the Armed Forces Institute of Pathology in Washington, D.C.
Although the prototype was successful, there were many limitations to commercializing
a telepathology system, most involving a lack of telecommunication infrastructure and
standards. But just as importantly, there was little perceived need for the technology.
Since it was not cost effective to purchase a satellite, cheaper alternatives were
sought, and the concept of “static telepathology” was introduced as an alternative.
In static telepathology, a pathologist captures and saves a digital image or series of
images from a camera mounted on a microscope, and then forwards the images to a
remote computer, where they may be reviewed by a second pathologist. E-mail and
File Transfer Protocol (FTP) servers were readily available to facilitate the transfer of
images and standards in image formats were evolving rapidly; however, the static nature
of the images severely limited clinical use. To fully represent a standard pathology
slide, it would be necessary to acquire thousands of static images, making routine
use impractical. Although few pathologists used these systems diagnostically, many
pathologists use them for tumor boards, teaching and other educations purposes.
107
The next step in evolution was the creation of “stitching software.” This technology
allowed the digital representation of an entire microscopic slide by digitizing individual
microscopic fields and then stitching them together to create a virtual slide. This
process was laborious and time consuming, and the computer processing and storage
requirements pushed the limits of available technology. Because of these limitations,
the next systems that were created were hybrids, containing elements of both static
and dynamic systems. These systems would digitize an entire slide at low power
magnification creating a tissue map for the pathologist to select areas of interest, which
would then be re-digitized at higher magnification and forwarded as a series of static
images. Most of the previous limitations now have been overcome, such that we can
effectively digitize an entire microscopic slide at resolutions comparable to that obtained
with a standard light microscope.
Scanning the Slide

The first step in virtual microscopy is to obtain a digital representation of a pathology
slide. Although the resulting image typically is stored as a two-dimensional file, pathology
slides are three-dimensional structures, with the z-axis ranging from three to seven
microns in thickness. With low magnification lenses, a single focal plane suffices, but
with higher magnification lenses, the depth of focus is less than the thickness of the
slide, necessitating that the scanning system have the ability to capture and average
several focal planes. Before scanning the slide, the system must first establish a focal
plane. All systems have the ability to autofocus, but because of patent issues, they
all do it in a slightly different manner. Some start above the tissue plane and focus
down, some start below the tissue plane and focus up, while others start within the
tissue plane. Advanced systems use a second camera to monitor and adjust the focus
continuously as the slide is scanned, but most methods simply create a map of the
tissue on the slide to be scanned, and then using principles such as “triangulation,”
create “focus points.” Then as the slide is scanned the system performs an autofocus
at each calculated focus point. In this way systems hope to overcome problems such
as variations in thickness and tissue folds.
The process of scanning a slide also differs between various systems. All processes
involve acquiring images in some fashion and then stitching them together to create a
representation of the slide. Older systems acquire images as tiles, while newer systems
use other methods such as “linear scanning,” or using an array of lens (10). Many of
the newer methods were developed merely to workaround patent issues while others
offered significant improvements in image acquisition.
Scanning systems generally are judged by two criteria: speed and resolution. The total
speed of acquisition involves not only acquiring the image, but also stitching the images
together and storing the resulting image on a computer. Since the purpose of acquiring
a virtual slide is to view it in the future, some additional processing often is implemented
to facilitate the viewing process. For example, to implement the full functionality of a
standard light microscope, the scanned image must be viewable at the same objective
108
Virtual Microscopy and Image Analysis
magnifications found on a standard microscope, namely, 1x, 2x, 4x, 10x, 20x and
40x. Assuming the slide was scanned, stitched and stored at the equivalent of a 40x
objective, viewing the 40x image would not require additional processing. However,
to view the image at the equivalent of a 4x objective, the 4x image would have to be
derived from the 40x image before it was displayed. This would result in a significant
delay between the time an objective was selected and the time it was displayed on a
monitor. To overcome this delay, some vendors process the acquired image in a format
that already has calculated the image at all intermediate magnification levels. While
this format, known as a pyramidal format, decreases the time to load intermediate
magnification views, it increases the image processing necessary following image
acquisition and produces a larger file to be stored (11).
The ability of the image acquisition system to resolve features present in the microscopic
slide is known as the absolute or, “point-to-point resolution” and is dependent on the
microscope objectives, the camera lens and the analog to digital conversion process.
What is more important is the actual resolution, which is also dependent on hardware
and software compression techniques, the video card and monitor used to display the
image. Many commercial digital cameras, for example, have chips that automatically
“clean” the image by performing tasks such as edge sharpening.
Viewing the Virtual Slide

There is currently no accepted standard for viewing virtual slides. Each hardware
vendor has created software for viewing the image files that they create. All software
programs perform similar tasks such as changing the apparent objective, moving the
slide in any direction, saving screenshots as image files, and annotating specific areas
of the virtual slide. Many programs have advanced features, including viewing multiple
slides simultaneously, slide synchronization and video conferencing.
109
The quality of the image viewed on a monitor is not only a function of the resolution with
which the slide was acquired, but also the resolution and color depth of the video card
and monitor itself. The apparent resolution viewed by the pathologist may be deemed
unsuitable, even if the image is acquired in high resolution. For example, if the image
is viewed on a poor resolution monitor, or a monitor being fed by a low resolution video
card, the image will be only as good as the hardware allows. Virtual microscopy systems
that use your existing desktop computer as the viewing station will be only as good
as the video card and monitor in that system. On the other hand, virtual microscope
systems are similar to a standard microscope, in that the pathologist can and should
manipulate the image. In the case of a standard light microscope, the pathologist
alters the light intensity, the condenser and the diaphragm to create the desired level
of brightness and contrast, while in video microscopy, the pathologist is provided with
controls to adjust the brightness and contrast to produce the desired image. It should
be noted that the video card/monitor systems can reduce the quality of the scanned
image, but cannot improve the resolution beyond the initial quality from when the slide
was scanned.
Capturing Images for Image Analysis

Collecting an image for subsequent analysis has a few more requirements than systems
that obtain images for virtual microscopy. Since the image is going to be analyzed,
procedures must be put in place to ensure that the image is captured reproducibly,
and that the system is operating in the detectable range of whatever is to be analyzed.
For example, when acquiring an image for the purpose of quantifying the amount of
antigen such as HER2/neu, the same image file must be produced whether the slide
is scanned today, tomorrow or six months from now. While this sounds trivial, it is not.
It is well known that all analog imaging systems are subject to drift over time, including
CCD cameras, which is just a camera with a built-in analog-to-digital converter. The
problem of drift is especially acute in color systems, because color is, in effect, the
ratio of the different color channels. Small changes in the signal of any channel can
give rise to large changes in apparent color. Other sources of variation that must be
considered include variation in the light source, variation in the transmission of the light,
variation in the camera, and variation in the analog-to-digital conversion process. It is
well known that as a bulb ages it becomes hotter, until the filament eventually burns
out. Unfortunately, as the bulb becomes hotter it alters the color spectrum that the
bulb emits. Adding further complexity, some of these factors vary at different level of
magnification. Luckily, calibration can be performed to adjust these variables.
All light sources can drift, and the rate of drift can be fast enough to require daily
calibration. An image collection system must either stabilize the bulb, adjust the camera
gain, or collect a reference image of a known-to-be-stable calibration object to correct
for this. Since the color temperature of the light source also might drift, this correction
needs to be done in each channel. Care must be taken to perform this calibration at
an intensity that will not saturate any channel, since saturation of the channels can give
rise to a false appearance of equality.
110
Virtual Microscopy and Image Analysis
The systems for illuminating a glass slide do not provide truly uniform illumination. Unless
corrected for, this will cause algorithms to give different results in different parts of the
field of view. A system must collect calibration images of known-to-be-stable, dust-free,
and blank fields to have enough data to correct the captured image to that of a flat field.
Since the calibration will be different at each level of magnification, this data must be
collected for each objective. Since dust profoundly affects calibration, algorithms must
be able to detect and correct for dust on the calibration target.
When a pathologist reviews a slide on a standard light microscope, the pathologist

manually adjusts for many of these variables as described previously. This is possible
because the human eye is very adept at correcting for these variations, and pathologists
use features for diagnosis that have proven to be reproducible over time. Don’t be lulled
into thinking that an image analysis system works like the human eye, it doesn’t. Of
course anyone can apply image analysis software to a digitized slide, but if the digitized
image is even subtly different each time the slide is acquired, over time the results from
the analysis will lack precision.
Systems used for image analysis therefore must undergo calibration prior to use. At a
minimum, the calibration must adjust for all of the aforementioned variables, and also
include a set of calibrators that help determine the minimal amount of chromogen that
can be detected; the maximal amount of chromogen that can be detected before
saturation of the signal occurs; and help establish that the system can detect the specific
chromogen in a linear fashion over the reportable range. This is identical to the sort of
calibration routinely performed on equipment in a clinical pathology laboratory.
Image analysis represents a significant step in standardizing the interpretation of

histologic slides. The creation of an image analysis is not an easy task. Just as it takes
considerable time and effort to create and validate a pharmacodiagnostic assay, so too
does it takes significant effort to create and validate a clinically useful image analysis
system. These systems are meant to complement pathologists, not replace them.
Accordingly they should not attempt to emulate what pathologists can do well, but rather
they should aid pathologists in tasks that the human eye does not do well. Additionally,
the principle of garbage-in, garbage-out cannot be overstated. There is no point in
attempting to quantify an immunostain unless one is sure that the immunohistochemical
procedure has been validated and is known to be linear, or at least follow a known
curve, across the range of analysis.
Virtual microscopy is an import new technology that already has penetrated pathology
education significantly. With recent improvements in the technology, other uses are
sure to follow quickly. If performing image analysis is an important consideration, care
must be taken to select acquisition systems that have calibrators appropriate for the
type of analysis to be performed (12).
111
Applications for Virtual Microscopy

° Telepathology
° Image analysis
° Education
° Quality assurance
° Cost reduction
° Higher throughput
° Research
References
1. Demichelis F, Della Mea V, Forti S, Dalla Palma P, Beltrami CA. Digital storage of glass
slides for quality assurance in histopathology and cytopathology. J Telemed Telecare
2002;8:138–42.
2. Harris T, Leaven T, Heidger P, Kreiter C, Duncan J, Dick F. Comparison of a virtual
microscope laboratory to a regular microscope laboratory for teaching histology. Anat
Rec 2001;265:10–4.
3. Heidger PM Jr, Dee F, Consoer D, Leaven T, Duncan J, Kreiter C. Integrated approach to
teaching and testing in histology with real and virtual imaging. Anat Rec 2002;269:107–12.
4. Helin H, Lundin M, Lundin J, Martikainen P, Tammela T, van der Kwast T, Isola J. Web-
based virtual microscopy in teaching and standardizing Gleason grading. Hum Pathol
2005;36:381–6.
5. Kumar RK, Velan GM, Korell SO, Kandara M, Dee FR, Wakefield D. Virtual microscopy for
learning and assessment in pathology. J Pathol 2004;204:613–8.
6. Marchevsky AM, Wan Y, Thomas P, Krishnan L, Evans-Simon H, Haber H. Virtual
microscopy as a tool for proficiency testing in cytopathology: a model using multiple
digital images of Papanicolaou tests. Arch Pathol Lab Med 2003;127:1320–4.
7. Okada DH, Binder SW, Felten CL, Strauss JS, Marchevsky AM. “Virtual microscopy”
and the internet as telepathology consultation tools: diagnostic accuracy in evaluating
melanocytic skin lesions. Am J Dermatopathol 1999;21:525–31.
8. Weinstein RS: Prospects for telepathology. Hum Pathol 1986;17:433-4.
9. Weinstein RS, Bloom KJ, Rozek LS: Telepathology and the networking of pathology
diagnostic services. Arch Pathol Lab Med 1987;111:646-52.
10. Weinstein RS, Descour MR, Liang C, Barker G, Scott KM, Richter L, Krupinski EA,
Bhattacharyya AK, Davis JR, Graham AR, Rennels M, Russum WC, Goodall JF, Zhou
P, Olszak AG, Williams BH, Wyant JC, Bartels PH. An array microscope for ultrarapid
virtual slide processing and telepathology. Design, fabrication, and validation Study. Hum
Pathol 2004;35:1303–14.
11. Glatz-Krieger K, Glatz D, Mihatsch MJ. Virtual slides: high-quality demand, physical
limitations, and affordability. Hum Pathol 2003;34:968–74.
12. Glatz-Krieger K, Spornitz U, Spatz A, Mihatsch M, Glatz D. Factors to keep in mind when
introducing virtual microscopy. Virchows Arch 2006;448:248-55.
112
Chapter 15 ° Controls
Ole Feldballe Rasmussen
Introduction
Many factors may introduce variations in immunohistochemistry: Differences in tissue
fixative and fixation time, day-to-day variations due to temperature, variations due
to different workers’ interpretations of protocol steps or in the conditions of reagents
applied on a particular day.
Most diagnostic reagents suppliers have implemented measures to safeguard the

quality of their reagents. However, many factors may influence an immunohistochemical
staining, so it is not always sufficient to assume that any given staining is correct.
It is important, therefore, to include reagent and tissue controls for verification of
immunohistochemical staining results for in vitro diagnostic use. It is also important to
understand what information a given control can provide and what information a control
cannot provide. This chapter will describe the range of controls that should be adapted
in a diagnostic laboratory.
Reagent Controls
The most important reagent in immunohistochemistry is the primary antibody. Without
good specificity of the primary antibody the IHC stain will be jeopardized. In addition
to the manufacturer’s quality guarantee, it is important for the user to ensure the quality
of the primary antibody prior to its use.
During development, most manufacturers ensure specificity using a range of

immunochemical techniques. These may include immunoelectrophoresis, Western
Blot, double diffusion, rocket immunoelectrophoresis and ELISA. Testing on transgenic
cells expressing the specific as well as closely related antigens also may be performed.
It is, however, imperative to test the primary antibody in immunohistochemistry. In
general, manufacturers first test antibodies on a range of positive tissues to identify
optimal antibody dilution in combination with chosen staining protocols. Next,
immunohistochemistry testing is extended to an expanded panel of additional tissues
known to either contain or not contain targeted antigens. For new antibody lots,
manufacturers typically perform quality control to ensure specificity and sensitivity
documented during development.
Users must control reagents within routine quality programs, documenting reagents,
dilutions, diluents, incubation times and dates to which any procedural changes are
introduced by proper record keeping. In laboratories with changing environmental
conditions, it is also advisable to keep track of the relative humidity and temperature.
113
Negative Controls
For monoclonal primary antibodies, nonspecific negative reagent controls may be
developed by different methods. The optimal method is an antibody of the same isotype,
present in the same immunoglobulin concentration, using the same diluent and exhibiting
no specific reactivity with the given human tissues tested. A less optimal alternative is
to use mixtures of antibodies representing all or most relevant IgG subtypes. Finally,
the diluent itself also may be used as an alternative, which, however, is neither efficient
nor desirable.
For polyclonal antibodies, negative reagent controls should be a dilution of

immunoglobulin fractions or whole serum of normal/non-immune serum of the same
animal source. Again, the negative reagent control should be applied in the same
concentration as the test antibody, and the same diluent should be used.
Using the same protocol as the primary antibody, the negative reagent control should
be applied to a sequential section of each patient specimen, to evaluate nonspecific
staining in that particular tissue.
NOTE: A special situation to be aware of is when two or more antibodies are applied to serial sections.
In this case, negative stain areas of one slide may serve as the negative/nonspecific binding background
control for other antibodies.
In cases where it is necessary to evaluate non-specific binding potentially caused

by sources other than the primary antibody, additional patient tissue sections may
be stained with selected reagents. For example, tissues may be stained with just
the secondary antibody and/or the enzyme followed by application of the substrate/
chromogen. In cases where the suspected non-specific staining may be the result of
endogenous enzyme present within the tissue, this can be confirmed by application
of the substrate/enzyme only.
Tissue controls
Tissue controls can be negative, positive, or internal. Each serves a different purpose.
Positive Tissue Controls

These are indicative of proper staining techniques and provide a measure of whether
the target retrieval procedure has been carried out correctly. They should assess correct
temperature and incubation period of water baths or other retrieval methods. Likewise,
positive tissue controls verify that all reagents were applied, that they performed
correctly, and the proper incubation time and temperature were used.
These controls are also indicative of properly prepared tissue. To be as accurate as

possible, positive tissue controls should be prepared in the same manner as patient
samples. Optimally autopsy/biopsy/surgical specimens should be fixed, processed
and embedded as soon as possible for best preservation of antigens. Please see the
section, Processing Control Indicator, next page.
114
Controls
One positive tissue control should be included for each set of tests. Ideally, this control
should contain a spectrum of weak to strongly positive reactivity. If such tissue is not
available, another option is to select a weakly positive tissue, as this provides the best
basis to evaluate whether a particular staining reaction is too weak or too strong.
During a staining run, positive tissue controls may be run on a separate slide, or included
on the same slide as the test specimen. If this second option is chosen, one method is
to use small arrays with selected tissue or cell lines to serve as a positive control for a
range of stains. In this method, one tissue may serve as a positive control, a different
tissue may serve as a negative control (see below).
If positive tissue controls do not perform as expected, results from test specimens
should be considered invalid.
Positive controls cut and stored in bulk with cut surfaces exposed for extended periods
should be tested to determine if the antigens are stable under these storage conditions.
Internal Tissue Controls

Internal controls, also known as “built-in” or intrinsic controls, contain the target antigen
within normal tissue elements, in addition to the tissue elements to be evaluated. Thus,
they can replace external positive controls. This is ideal, as the tissue elements to be
evaluated have been treated exactly as the positive control. One example of a “built-in”
control is the presence of S-100 protein in both melanoma and normal tissue, such as
peripheral nerves and dendritic reticulum cells. Other examples include vimentin, which
is distributed ubiquitously, and desmin, which is present in blood vessel musculature.
Negative Tissue Controls

Positive staining of negative controls could indicate a lack of specificity of the antibody
or nonspecific background staining. Just as in positive controls, tissue used for negative
controls should be prepared in the same manner as the patient sample. Additionally,
the selected tissue should not contain the specific antigen to be tested. One example
would be use of normal liver tissue as a control for hepatitis B surface antigen, or a
HER2/neu-negative tissue for testing with Dako HercepTest™ kit.
If positive staining occurs in the negative tissue control, consider test specimen
results invalid.
Processing Control Indicator

There is currently no optimal way to evaluate whether tissue processing has occurred
satisfactorily. Battifora (1) has suggested using vimentin, a substance present in
virtually every tissue specimen. Furthermore, the vimentin V9 clone recognizes an
epitope that is partially susceptible to fixation with formaldehyde and can function as a
“reporter” for the quality of fixation. Proper processing should give uniform distribution
of vimentin reactivity in tissue vessels and stromal cells. Good, uniform vimentin staining
115
demonstrates adequate fixation, while heterogeneous staining indicates variable and

suboptimal fixation. In these cases only fields demonstrating the best staining intensity
and homogeneity should be used in the patient sample analysis.
Cell Line Controls

Several FDA-approved predictive IHC assays contain cell line controls as part of the
diagnostic kit or are sold separately. These are developed specifically to monitor staining
of the antigen of interest, and should be included in all stain runs as an additional
protocol control.
Just as with tissue controls, cell line controls may be positive or negative. Positive
cell line controls monitor staining performance by assessing target retrieval, blocking,
antibody incubation and visualization. Negative cell line controls assess specificity and,
depending on the characteristics of the chosen cell line, also may provide information
on performance.
An ideal negative cell line control will contain an amount of target antigen, sufficiently
low to produce no staining if the procedure has been performed correctly. At the same
time, the amount should be sufficiently high to produce a weakly positive stain if the run
has been performed under conditions that produce an excessively strong stain.
An ideal positive cell line control would contain a number of target antigens producing
a medium intensity stain. This would allow the control to assess both stains that are too
weak and stains that are too strong.
An example of the way in which cell line controls can be used is illustrated by
Dako’s HercepTest™ kit, which contains three cell line controls: A negative, a 1+
(weak staining) and a 3+ (strong staining). All are designed to be placed on the same
microscope slide.
Figure 15.1, next page, shows examples of staining HercepTest™ control cells.
Fluorescent in situ hybridization kits such as HER2FISH pharmDx™ do not contain
cell line controls because they include probes against both the target gene and the
respective centromere, in order to evaluate the amplification ratio (or deletion) of the
target gene. In this way, the centromere probe also serves as internal control.
116
Controls
Negative cell line 1+ cell line 3+ cell line
Figure 15.1. Cell line controls for Dako HercepTestTM
Control Programs
Immunohistochemical stain test results have no common quantitative measures. Instead,
results typically are based on subjective interpretation by microscopists of varying
experience (2-4). Quality control and assurance, therefore, remain crucial and need
high attention by both manufacturers and laboratory users.
A number of scientific bodies have quality programs or quality assessment services.

These programs should be seen as an aid or external assistance and should never
replace national requirements for internal quality control.
One highly regarded program is the non-profit United Kingdom National External
Quality Assessment Service (UK NEQAS), established in 1995 to “advance
education and promote the presentation of good health by providing external quality
assessment services for clinical laboratories.” UK NEQAS includes a range of specific
external quality assessment (EQA) services, each focusing on areas such as breast
screening pathology.
Likewise, in the United States the College of American Pathologists (CAP) provides a
similar proficiency testing service for its member laboratories.
Also the external quality assessment program run by Nordic Immunohistochemical

Quality Control (NordiQC), established in 2003, should be mentioned. It now has more
than 100 laboratories participating.
Each organization provides proficiency testing in IHC for participating laboratories by

sending out tissue samples to be included as part of a laboratory’s routine IHC staining
procedures. Laboratories then return their results, which are compared with all other
participating laboratories and summarized in a final report.
Contact information for CAP can be found at the Web site, www.cap.org, for UK NEQAS
at the Web site, www.ukneqas.org.uk, and for NordiQC at the Web site, www.nordiqc.org.
117
Future Aspects
To ensure quality diagnosis, immunohistochemistry quality control will become even
more important. It is expected that the next five years will see increased participation
in proficiency testing, as an increase in the number of laboratories that become
accredited. New technologies on the horizon also will facilitate more efficient means of
quality control.
References
1. Battifora H. Am J Clin Pathol 1991;96:669-71.

2. Taylor CR. Applied Immunohistochem 1993;1:232-43.
3. Elias JM et al. Am J Clin Pathol 1989;92:836-43.
4. Taylor CR. Arch Pathol Lab Med 2000;124:945-51.
118
Chapter 16 ° Background
Helle Grann Wendelboe and Kirsten Bisgaard
Introduction
As immunostaining of histological tissue specimens becomes more diversified in
methodology and more sensitive in detection, background staining has developed into
one of the most common problems in immunohistochemistry. Background staining in
tissue sections may be due to several factors, some of which are specific to the antigen
and antibody reaction or detection method, and others, which are of a more general
character. The terminology used in this chapter uses the term “unwanted specific
staining” if the staining is mediated by interactions between any antibodies and their
respective epitopes and “nonspecific staining” for all other interactions. The following
description will cover the major causes of background staining related to antibodies,
detection methods, and other general factors and will offer possible solutions to
these problems.
Background Associated with Detection Methods
Horseradish Peroxidase-Based Detection Methods
Endogenous Peroxidase Activity
For practical purposes in immunohistochemistry, endogenous peroxidase activity can

be defined as any activity that results in the decomposition of H202. Such activity is
a common property of all hemoproteins, such as hemoglobin (red cells), myoglobin
(muscle cells), cytochrome (granulocytes, monocytes) and catalases (liver and kidney).
Peroxidase activity also may be encountered in tissue areas adjacent to vascularized
areas due to the diffusion of blood prior to fixation.
The most commonly used procedure for suppressing endogenous peroxidase activity
in formalin-fixed tissue is the incubation of sections in three percent H2O2 for five to 10
minutes (Figure 16.1). Methanolic H2O2 treatment (11 parts, three percent H2O2 plus
four parts absolute methanol) for 20 minutes also is used, but is not recommended for
specimens where cell surface markers are to be stained. Methanolic treatment also may
detach frozen sections from their carrier glass. Endogenous peroxidase activity also
can be suppressed by a mixture of sodium azide and H2O2 (1). However, in most work
with formalin-fixed tissue sections, the interpretation of specific staining is not impaired
by any endogenous peroxidase activity. If the formalin-fixed tissue is rich in blood-
containing elements then it will be a good idea to quench endogenous peroxidase
activity. In cell preparations and frozen sections, routine quenching of endogenous
peroxidase is also advisable.
119
Specimens rich in endogenous peroxidase activity may be processed using an

alkaline phosphatase detection method instead of a peroxidase method, eliminating
the background.
(a) Before (b) After
Figure 16.1. Red blood cells showing endogenous peroxidase activity (a) before, and (b) after blocking with three percent
hydrogen peroxide.
Alkaline Phosphatase-Based Detection Methods
Endogenous Alkaline Phosphatase
Endogenous alkaline phosphatase activity is encountered frequently in intestine, kidney,

osteoblasts, endothelial cell surfaces, neutrophis, stromal reticulum cells, lymphoid
tissues, and placenta. In frozen tissue, where endogenous alkaline phosphatase
activity is pronounced most, routine quenching of endogenous alkaline phosphatase
is recommended. In most formalin-fixed tissue sections, interpretation is not usually
impaired by endogenous alkaline phosphatase, which makes quenching an optional
choice. Most forms of endogenous alkaline phosphatase can be quenched by including
five mM levamisole in the chromogen substrate solution (Figure 16.2). The intestinal
form of alkaline phosphatase is the exception and resists this treatment, but it can be
quenched by treating the tissue sections with a weak acid wash prior to the application
of the primary antibody.
120
Background
Figure 16.2. Placenta showing endogenous alkaline phosphatase activity (a) before, and (b) after blocking with levamisole.
Double Staining
Combined Endogenous Peroxidase and Alkaline Phosphatase

Double staining using these enzymes requires quenching of both endogenous activities.
To achieve this, use the H2O2 method for endogenous peroxidase and the weak acid
method for endogenous alkaline phosphatase. The sequence of blocking endogenous
activities is optional: The procedure will work effectively conducting either step first.
Also, reagents that block both endogenous peroxidase and alkaline phosphatase in
one step are available.
Biotin/Streptavidin-Based Detection Methods

Endogenous avidin-binding activity (EABA) has been observed with all biotin-based
techniques, due to its presence in a wide variety of tissues. Biotin is bound to enzymes
and other protein, especially in the liver (hepatic nodules), kidney (tubular epithelia)
and lymphoid tissue (paracortical histiocytes) (Figure 16.3). EABA usually is observed
within cytoplasm and is pronounced most when using frozen tissue sections. Paraffin-
embedded tissues also hold substantial endogenous biotin. Other examples of EABA
include the nonimmunochemical staining of myelin (2) and mast cells (Figure 16.4)
in both frozen and paraffin-embedded tissue (3). Guesdon et al (4) found EABA in
granulocytes from mouse spleen.
121
Figure 16.3. Endogenous biotin expression in the kidney.
EABA is suppressed best by sequential incubations of 10 to 20 minutes of tissue

sections, first with 0.01 percent to 0.1 percent, avidin followed by 0.001 percent to 0.01
percent biotin prior to the staining protocol (5). Avidin has four binding sites for biotin
while each biotin molecule can bind to only one avidin molecule. The first incubation
with avidin effectively blocks endogenous biotin but simultaneously adds three more
potential biotin-binding sites to the specimen. This means there are extra biotin binding
sites open to link antibodies or detection systems that can give background staining.
Therefore, it is important to block these extra biotin binding sites with a subsequent
biotin incubation.
Because avidin is a glycoprotein containing 10 percent carbohydrates and has a

pI of 10, it tends to bind nonspecifically to lectin-like and negatively charged tissue
components at physiological pH. Streptavidin contains no carbohydrates and has a pI of
five. Its introduction to IHC largely has eliminated these problems. A sugar solution can
block the lectin-like elements. Many commercially available Avidin detection systems
contain modified avidin to minimize nonspecific avidin background.
122
Background
Figure 16.4. Avidin-biotin-complex (ABC) binding to mast cells in submucosa (a) before, and (b) after blocking for
endogenous avidin binding activity (EABA).
Polymer-Based Detection Methods

Use of polymer detection systems avoids endogenous avidin/biotin background
completely. General overall background staining may occur if insufficient washing is
performed after polymer application. Due to the large size of polymer conjugates, the
diffusion rate of these molecules is lower than for low-molecular weight conjugates. In
addition, polymer conjugates based on a hydrophobic backbone have a tendency to
be sticky. This can be resolved by applying multiple wash steps, adding detergent to
the wash buffer and by prolonging washing time.
Antigen Retrieval
This has been reported both to eliminate and introduce cytoplasmic and nuclear
background in immunohistochemical procedures (6). A possible explanation is that
antigen retrieval influences antigen-antibody binding activity, and thereby affects
binding of the antibody to tissue proteins. Different types of antigen retrieval solutions
with different buffer compositions, pH and chelating abilities exist. Citrate pH 6.0, TRIS/
EDTA pH 9.0, and TRS pH 6.0 retrieval solutions vary in the way they influence antigen-
antibody binding. Retrieval time also can influence antigen-antibody binding, so for
new antibodies it is advisable to investigate which antigen retrieval solution and time
are best to optimize signal and minimize background.
General Factors
Antigen Diffusion
Unwanted specific background staining may occur when the tissue marker to be stained
has diffused from its sites of synthesis or storage into the surrounding tissue. Because
many fixatives penetrate tissues slowly, it is important to keep tissue specimens as
123
small as possible and to fix immediately. Otherwise the antigens may not be adequately
fixed and may be extracted or displaced by the subsequent tissue processing steps.
Extracellular antigens or those of low molecular weight are more likely to diffuse than
high-molecular-weight antigens.
A typical example is the diffusion of thyroglobulin from thyroid follicular epithelium and
colloid-containing lumen into surrounding stromal tissue. Similarly, specific background
may result when the tissue marker also is present in high concentrations in blood plasma
and has diffused in the tissue prior to fixation. This can be seen when tonsil tissue is
stained for immunoglobulin heavy and light chains (Figure 16.5), particularly when
fixation was not performed promptly and when antisera were not diluted sufficiently.
Ingestion of target antigens by phagocytes also may produce specific background
staining, resulting in stain patterns not normally seen in such cells.
Figure 16.5. Undesirable staining of plasma proteins with antibody to kappa light chain. Plasma cells stain specifically.
124
Background
Natural and Contaminating Antibodies
Natural Antibodies
Low-level natural antibodies present in the antiserum as a result of prior environmental
antigenic stimulation may increase in titer during immunization with use of adjuvants.
As a consequence, they can give rise to nonspecific staining. In 1979, Osborn et al (7)
reported that sera from non-immunized rabbits and goats, but not from guinea pigs,
contained environmental antibodies to keratins. This may be an example of specific
epithelial background staining caused by natural antibodies. Although also observed
by others, attempts to isolate or remove these antibodies from the antiserum were
not successful (8).
Most natural antibodies are of the nonprecipitating type and occur only in relatively
low concentrations. These antibodies usually are rendered non-reactive on tissue
if the antiserum is used at a sufficiently high dilution or by shortening the
incubation periods.
Contaminating Antibodies
Isolated antigens used for immunization are rarely pure. If a host’s immune system reacts
to impurities, contaminated antibodies will result. Usually these contaminating antibodies
are present in low concentration and will not detract from the immunohistochemical
specificity of high-titered antisera provided they are diluted sufficiently.
Contaminating antibodies may be related to infectious agents, other animal species

kept in the same facilities, or carrier proteins used for immunization. These antibodies
may be of special concern when dealing with antisera against synthetic peptide. Small
peptides are not antigenic, and therefore must be coupled to carrier proteins prior
immunization. The antisera produced therefore will contain antibodies against the carrier
protein and the peptide.
However, if contaminating antibodies do interfere with specificity, affinity absorption of

the antiserum usually is performed. “Batch-absorbed” antisera almost always contain
residual levels of contaminating antibodies (mostly of the non-precipitating type) and
will cause nonspecific staining of tissue if used at excessively high concentration (8).
Monitoring and evaluating the results of absorption by use of such techniques as

immunodiffusion, immunoelectrophoresis and rocket immunoelectrophoresis can be
used only to determine non-specificity. This monitoring cannot establish the specificity of
an antiserum. Ultimate mono-specificity must be demonstrated by use of the designated
technique and by extensive use of tissues.
Problems stemming from natural and contaminating antibodies, of course, do not

occur with monoclonal antibodies produced in tissue culture, but may be present in
monoclonal antibodies prepared from ascites fluid.
125
Cross-Reactivity
Background staining due to antibody cross-reactivity may result when target
tissue antigen epitopes are shared with other proteins. A typical example is the
use of unabsorbed antiserum to carcinoembryonic antigen (CEA). Because CEA
shares epitopes with some normal tissue proteins and blood group antigens, non-
specific staining may result. Careful absorption of such antisera or in the case
of monoclonal antibodies careful screening of clones, will eliminate this type of
background staining.
Nonspecific antibody cross-reactivity with similar or dissimilar epitopes on different

antigens may also be the cause of confusing background staining. This is rare however,
and can be avoided by using antibodies from hyper-immunized animals or carefully
selected clones.
Cross-reactivity of antigens from related species is a common problem in multi-staining.
This often can be avoided by using affinity purified antibodies, sub-type specific
antibodies or site/ region specific antibodies. For more detail on cross-reactivity, see,
Antibodies, Chapter 1.
Fc Receptors
Fc receptors (FcR) are a family of detergent-soluble membrane glycoproteins with
approximate molecular weights of 50–70 kD. They comprise less than one percent of
the total membrane proteins and are present most frequently on macrophages and
granulocytes. They also have been reported on B cells and some T cells. The intrinsic
affinity of the FcR for monomeric IgG is approximately 1x106 to 1x108 M–1, but is higher
for polymers and immune complexes of IgG. There is considerable class/subclass and
species specificity among different FcR’s. For example, the FcR on some human cells
was found to bind mouse monoclonal IgG2a and IgG3 but not other IgG subclasses (9).
Goat sera do not react with FcR’s of human leucocytes (10).
Background staining due to FcR is more common in frozen sections, smears and in
lightly fixed than in tissues fixed by harsher procedures. It can be avoided by use
of F(ab’)2 fragments instead of whole IgG molecules and by careful screening of
monoclonal antibodies.
Hydrophobic Interaction
In aqueous media, hydrophobic interactions between macromolecules occur when
surface tensions are lower than that of water (called van der Waals forces). These
interactions can be interatomic as well as intermolecular, and originate through the
fluctuating dipolar structure within these macromolecules.
Hydrophobicity is a property shared to varying degrees by most proteins and is imparted

primarily through the side chains of neutral aromatic amino acids phenylalanine, tyrosine
and tryptophan. By their lower attraction for water molecules, these amino acids tend
126
Background
to link to one another, thus expelling water from the molecule. While hydrophobicity
is one of the natural forces that confer stability on the tertiary structure of peptides, it
also imparts stability to formed immune complexes and depending on environmental
factors, can exist between different protein molecules.
Tissue Proteins
In tissue, proteins are rendered more hydrophobic by fixation with aldehyde-containing
reagents such as formalin and glutaraldehyde. Increased hydrophobicity often results
from cross-linking reactive epsilon- and alpha-amino acids within and between adjacent
tissue proteins. The extent of this hydrophobic cross-linking during fixation is primarily a
function of time, temperature and pH. Changes in these factors likely will result in variable
hydrophobicity due to variable cross-linking of tissue proteins. Therefore once optimized
fixation procedures must be maintained and controlled. Tissues that commonly have the
most background staining as a result of hydrophobic, as well as ionic, interactions are
connective tissue: Collagen laminin, elastin, proteoglycans and others and squamous
epithelium (keratins) and adipocytes (lipoids) if incompletely removed during processing
with xylene. Excessive background staining due to overfixation with formalin may be
remedied by postfixation with Bouin’s, Zenker’s or B5 fixative (11).
Antibodies
Of the major serum proteins, immunoglobulins unfortunately are particularly hydrophobic.
In general, mouse antibodies of subclass IgG3 and IgG1 are more hydrophobic than
those belonging to subclasses IgG2 and IgG4. Furthermore, some isolation procedures
for IgG class antibodies promote the formation of aggregates, thereby further increasing
their hydrophobicity. Storage of immunoglobulins also may increase their hydrophobicity
and lead to aggregation and polymerization. This frequently leads to a diminution in, or
loss of, immune reactivity. Attendant increase in non-specific background staining by
use of a polyclonal IgG fraction when compared to that obtained by use of the original
whole antiserum has been demonstrated (12).
The diluent buffer’s formulation also can influence hydrophobic binding between
monoclonal IgG and tissue proteins: the greater the proximity of diluent pH and the
isoelectric point (pI) of antibodies, the stronger hydrophobic interaction will be. The
lower the ionic strength of the diluent, the weaker will be the strength of hydrophobic
attraction. The following anions and cations are arranged in order of their diminishing
effect on hydrophobicity:
Anions: PO4-3, SO4-2, Cl-, NO3-, SCN -
Cations: NH4+, K+, Na+, Ca+2
Other possible methods to reduce hydrophobic interactions between tissue and reagent
proteins include adding detergent, for example Tween 20, or ethylene glycol to the
diluent, or by raising the pH of the diluent used for polyclonal antibodies only.
127
The most widely practiced measure to reduce background due to hydrophobic

interaction is to use a protein blocking solution either in a separate step, or by adding
it to the antibody diluent. However this will be successful only if the blocking protein
is a type that can compete effectively with IgG or its aggregates or conjugates, for
hydrophobic binding sites. Separate incubation with a solution containing blocking
protein is best when carried out immediately prior to application of the primary antibody.
The solution should contain proteins identical to those present in the secondary link or
labeled antibody, but not to those in the primary antibody, in order to prevent nonspecific
binding of the secondary antibody.
The addition of one percent bovine serum albumin (BSA) to the primary antibody diluent
is probably the most widely practiced step for reducing non-specific binding due to
hydrophobic interaction. Use of non-fat dry milk (13) or of casein (14) for reducing
background staining also is recommended. Casein, when used as a blocking agent,
an antibody diluent and in the wash buffer, was found to result in significantly less
background staining compared to normal swine and sheep sera (14).
Because of the different uses of biotinylated antibodies today, it should be of interest

to note that biotinylation can change the pI of the antibody in excess of three units,
for example from a pI of eight for the antibody to less than five for the conjugate (15).
This may have a marked effect on the solubility of these conjugates, possibly due to
increased hydrophobicity.
Ionic and Electrostatic Interactions

Ionic interactions are one of the prime forces that control immunochemical interaction
between antigens and their corresponding antibodies. However, they also may contribute
to non-specific background.
The pI of the majority of polyclonal IgG ranges from approximately 5.8 to 8.5. At
physiological pH and at the pH commonly used for diluents, antibodies can have either
net negative or positive surface charges. Ionic interaction of some antibodies with tissue
proteins can be expected if the latter possess opposite net surface charges. Negatively
charged sites on endothelia and collagen fibers have been reported to interact with
cationic conjugates composed of rabbit Fab fragments and horseradish peroxidase
type VI (pl 10.0) (16). In general, interactions of the ionic type can be reduced by use
of diluent buffers with higher ionic strength. Addition of NaCl to the diluent buffer can
reduce background staining stemming from ionic interactions but its routine use in
diluents for monoclonal antibodies is not recommended (17).
Unfortunately, most diffuse background staining results from a combination of ionic and
hydrophobic interactions. Remedies for one type of interaction may aggravate the other.
128
Background
Complement-mediated Binding
Complement-mediated binding occasionally may be a cause of background in frozen
tissue when whole antisera are used. However, by the time large pools of antisera have
been prepared for use, several of the complement factors usually are inactivated.
Miscellaneous Sources
Physical injury to tissue, drying out prior to fixation or incomplete penetration of fixative
may cause diffuse staining of all or most tissue elements within an affected area. Similar
diffuse background staining of both the section and the glass slide, usually limited to the
area of antibody incubate, has been observed and may be due to residual embedding
medium. Sections mounted routinely in water baths containing protein additives such as
Knox gelatin or Elmer’s glue also may show this type of diffuse background, especially
in procedures of high staining sensitivity. Water baths should be free of bacterial or
yeast contamination.
Nonspecific staining due to undissolved chromogen granules also, on occasion, may

be encountered.
Nonimmunologic binding of horseradish peroxidase (either in free form or as a conjugate)

to HbsAg in hepatocytes was reported by Omata et al (18). The precise nature of this
binding was not known.
Necrotic areas of tissue may stain with all reagents. Nadji and Morales (19)
provide an excellent collection of color plates illustrating background staining and
accompanying explanations.
Excessive counterstaining may compromise the specific staining signal.
General Aspects
While it is clear that background staining can be caused by the factors outlined above,
it is also important to work with well-characterized reagents and established protocols
in order to avoid background or to troubleshoot background staining. Many IHC
reagent providers offer “system solutions,” which are IHC product lines with carefully
optimized buffers, target retrieval reagents, primary antibodies, detection reagents and
substrates to be run on an automated platform. These are designed to provide users
with consistent, optimal staining. Several countries have established national quality
programs, such as United Kingdom National External Quality Assessment Service
(UK NEQAS) (20), and Nordic Immunohistochemical Quality Control (NoridQC) (21),
formed to raise awareness of the need for quality and best practices in IHC laboratories,
including improving the reduction of background staining. See Chapter 15, Controls,
for further discussion. Information on individual national programs can be found on
each program’s Web site.
129
References
1. Li C-Y et al. J Histochem Cytochem 1987;35:1457-60.

2. Sternberger LA and Sternberger NH. J Histochem Cytochem 1986; 34:599-605.
3. Hsu S-M and Raine L. In DeLellis RA(ed) Advances in Immunohistochemistry. New York:
Masson 1984:31-42.
4. Guesdon J-L et al. J Histochem Cytochem 1979;27:1131-9.
5. Wood GS and Warnke R. J Histochem Cytochem 1981;29:1196-204.
6. Wieczorek R et al. J Histotech 1997;20:139-43.
7. Osborn M et al. Proc Natl Acad Sci (USA) 1977;74:2490-4.
8. Conway de Macario E et al. J Immunol Meth 1986;90:137-41.
9. Gadd J and Ashman LK. Clin Exp Immunol 1983;54:811-8.
10. Alexander EL and Sanders SK.J lmmunol 1977;119:1084-8.
11. Caron BL and Banks PM. Lab Investig 1979;40:244-5.
12. Boenisch T. Unpublished observations.
13. Duhamel RC and Johnson DA. J Histochem Cytochem 1985;7:711-4.
14. Tacha DE and McKinney LA. J Histotech 1992;15:127-2.
15. Wadsley JJ and Watt RM. J Immunol Meth 1987;103:1-7.
16. Pino RM. J Histochem Cytochem 1985;33:55-8.
18. Omata et al. Am J Clin Pathol 1980;5:626-32.
19. Nadji M and Morales AR Immunoperoxidase Techniques: A Practical Approach to
Tumor Diagnosis. Chicago: American Society of Clinical Pathologists, 1986.
20. United Kingdom National External Quality Assessment Service (UK NEQAS):
www.ukneqas.org.uk.
21. Nordic Immunohistochemical Quality Control (NordiQC): www.nordiqc.org.
130
Chapter 17 ° Troubleshooting
Karen N. Atwood and Dako Technical Support Group
Introduction
Immunohistochemistry is a multi-step process that requires specialized training in the
processing of tissue, the selection of appropriate reagents and interpretation of the
stained tissue sections. In general, IHC staining techniques allow for the visualization
of antigens by sequential application of a specific antibody to the antigen, a secondary
antibody to the primary antibody, an enzyme complex and a chromogenic substrate.
The enzymatic activation of the chromogen results in a visible reaction product at the
antigen site. Because of its highly complex nature, the causes of unexpected negative
reactions, undesired specific staining or undesired background could be difficult to
isolate. The information contained in this chapter should enable you to rapidly pinpoint
and resolve problems encountered during the staining procedure.
Section One is a compilation of common problems encountered when using

immunohistochemical-staining reagents, the underlying causes of staining failure
and recommended corrective actions. The chart is divided into sections describing
inadequate or no staining, general background staining and limited background staining.
Section Two presents a method of systematically adding one IHC reagent at a time
to determine at which stage non-specific or undesired staining may be occurring in a
peroxidase, streptavidin-biotin staining system.
Section Three is a simple chart used to define the type of tissue specimen, the IHC
staining and ancillary reagents already in place in the laboratory, and the staining
protocol used by the laboratory personnel. You are encouraged to copy this chart
and use it to help troubleshoot any problems you may encounter with your staining
systems.
Section Four is a guide to reading manufacturers’ specification sheets for IVD antibodies.
This includes general information for use in immunohistochemistry including fixation,
recommended visualization systems, recommended titer and diluent, pretreatment,
and selection of required controls.
131
Section One:
Troubleshooting problems commonly encountered during immunohistochemical staining.
Figure 17.1a. anti-CD30 diluted 1:50 with Tris-HCI, pH 7.6. Figure 17.1b. anti-CD30 diluted 1:50 with PBS, pH 7.0.
Figure 17.1a and 1b. Ongoing studies performed in the DakoCytomation Research & Development laboratory confirm that
the pH and ion content of the antibody diluent may have a significant effect on the sensitivity of monoclonal antibodies.
(Hodgkin’s lymphoma stained with CD30 (clone Ber-H2) antibody, using a three-stage immunoperoxidase staining system.)
Inadequate Staining
Little or no staining of controls or specimen tissue, except for counterstain.
May show little or no background staining.
Possible Cause Solution See Page
Primary antibody or labeled Repeat the procedure using the manufacturer’s staining system 47-53
reagent omitted. Reagent specification sheet or standard operating procedure reagent
used in wrong order. checklist as established by the individual laboratory.
Excessively diluted or Determine correct concentration for each reagent. Depending on 10, 15-16
excessively concentrated the degree of staining obtained, if any, a two- to five-fold change
reagents; inappropriate in concentration may be needed. Incubation temperature and
incubation time and incubation time are inversely proportional and will affect results.
temperature. To determine optimal incubation protocol, vary either the time
or temperature for each reagent in the IHC staining system.
Generally, incubation times can be extended if little or no
background was detected.
132
Troubleshooting
Inadequate Staining (continued)
Primary antibody diluted Check formula and compatibility of antibody diluent. A change 47-53
with inappropriate buffer. of ion content and/or pH of the antibody diluent can cause
a diminution in the sensitivity of the antibody. Addition of
° Use of PBS or TBS as an
NaCl should be avoided. This problem is seen primarily with
antibody diluent.
monoclonal antibodies.
° Lack of stabilizing or
carrier protein.
° Detergent in diluent.
Primary antibody defective; Replace defective or expired antibody; repeat staining protocol, 10-11
one or several secondary or replacing one reagent at a time with fresh, in-date reagents.
ancillary reagents defective. ° Store products according to each product specification
Do NOT use product after sheet or package insert.
expiration date stamped ° If using a neat or concentrated antibody, and directed by
on vial. the manufacturer to store frozen, it may be aliquoted to
avoid repeated freezing and thawing.
° Do not freeze ready-to-use or customer diluted products.
° Follow manufacturer recommendations on product
specification sheets, package inserts and reagent labels.
Dissociation of A feature of low-affinity antibodies: 7-8

primary antibody during ° Polyclonal primary antiserum: Attempt staining at
washing or incubation with low dilutions.
link antibodies. ° Monoclonal primary antibody: Replace with higher affinity
antibody of identical specificity.
° Re-optimize incubation times for washing buffer and
link antibody.
Use of alcohol-based ° Repeat staining, using water-based counterstain and 21-22

counterstain and/or mounting media.
alcohol-based mounting ° Use a permanent chromogen, such as DAB/DAB+, that is
media with aqueous– not affected by organic solvents.
based chromogens.
Excessive counterstaining Use a counterstain that: 119-129

may compromise proper ° Will not excessively stain tissue sections.
interpretation of results. ° Can be diluted so as not to obliterate the specific signal.
° Reduce incubation time of the counterstain.
Incorrect preparation of ° Repeat substrate-chromogen treatment with correctly Spec

substrate-chromogen mixture. prepared reagent. Sheet
° Staining intensity is decreased when excess DAB/DAB+ is
present in the working reagent.
133
Incompatible buffer Check compatibility of buffer ingredients with enzyme and 47-53
used for preparation of substrate-chromogen reagents.
enzyme and substrate- Repeat staining.
chromogen reagents: ° Commercial phosphate buffers may contain additives that
will inhibit alkaline phosphates activity.
° Use of PBS wash
° Avoid sodium azide in diluents and buffers.
buffer with an
A concentration of 15 mM/L sodium azide, which
alkaline phosphatase
is added routinely to IHC reagents to inhibit bacterial
staining system.
growth, will not impair HRP conjugated labels.
° Sodium azide in reagent
diluent or buffer baths
for immunoperoxidase
methodologies.
Antigen levels are too ° Utilize a higher sensitivity staining system. 47-53
low for detection by the ° Prolong incubation time of primary antibody.
employed visualization ° Re-optimize incubation times and concentrations of
system. ancillary reagents.
° Perform antigen retrieval, if applicable, using a range
May be due to loss of
of pH buffers.
antigenic differentiation
in some tumors or loss of
antigenicity due to sub-
optimal tissue fixation.
Steric hindrance due to high Re-optimize concentration of the primary antibody and ancillary 47-53
antigen level and possible reagents. Antibody concentration of the primary antibody may be
prozone effect. too high.
Use of inappropriate Check manufacturer’s specifications regarding recommended fixative. 27-33

fixative.
° Use of certain fixatives
may damage or destroy
antigens or epitopes in
the tissue specimen.
° Use of non-cross linking
fixatives may allow
the elution of antigens
soluble in IHC reagents.
° Different fixatives may
affect standardization
of cells.
134
Troubleshooting
Immunoreactivity Use a paraffin wax with a melting temperature ~ 55-58 ºC. Wax 27-33
diminished or destroyed used for embedding should not exceed 60 OC.
during embedding process.
Immunoreactivity Oven temperature not to exceed 60 ºC. 27-33

diminished or destroyed NOTE: The intensity of immunostaining may be diminished when
during dewaxing at high tissue is exposed to prolonged heat. Refer to the primary antibody
oven temperature. specification sheet for additional information.
Immunoreactivity The intensity of immunostaining may be diminished when pre-cut 27-33

diminished or destroyed on tissue sections are exposed to air. Use freshly cut sections and
pre-cut tissue sections. reseal paraffin-embedded blocks.
Immunoreactivity More common on frozen sections: apply the primary antibody 13, 30,
diminished or destroyed prior to the enzymatic block to insure its reaction. In such cases 31, 58,
by the enzyme blocking the blocking reagent can be applied at any point after the primary 107, 119,
reagent altering a and before the enzyme labeled components. 126
specific epitope.
Excessive wash buffer or Excess reagent will dilute the next consecutive reagent. Repeat 15-16
blocking serum remaining staining, making sure to wipe away excess washing buffer and
on tissue section prior to blocking serum.
application of IHC reagents.
Demasking protocol is Some tissue antigens require proteolytic enzyme digestion 27-33
inappropriate or has been or heat-induced antigen retrieval performed prior to staining.
omitted. The need for pretreatment depends on the type and extent of
fixation, specific characteristics of the antigen and the type
of antibody used. Use the pretreatment method recommended
by the manufacturer. No single pretreatment is suitable for
all applications.
Repeated reuse of antigen Do not reuse buffer. Spec

retrieval buffer. Sheet
Sections incorrectly Prepare new sections and deparaffinize according to standard 119-129
dewaxed. laboratory protocol, using fresh xylene or xylene substitute.
135
Failure to achieve the ° When using a waterbath or steamer, allow sufficient time 41-44
optimal temperature for the retrieval buffer to equilibrate to a temperature range
required for heat induced of 95-99 ºC.
antigen retrieval. ° At high altitude (greater than ~ 4,500 feet), the buffer will
boil at less than 95 ºC.
° Utilize a closed heating system such as a pressure cooker,
autoclave or Pascal, or utilize a low temperature protocol if
standardization of the validated procedure is not affected.
Excessive or incomplete Re-optimize concentration of counterstain and incubation time. 41-44

counterstaining.
Instrument malfunction. Ensure automated stainer is programmed correctly and is running 95

to manufacturer’s specifications.
Positive control tissue shows adequate specific staining with little or no background
staining. Specimen tissue shows little or no specific staining with variable background
staining of several tissue elements.
Specimen held for too long Standardize routine fixation. Proteolytic digestion or antigen 41-44
in a cross-linking fixative, retrieval will break down cross-linking and render some tissue
usually in formalin, causing antigens reactive. Refer to the primary antibody specification
“masking” of antigenic sheet for additional information.
determinants due to
aldehydes cross-linking and
increased hydrophobicity of
tissue.
Sectioned portion contains Serum proteins diffuse through tissue and are fixed in place. 119-129
crush artifact caused by Re-cut tissue using sharp blade.
grossing tissue with dull
scalpel or razor.
Sectioned portion of Ignore physically damaged portions of stained tissue sections. 41-44
specimen contains
necrotic or otherwise
damaged elements.
136
Troubleshooting
Section portion of specimen Fix tissue biopsy for longer period of time or fix smaller pieces 27-33,
not penetrated by fixative. to ensure complete penetration. Unfixed tissue tends to bind all 119-129
Loss of antigenicity in reagents nonspecifically.
unfixed tissue.
General Background
Background seen in all control tissue and specimen tissue. May see marked background
staining in several tissue elements such as connective tissue, adipose tissue and
epithelium.
Excessive incubation Reduce incubation time. Spec

with substrate- Sheet
chromogen reagent.
Substrate-chromogen Repeat incubation with correctly prepared chromogen reagent. Spec

reagent prepared incorrectly. Sheet
Secondary or link antibody Absorb link antibody with tissue protein extract or species- 47-53
cross-reacts with antigens specific normal serum from tissue donor.
from tissue specimen.
Secondary or link antibody Repeat staining. Determine correct concentration for each 16-18
and /or tertiary reagents reagent. Incubation temperature and incubation time will
too concentrated. affect results. To determine optimal incubation protocol, vary
both the time and temperature for each reagent in the IHC
staining protocol.
Slides inadequately rinsed. Gently rinse slide with wash buffer bottle and place in wash 7-8
bath for five minutes. Gentle agitation of the wash bath may
increase effectiveness when used with cytoplasmic or nuclear
staining protocols.
Insufficient saline or High-sensitivity staining systems may require higher 119-129

detergent in wash buffer. concentrations of saline or detergent in the wash buffer. Refer to
the staining system specification sheet for optimal formulation.
137
General Background (continued)
Blocking serum or wrong Block with serum from the host of the secondary or link antibody. 119-129
blocking serum used. Avoid serum that contains auto-immune immunoglobulins.
Alternatively, a serum-free protein block, lacking
immunoglobulins, may be substituted for the serum block.
Sections incorrectly dewaxed. Prepare new sections and deparaffinize according to standard 119-129
laboratory protocol using fresh xylene or xylene substitute.
Non-specific binding of the Use a secondary antibody that has been absorbed against a 47-53
secondary antibody with an species specimen, or use a secondary antibody produced
animal tissue specimen. in a host that exhibits little or no cross-reactivity with the
tissue source.
Instrument malfunction. Ensure automated stainer is programmed correctly and is 95

running to manufacturer’s specification.
Specimen tissue and negative reagent control slides show background staining. Positive
and negative control tissue show appropriate specific staining. May involve several
tissue elements such as connective tissue, adipose tissue and epithelium.
Specimen held for too long Standardize routine fixation. Proteolytic digestion or antigen 27-33
in a cross-linking fixative, retrieval will break down cross-linking and render some tissue
usually in formalin, causing antigens reactive. Refer to the primary antibody specification
“masking” of antigenic sheet for additional information.
determinants due to
aldehydes cross-linking
and increased
hydrophobicity of tissue.
Sectioned portion of Fix tissue biopsy for longer period of time or fix smaller pieces 27-33
specimen not penetrated by to ensure complete penetration.
fixative. Loss of antigenicity
in unfixed tissue. Unfixed
tissue tends to bind all
reagents nonspecifically.
138
Troubleshooting
Sectioned portion contains Serum proteins diffuse through tissue and are fixed in place. 119-129
crush artifact caused by Re-cut tissue using sharp blade.
grossing tissue with dull
scalpel or razor. Serum
proteins diffuse through
tissue and are fixed in place.
Sectioned portion of Ignore physically damaged portions of stained tissue sections. 119-129
specimen contains
necrotic or otherwise
damaged elements.
Excessive or unevenly Some IHC reagents may bind to these products, resulting in 119-129
applied subbing agent on a light stain over the entire slide surface. Some slides may be
poly-L-lysine, charged, or unevenly coated, and will exhibit the above problems on only a
silanized slides. portion of the tissue or glass.
Antigen diffusion prior to Avoid delays in fixation of the tissue. 119-129

fixation causing specific
background outside the
expected antigen site.
Tissue sections too thick. Cut tissue sections thinner. Formalin-fixed paraffin-embedded 27-39
tissue sections should be approximately 4-6 µm; cryostat
section 10 <µm.
Incomplete permeabilization Seen in frozen sections, cell smears and non-paraffin embedded 99
of tissue sections. tissue: Incomplete permeabilization of cells allows unattached
reagents to become trapped within the cells and resistant to
removal by wash buffer.
139

Negative reagent control slide shows background. Positive control tissue, negative
control tissue and specimen tissue show expected specific staining.
Negative control serum Use properly diluted negative reagent control serum 113-118
insufficiently diluted. ° For polyclonal antibodies, dilute the negative reagent
control serum until the protein concentration is equal to
that of the primary antibody.
° For monoclonal antibodies, dilute the negative reagent
control serum until the Ig concentration is equal to that of
the primary antibody.
Contaminating antibodies Replace the negative reagent control serum; repeat 113-118
in the negative control staining protocol.
serum are cross-reacting
with proteins from the
specimen tissue.
Negative reagent control Replace product with non-contaminated serum. 12-13

serum contaminated with
bacterial or fungal growth.
Limited Background
Areas of inconsistent staining on controls, specimens and glass slides.
Protein trapped beneath the Avoid the use of commercial adhesives, glue starch or gelatin 35-39,
tissue during the mounting in water baths when mounting tissue sections. Avoid allowing 119-129
process will allow partial water from an initial section mounting to flow over an area
lifting of the section. where additional sections will be mounted. This is particularly
Pooling of IHC reagents important when using charged or silanized slides.
beneath the section, or
partial detachment of
the tissue from the slide
may occur.
Undissolved granules of Insure that chromogen in tablet or powder form is completely 119-129
chromogen. dissolved, or switch to a liquid chromogen.
140
Troubleshooting
Limited Background (continued)
Incomplete removal of Remove embedding medium thoroughly, using fresh reagents 119-129
embedding medium.
Incomplete dezenkerization Perform dezenkerization with fresh reagents. 27-33

of tissue fixed with B5 or
mercury containing reagents.
Bacterial or yeast Clean and refill waterbath. 119-129

contamination from
mounting waterbath.
Partial drying of tissue prior ° Immerse tissue promptly in fixative or holding reagent. 119-129
to fixation. Unaffected areas ° Keep moist during the entire staining process.
show normal staining. ° Use a humidity or moist chamber during incubation steps.
° When using an automated staining instrument, addition
of wet towels to the sink may prevent drying of slides.
Instrument malfunction. Ensure automated stainer is programmed correctly and is 95, 119-
running to manufacturer’s specification. 129
Adipose or connective tissue in specimen, negative control tissue, positive control tissue
and negative reagent control slides. Background in connective and epithelial tissue.
Hydrophobic and ionic Nonspecific staining of fatty tissue rarely interferes with 119-129
interactions between interpretation of specific staining and usually can be disregarded.
immunoglobulins and lipoid
substances in fatty tissue.
Primary antibody and Reoptimize the dilution of the primary antibody and negative 15-16
negative reagent control control serum.
serum are diluted
insufficiently.
141

Epithelial tissue in specimen, negative control tissue, positive control tissue and
negative reagent control slides. Staining is moderate to marked, especially in epidermal
epithelium. Background in epithelia accompanies background in connective tissue.
Both the primary antibody and ° Use a higher dilution of the primary antibody and negative 5-7, 119-
negative control serum contain control serum. 129
contaminating antibodies to ° Increase the incubation time.
epithelial elements, possibly ° Replace the antibody.
cytokeratins.
Excessive formalin fixation of Proteolytic digestion or antigen retrieval will break down 27-33,
tissues may increase protein cross-linking and render some tissue antigens reactive. Refer 119-129
cross-linking, resulting in to the primary antibody and/or the negative reagent control
tissue hydrophobicity. specification sheet for appropriate pretreatment.
Focal cytoplasmic staining observed in epithelium in the specimen tissue.
Focal cytoplasmic staining This observation is rare and should not interfere with 119-129
is seen, particularly in interpretation of specific staining.
intermediate and superficial
layers of the epidermis.
May be caused by passive
absorption of plasma
proteins into degenerating
epidermal cells.
142
Troubleshooting

Background seen in all control and specimen tissue when using an immunoperoxidase
staining system.
Unquenched endogenous ° Use alternate or prolonged peroxidase blocks or use 119-129

peroxidase activity may be another enzyme label such as alkaline phosphatase.
seen in all hemoprotein- ° Eosinophils and mast cells are particularly resistant to
containing specimens, peroxidase quenching. Use a peroxidase blocker.
including hemoglobin in ° Use special stains: Eosin will stain eosinophils a bright
erythrocytes, myoglobin in red-orange.
muscle cells, cytochrome in
granulocytes and monocytes
and catalases in liver and
kidney.
Background seen in all control and specimen tissue when using an alkaline phosphatase
staining system.
Unquenched endogenous Add levamisole to the alkaline phosphatase chromogen reagent 119-129
alkaline phosphatase activity or use another enzyme label such as horseradish peroxidase.
may be seen in leucocytes, Intestinal alkaline phosphatase is not quenched by the addition
kidney, liver, bone, ovary of levamisole. Pretreat the tissue with 0.03 N HCl.
bladder, salivary glands,
placenta and gastro-intestinal
tissue.
143

Background seen in all control and specimen tissue when using a biotin-streptavidin
staining system.
Endogenous protein-bound Use a biotin block or chose another non-biotin based 119-129
biotin (water-soluble B staining system.
vitamin). High amounts of
biotin are found in adrenal,
liver, and kidney. Lesser
amounts are found in the GI
tract, lung, spleen, pancreas,
brain, mammary gland,
adipose tissue, lymphoid
tissue, and cells grown in
culture media containing
biotin as a nutrient.
Background of skeletal or smooth muscle tissue in positive control tissue, negative

control tissue, specimen tissue and negative reagent control.
Cause is not understood. Should not interfere with interpretation of specific staining. 119-129
It is possibly due to antibodies
to muscle antigens in primary
and negative reagent
control serum.
Undesired “Specific” Staining

Positive staining of leucocyte membranes in specimen tissue, positive control, negative
tissue control and negative reagent control.
Binding of the Fc portion of Use F(ab’)2 or F(ab) fragments for the primary and secondary 119-129
Ig by Fc receptors on the cell antibodies rather than intact antibodies. Add detergent to the
membrane of macrophages, wash buffer.
monocytes, granulocytes and
some lymphocytes.
144
Troubleshooting
Positive staining of histiocytes and granulocytes in the specimen tissue only, with a
marker not normally reactive with these cells.
Phagocytosis of antigens may Rare. Should not interfere with interpretation of specific staining. 119-129
render phagocytes positive
for the same.
Positive membrane staining of specimen tissue and negative reagent control tissue
when using a horseradish peroxidase staining system.
Tissue from persons infected Utilize a non-peroxidase staining system. 119-129

with Hepatitis B virus and
expressing Hepatitis B
surface antigen may exhibit
undesired staining.
Miscellaneous
Loss of viability of cell cultures.
Some manufacturers produce Utilize an in vivo product for application on viable cells. 119-129
antibodies and reagents For use on cell cultures only: Sodium azide may be dialyzed
for in vitro use only. These out of some reagents. Contact Dako Technical Support for
products may contain additional information.
preservatives, usually
sodium azide, which is a
known poison.
145
Section Two:
Troubleshooting flow chart: Use this flow chart to determine source(s) of non-specific
staining when using an immunohistochemical protocol.
Background Staining Encountered with HRP-Peroxidase Reagents
Reagents Result/Action
Brown endogenous pigment (such as melanin) observed:

Slide #1
° To distinguish melanin pigment from DAB

Positive Control Tissue:
chromogen, Azure B can be used as a counterstain.
Counterstain with hematoxylin
The melanin stains blue-green, while the DAB
remains brown.
° An alternate method is to use AEC as the
NO STAINING SEEN. GO TO NEXT STEP. chromogen. However, if high levels of pigment exist
q
in the tissue, the red chromogen may be partially
obscured. Since bleaching protocols to remove
melanin may compromise tissue antigenicity, it
should be avoided if at all possible.
Brown/Red color observed:

Slide #2
Positive Control Tissue: ° Indicates endogenous peroxidase activity in the

DAB/AEC + Counterstain tissue sections. It is present in all hemoprotein
containing tissue including erythrocytes, muscle,
liver, kidney, granulocytes and monocytes.
° Block with three percent hydrogen peroxide or
NO STAINING SEEN. GO TO NEXT STEP.
other peroxidase blocking reagent. Using a new
q
bottle of hydrogen peroxide, perform a three percent
H20 2 peroxidase block, followed by DAB and an
appropriate counterstain.

Slide #3
° Indicates endogenous biotin activity in the tissue

Peroxidase Block + Secondary Antibody + sections. Protein-bound biotin may be found in
Streptavidin-HRP + DAB/AEC + Counterstain adrenal, liver, kidney, GI tract, lung, spleen, brain,
mammary gland, adipose tissue, lymphoid tissue
and cell grown in culture media containing biotin
(RPMI, NCTC, MEME).
q
° Block with a biotin block or switch to a staining
system that is not dependent on the streptavidin/
biotin reaction.
146
Troubleshooting
Positive Control Tissue: Brown/Red color observed:

Slide #4
Peroxidase Block + Biotin Block (if required) + ° Indicates endogenous biotin activity in the tissue
Secondary Antibody + Streptavidin-HRP sections. Protein-bound biotin may be found in
+ DAB/AEC + Counterstain adrenal, liver, kidney, GI tract, lung, spleen, brain,
and cell grown in culture media containing biotin
(RPMI, NCTC, MEME).
q
biotin reaction.

° May indicate non-specific binding of the primary
Slide #5
Peroxidase Block + Biotin Block (if required)+

antibody carrier-protein. Perform a protein block
Negative Reagent Control + Secondary
with normal serum from the host of the link antibody
Antibody + Streptavidin-HRP + DAB/AEC
add 0.05-0.1% TWEEN 20 to wash buffer to
decrease protein attachment.
NO STAINING SEEN. GO TO NEXT STEP. ° Antigen retrieval lipofusion-artifact may appear as
q
granule staining in liver and cardiac tissue, or as
specific staining in pancreatic sections.
Brown/Red color observed on Negative Control Tissue:

Slide #6
° Monoclonal antibody: Possible contamination.

Negative Control Tissue:
° Polyclonal antibody: Possible contamination or
Perform complete staining protocol.
undesired antibody in the host Ig fraction.
° Antigen retrieval lipofusion-artifact may appear as
Background Staining Encountered with Alkaline Phosphatase
Red/Blue color observed:

Slide #1
° Indicates endogenous alkaline phosphatase activity

Fast Red, Fuchsin or BCIP/NBT + in the tissue sections. It is present in liver, kidney,
Counterstain GI tract, bone, bladder, ovary, salivary gland,
placenta, leukemic, necrotic or degenerated cells.
° Block with levamisole (Intestinal alkaline
phosphatase may be quenched by the
q
addition of 0.03 N HCl prior to the addition
of the alkaline phosphatase).
147
Red/Blue color observed:

Slide #2
° Indicates endogenous biotin activity in the tissue
Streptavidin-AP + Fast Red, Fuchsin or sections. Protein-bound biotin may be found in
BCIP/NBT + Counterstain adrenal, liver, kidney, GI tract, lung, spleen, brain,
and cells grown in culture media containing biotin
(RPMI, NCTC, MEME).
q
biotin reaction.
Positive Control Tissue: Red/Blue color observed:

Slide #3
Biotin Block (if required) + Secondary ° Indicates non-specific or undesired binding of

Antibody + Streptavidin-AP + Fast Red, the secondary antibody to the tissue sections.
Fuchsin or BCIP/NBT + Counterstain This primarily occurs when the secondary
antiserum has not been prepared for use on a
specific species tissue.
° To determine if this is the problem, absorb out non-
q
specific proteins by adding 2, 5 or 10 µL of normal
serum (from the species of tissue to be stained) per
100 µL of the secondary antibody.
Positive Control Tissue: Red/Blue color observed:

Slide #4
Biotin Block (if required) + Negative Reagent ° May indicate non-specific binding of the primary
Control + Secondary Antibody + Streptavidin-AP + antibody carrier-protein. Perform a protein block
Fast Red, Fuchsin or BCIP/NBT + Counterstain. with normal serum from the host of the link antibody
or a protein block; add 0.05-0.1% TWEEN 20 to
wash buffer to decrease protein attachment.
q
granule staining in liver and cardiac tissue or as
Red/Blue color observed on Negative Control Tissue:

Slide #5
° Monoclonal antibody: Possible contamination.

Negative Control Tissue:
° Polyclonal antibody: Possible contamination or
Perform complete staining protocol
undesired antibody in the host Ig fraction.
148
Troubleshooting
Negative Control Reagent
° (Human tissue) Perform the peroxidase blocking

Negative Control Reagent: protocol from Slide #2 under “Background Staining
Perform complete staining protocol. Encountered with HRP-Peroxidase Reagents.”
° Perform a biotin block if required, protein block if
required, apply the appropriate negative reagent
control (see below), apply biotinylated secondary
antibody, apply streptavidin/HRP reagent and DAB.
Prepare a negative reagent control

° Polyclonal: Non-immunized sera from the same species, diluted to the same protein concentration as the
primary antibody.
° Monoclonal: Negative reagent control that matches the isotype as the primary antibody. Additionally, the diluent used
to manufacture a monoclonal primary antibody and isotypic negative control should contain the same ions. Diluents
containing sodium or phosphate ions may change the sensitivity of some monoclonal antibodies.
° Calculation:
° Ig or total protein concentration of primary antibody divided by dilution factor of primary antibody = x.
° Ig or total protein concentration of negative reagent control divided by x = dilution factor of negative reagent control.
149
Section Three:
Tissue Specimen
Tissue Specimen: Successful staining of tissue with an IHC marker is dependent on the
type and preparation of the specimen. Record in the chart below, the species of the animal
to be tested, the tissue source or organ from which it was collected, the collection method,
how the specimen was fixed and tissue.
Species:
Organ/tissue source:
Collection:
£ Surgical specimen/biopsy
£ Post-mortem specimen
£ Fine-needle aspirate
£ Peripheral blood (include anti-coagulant)
£ Brushing
£ Biologic fluid
£ Cell culture
£ Other
Tissue preparation:
£ Paraffin-embedded
£ Plastic-embedded
£ Cryostat section
£ Cytospin
£ Cell smear
£ Mono-layer cultured cells
£ Other
Tissue fixation:
Type of fixative
Length of time
Size of specimen
Tissue mounting:
£ Slide mount
£ Tissue thickness
£ Gelatin, glue commercial adhesive or starch in the water bath
£ Other
150
Troubleshooting
Endogenous Blocks
Background staining is defined as unexpected or undesirable staining seen on the
test or control tissue, which does not represent the target antigen. Frequent causes of
background staining are endogenous enzyme activity and endogenous biotin.
Peroxidase is an enzyme of the oxido-reductase class that reacts with a substrate

containing hydrogen peroxide as the electron acceptor. To block this activity, a variety
of hydrogen peroxide reagents can be applied to cells producing this enzyme.
Alkaline phosphatase is an enzyme having various isoforms, which are produced

in the leukocytes, liver, bone, intestine, placenta and Regan (carcinoma). Addition of
levamisole to the chromogen/substrate will inhibit endogenous alkaline phosphatase
activity, with the exception of the intestinal isoform. If necessary, this can be blocked
with a weak acid wash, such as 0.03-0.5 N HCl.
Biotin, a B vitamin, may be protein-bound to tissue and can interfere with proper
interpretation of staining patterns when using a streptavidin or avidin reagent. To block
this binding, a biotin/avidin block.
Peroxidase block:
£ 3% H2O2
£ Methanol/H2O2
£ Sodium azide
£ Peroxidase Block (Dako Code S2001)
£ Other
Alkaline Phosphatase block:

£ Levamisole
£ 0.03 N HCl (not for use on cryostat tissue)
£ Other
Biotin block:
£ Biotin Block (Dako Code X0590)
£ Other
Protein block:
£ Protein Block (Dako Code X0909)
£ Normal sera from host species of the secondary antibody
£ Other
151
Section Four:
Using a Typical Specification Sheet for an IVD Antibody
Information Information Located on the Specification Sheet Comments

You Need to
Know
Regulatory Intended use Indicates that a product meets the

Status of the ° For in vitro diagnostic use. FDA requirements as a clinical
Primary diagnostic product. Likewise, a CE
Antibody icon indicates the reagent meets
European Union requirements.
Patient test results do not require an
FDA disclaimer.
Tissue Specimen preparation Indicates the type of specimen that

Preparation ° Paraffin sections: The antibody can be was used during validation studies.
used for labeling paraffin- embedded tissue In many cases this would include
sections fixed in formalin. Pre-treatment of formalin-fixed tissue and frozen
tissues with heat-induced epitope retrieval sections. Use of other fixatives
is required. Optimal results are obtained requires validation by each
with 10 mmol/L citrate buffer, pH 6.0. Less individual laboratory.
optimal results are obtained with 10 mmol/L This section also indicates the
Tris buffer, 1 mmol/L EDTA, pH 9.0. The optimal epitope retrieval procedure
tissue sections should not dry out during and warns against procedures that
the treatment or during the following may destroy the epitope.
immunocytochemical staining procedure.
° Frozen sections and cell preparations: Specimen preparation and staining
The antibody can be used for labeling frozen procedure sections can and will
sections or fixed cell smears . change periodically, to reflect
changes in technology. So remem-
ber to retain copies of each version
of the reagent specification sheet.
Version numbers are usually found
on each page.
152
Troubleshooting
Using a Typical Specification Sheet for an IVD Antibody (continued)

You Need to
Know
Choosing the Staining procedure Indicates the recommended

Visualization ° Visualization: This antibody can be used with visualization system to be used
System an immunperoxidase staining method. with the antibody.
Follow the procedure enclosed with the It also indicates that the antibody
selected visualization kit. can be used for automated staining.
° Automation: The antibody is well-suited NOTE: If your state regulatory agency
for immunocytochemical staining using requires written documentation that
automated platforms. a reagent can be used for automated
staining and this indication is not
listed on the specification sheet, you
may wish to contact the manufacturer’s
technical support group for further
information.
Diluting the Staining procedure Includes a suggested dilution

Primary ° Dilution: Monoclonal Mouse Anti-Vimentin, range for the antibody and the
Antibody may be used at a dilution range of 1:50-1:100 recommended diluent.
when applied on formalin-fixed, paraffin- The dilution range is merely a
embedded sections of human tonsil. suggested starting point for an
individual laboratory. Optimal
conditions may vary depending
on specimen, preparation method,
temperature of the laboratory or
automated instrumentation.
Negative Reagent provided Use of a negative reagent control is

Reagent ° Isotype: IgG1, kappa. required by the College of American
Control Staining procedure Pathologists (CAP), based on
° The recommended negative control is mouse Clinical Laboratory Improvement
monoclonal IgG1, diluted to the same mouse Amendments (CLIA 2003), for
IgG concentration as the primary antibody. each patient or patient block in a
Positive and negative controls should be run staining run.
simultaneously with patient specimen.
153

You Need to
Know
Positive Performance characteristics CLIA 2003 Sec. 493.1273 (3)

Control Tissue ° Normal tissues: In general, most human Mandates that fluorescent and
mesenchymal cells are labeled by the immunohistochemical stains must
antibody, including fibrocytes, lipocytes, be checked for appropriate positive
smooth muscle cells, vascular endothelial and negative reactivity each time
cells, astrocytes, peripheral nerve (Schwann) they are used.
cells, macrophages (including Kupffer cells), Most IVD antibody specification
as well as myoepithelial cells of sweat and sheet will list tissue that will exhibit
salivary glands and of breast, which are all positive and negative staining
labeled strongly. Also positive, with variable patterns in the Performance
intensity and distribution, are the follicular Characteristics section.
cells of the thyroid, adrenal cortex, renal
distal tubules, and mesangial and endothelial NOTE: abnormal tissue will not
cells of the renal glomerulus, as well as necessarily be labeled.
pancreatic acinar cells (1,2). In the human Both negative and positive tissue
eye, the antibody labels the pigmented controls should be processed using
posterior and the anterior epithelia of the the same fixation, embedding,
human iris, including the muscle portion mounting, drying, epitope retrieval
(dilator pupillae) of the anterior epithelium, and immunostaining protocols as
as well as the nonpigmented and pigmented the patient tissue.
ciliary epithelia (4). In the ciliary epithelia,
vimentin was coexpressed with cytokeratin (4).
° Abnormal tissues: The antibody labeled
17/20 sarcomas, 16/18 melanomas, 4/4
meningeomas, and 3/3 schwannomas, and
was the sole intermediate filament present
in these tumours. In addition, variable
percentages (10 to 57 percent) of carcinomas,
neuroendocrine carcinomas, neuroblastomas,
thymomas and mesotheliomas were positive
with the antibody. With the exception of the
neuroblastomas, cytokeratin was coexpressed
with vimentin in these tumours. Among
adenocarcinomas, more than 50 percent
of papillary carcinomas of the thyroid as
well as renal, endometrial, ovarian and lung
carcinomas were labeled by the antibody and
coexpressed keratins and vimentin.
154
Troubleshooting

You Need to
Know
Negative Performance characteristics

Control Tissue ° Normal tissues: Skeletal and cardiac muscle
cells, epidermal, squamous, urothelial,
colonic and gastric mucosal, and glial cells,
as well as neurons are consistently negative
with the antibody .
References
1. Wood G, et al. Suppression of Endogenous Avidin-Binding Activity in Tissues and
Its Relevance to Biotin-Avidin Detection Systems. Journal of Histochemistry and
Cytochemistry 2981;29(10):1196-204.
2. Sayaki H, et al. Azure B as a Counterstain in the Immunohistological Evaluation of Heavily
Pigmented Nevomelanocytic Lesions. Applied Immunohistochemistry 1995;3(4):268-71.
3. Federal Register: January 24, 2003;68(12) 42CFR Part 493.
4. College of American Pathology; Anatomic Pathology Checklist, October 2005.
155
156
Glossary
This Glossary was not intended to be an all-encompassing list of terminology as used

in immunochemical staining. Rather, it assumes a basic level of technical knowledge
beyond which the included definitions were selected to help in clarifying the text of
this Guide.
Adjuvant In immunology, any substance that enhances the immunogenicity of an

antigen and results in a superior immune response. There are two types, those that
possess the ability to enhance both cellular and humoral response to a large number
of antigens (general potentiation), and those that strengthen specific response to only
a few antigens (specific potentiation). Adjuvants work by several mechanisms including
prolongation of antigen release, improving immunogenicity by antigen denaturation,
recruitment of other immunocompetent cells and induction of inflammation.
Affinity Absorption A method of separation by affinity chromatography. It may be

used, for example, to remove unwanted antibodies from an antibody preparation. The
preparation is passed through a column matrix containing antigens against which the
unwanted antibodies are directed. Thus, the unwanted antibodies remain bound to the
column. The antibody solution leaving the column contains only the desired antibodies,
purified by affinity absorption.
Affinity Isolation A method of separation by affinity chromatography. For example,

affinity isolated antibodies may be prepared by passing the antibody solution through a
column matrix to which antigens are coupled. Antibodies directed against the coupled
antigens remain bound on the column and may then be eluted using a solution which
disrupts antigen-antibody binding.
Agglutination The clumping of cells that are distributed diffusely in a fluid. It is

caused by agglutinins, antibodies developed against that specific cell type, and is
seen when a bacterial culture is treated with serum from an animal immunized against
that particular organism or when a suspension of cells, particularly red blood cells, is
exposed to antisera. This phenomenon commonly is employed in blood banking as
an indicator of antigen-antibody reaction between red cells and specific antiserum or
donor plasma.
Antigen A molecule that is capable of binding to an antibody.
Antigenic Determinant See Epitope.
Antigen Retrieval (AR) Also known by the terms “epitope retrieval” or “target retrieval,”
pertains to the restoration of antigenicity (immunoreactivity) to an immunogen.
Antiserum A serum that contains antibodies.
Ascites or Ascitic Fluid An accumulation of fluid in the abdominal cavity.
157
Background Unless defined otherwise, background staining includes all nonspecific

staining as a result of procedural artifacts. Occasionally, it may also include “undesirable”
staining, eg, due to diffused antigen.
Chromogen One of a group of chemical species that can form a particular colored
material or can be identified by such a reaction with an appropriate reagent.
Counterstain A second stain that provides a contrasting effect to another stain.
Cross-reactivity The ability of an antibody to react with antigens other than the
immunogen. The term should not be used when referring to reactions occurring between
an antibody and different cell or tissue components.
Epitope The structural part of an antigen that reacts with an antibody. These are
groupings of amino acids in globular proteins and sugar side-chains in polysaccharides.
The most critical part is called the immunodominant point.
Epitope Retrieval See Antigen Retrieval.
Expiration Date This term signals the minimum expected shelf life of biological
materials, including immunochemicals. (See Shelf Life).
Hyperimmunization The practice of establishing a heightened state of the actively

acquired immunity by the administration of repeated doses of antigen.
Idiotype Traditionally, antigenic determinants that relate to the specificity of the antibody.
Idiotypic arrangement of several groups of amino acids in the hypervariable regions
of light and heavy chains were thought to bestow unique antigenic determinants to the
antibody molecule and, as a consequence, a high degree of specificity. However, anti-
sera directed against these antigenic determinants have since been found to cross-
react with other antibody molecules. The term idiotype has yet to be redefined.
Immunochemistry The branch of immunology concerned with the chemical substances

and reactions of the immune system, the specific study of antigens and antibodies and
their interactions with one another.
Immunocytochemistry Immunochemistry applied to the study of intracellular activities.

(Now frequently used interchangeably with immunohistochemistry.)
Immunogen Any substance capable of generating an immune reaction, in contrast to

any substance that binds to an antibody (ie, an antigen).
Immunogenicity The ability of an immunogen to elicit an immune response.

Immunogenicity depends upon foreignness to the host, the size of the immunogen,
the complexity of its molecular structure, the length of time it remains in the host and
its ability to reach certain immunocompetent cells in order to generate immunity.
Immunohistochemistry Immunochemistry applied to the study of cells and tissues.

(Now frequently used interchangeably with immunocytochemistry.)
In Situ Hybridization An assay for nucleic acids “on site” in fixed tissue sections by the
use of heat to first denature and then to reanneal with specific DNA, RNA or PNA probes.
158
Glossary
Internal Tissue Control A specimen from the patient donor, which contains the target
marker, not only in the tumor to be identified, but also in adjacent normal tissue. Thus,
no separate positive control sections are needed.
Ligand A molecule, ion or atom that is bound to the central atom (usually a metal atom)
of a coordination compound or chelate.
Link Antibody See Secondary Antibody.
Monoclonal Antibodies Immunochemically identical antibodies produced by one

clone of plasma cells that react with a specific epitope on a given antigen. Produced
commercially using hybridomas.
Monospecific Having an effect only on a particular kind of cell or tissue, or reacting

with a single antigen, as a monospecific antiserum.
Negative Tissue Control A tissue specimen from the same organ lacking the target
antigen and processed by use of the primary antibody.
Nonimmune Serum Serum obtained from animals which have not been immunized.
Polyclonal Antibodies Immunochemically dissimilar antibodies produced by different

cells and reacting with various epitopes on a given antigen.
Positive Tissue Control A specimen previously shown to stain specifically for the target
antigen after exposure to primary antibody. Nonspecific background staining should
be at a minimum. Note that, for some target antigens (e.g., prostate specific antigen),
the staining intensity ideally should be less than maximal to allow monitoring not only
for positivity, but also for variation in intensity.
Primary Antibody The first antibody used in a staining procedure.
Prozone Phenomenon The phenomenon exhibited by some sera, which give effective
agglutination reactions when diluted several hundred- or thousand-fold, but do not
visibly react with the antigen when undiluted or only slightly diluted. The phenomenon
is not simply due to antibody excess, but often involves a special class of antibodies
(blocking or incomplete) which react with the corresponding antigen in an anomalous
manner. The bound antibody not only fails to elicit agglutination, but actively inhibits it.
The phenomenon may also occur with precipitation or other immunologic reactions.
Quenching Refers to the inactivation of a chemical activity by an excess of reactants or
products. In enzymology, excess substrate or product may inhibit the enzymatic activity.
Secondary Antibody The second antibody used in a staining procedure; it reacts

with the primary antibody, now the antigen, and forms a bridge between the primary
antibody and a subsequent reagent, if any. Also known as “link” antibody.
159
Shelf Life This term refers to the expected duration of the functional stability of
biological substances, including immunochemicals, and most commonly is assessed
by experimental tests, statistical work and observation. Within the user’s laboratory,
periodical comparisons of the working solution with aliquots kept frozen at –20 °C is
recommended. The shelf life is terminated by an Expiration Date.
Specific Staining Positive staining of tissue or cells by use of primary antiserum.

Occasionally this includes diffused, absorbed or phagocytosed antigen, giving rise to
“undesirable” staining. The staining seen due to contaminating antibodies in the primary
antiserum should be considered as nonspecific.
Standardization Classically, to standardize means to compare with or conform an

assay of unknowns to established standards. In quantitative analytical work numbers
readily allow for conforming to such standards. In semi-quantitative or qualitative assays
such as immunocyto- or immunohistochemistry, which frequently conclude with an
opinion, only subjective comparisons to carefully selected tissue and reagent controls
can be used to monitor and maintain excellence.
Target Retrieval See Antigen Retrieval.
Titer In immunohistochemistry, the highest dilution of an antiserum, which results in

optimal specific staining with the least amount of background.
160
Index calf intestine phosphatase (AP) 19-21
composition 20-21
method 21
ABC (Avidin-biotin-enzyme-complex) 48 molecular weight 21
and catalyzed signal 52-53, 64 3-Amino-9-ethylcarbazole (AEC) 22-23,
amplification (see also CSA) 36, 38, 51- 65, 146-147
54, 62-66, 89-93, 116, 161, 163, 171 amplification (see also CSA) 48, 36, 38,
formation of complex 48-50 51-53
general procedure 48 amplification reagent, 48, 51-54
and ABC 48
Acetic acid-zinc chloride fixative 30
Animal cross-reactivity 7, 9, 11, 62-65, 126, 138
Acetone 30, 31, 58
Animal Research Kit (ARK™) Peroxidase 64
Adipocytes 127
Antibodies 1, 5-12, 79, 125-127, 157-159
Adjuvant 5, 125 adsorption 12
affinity 7-10, 15-18
AEC (3-Amino-9-ethylcarbazole) 22-23, aggregates 10-11, 15, 127-128
65, 146-147 anti-ruminant 5-7
association constant 7-8
Aerosil 13 avidity 7-8, 15-18
conjugates 21-22
Affinity 7, 9
conjugation 11, 21-22, 57
absorption 7, 58, 125-126, 142, 157
possible effects of 127-128
chromatography 5-10
contaminating 125
functional 7-8, 21, 55, 107, 160
cross-reactivity 7, 9, 11, 62-65, 126, 138
and insoluble immune complex 7-10
animal 9-10
intrinsic 7-8, 15-18, 115, 126-127
definition 9-10
maturation 7-9
and shared epitopes 9-10
of antibodies 7-10
dilutions 15-18
and precipitation 6-8
and incubation temperature 15-18
and wash cycle 7-8
and incubation time 15-18
Air-drying 18, 29, 33, 58-59, 97, 99, 129 and 125
and rapid staining 36, 47, 105
Albumin, bovine 12 serial 15-18
isolation, effects of 10-12
Alcohol (see Methanol and Ethanol) environmental 113
equilibrium, with antigen 15-18
Alkaline phosphatase 21-25, 74-75, 78, 99- expiration dates 10-12
100, 120-121, 143, 147, 151 Fab fragment 1-3, 65, 129
activity 21, 119-120 F(ab’)2 fragment 1-3, 65, 129
chromogens 22 Fc fragment 1
endogenous 99, 119-120 Fc receptor 58, 126
suppression of 17, 21, 119, 123 formation of 2-7
inhibitors 20, 74 half life 2-4
metal activators 21 handling 10-12
molecular weight 21 hinge region 2-4
substrates 21-23 incubation 10, 125
substrate-chromogen 21 time 15-18
reagent 20-25 temperature 15-18
irrelevant specificity 1-9, 51, 53, 71, 83,
Alkaline phosphatase-anti-alkaline
113, 115, 117, 125, 127
phosphatase complex (APAAP)
monoclonal (see Monoclonal
10, 17, 21, 53
antibodies)
advantages 21
pI 78
161
polyclonal (see Polyclonal antibodies) and cross-reactivity 9-10

polymerization 12-13 and cytology 43-44
prediluted 12-13 of diagnostic markers 44
production and doublestaining 43-44
latent period in 2-4 heating methods 43-44
reaction rates 9-10 mechanism 43-44
and molecular size 9-10 principle 41-42
signal-to-noise ratio 15-18 and proteolytic digestion 2, 38-44, 58,
stability 10-13 61, 73, 91-92
and expiration 10-11 retrieval solutions 41-42
tests for 10-11 and specificity, loss of 1-9, 51, 53, 71,
storage 10-13 83, 113, 115, 117, 125, 127
containers 12-13 technique 41-42
temperature 12-13
thawing of 12-13 Anti-ruminant antibodies 5-7
tissue penetration 9-10
titer 15-18 Avidin-Biotin 48
definition of 15-18
B5 fixative 30, 126
enhancement of 15-18
titration 15-18 Background 8, 10, 15-18, 50, 52, 79,
use and care 112-13 115, 119, 122-129, 131-132, 136-138, 151,
158-159
Antigens (see also Epitope) 2-10, 15-18,
in adipocytes 127
20, 27-33, 38, 41-45, 47, 50, 52-53, 71-75,
antigen diffusion 128-129
78-79, 99, 110, 115-116, 119, 126, 131-151,
and antigen retrieval 7-10, 15-18, 38,
157-160
41-45, 50, 71, 99, 123, 134-136, 138, 142
carbohydrate 2, 52, 73
and biotinylated antibodies 49, 128, 149
cytoplasmic 10, 26, 96, 122
in collagen 127
diffusion 66, 112, 118, 122-125
complement 14, 52, 59, 78, 110, 128
injection 5-7
connective tissue 127
lipid-containing 12
contaminating antibodies 13, 60, 103,
masking 31, 73
129, 141, 147-148
phagocytic ingestion 124
cross-reactivity 7-10, 11, 62-65, 126, 138
preservation 35-38, 41, 114
endogenous avidin-binding (EABA)
purified 11, 126
121-123
purity 11. 126
elastin 127
retrieval (see Antigen retrieval)
endogenous enzyme activity
surface membrane 26, 42, 56, 72, 96,
(see also APAAP and PAP) 21,
99, 126
119-120, 143, 146
unreactive detection of 31, 119-120
Fc receptors 58, 126
Antigen-antibody interactions 8 HbsAg 128
association constant of 7-8 hydrophobicity 11, 127-128, 136, 138, 142
dissociation 7-8 incubation time 7-10, 125
distance 2-4 ionic interactions 79, 128
equilibrium 9-10, 15-18 miscellaneous sources 128
precipitates 9-10 natural antibodies 125
reaction rates 7-10 nuclear staining 137
phagocytosis 37
Antigen-binding fragments specific 144
(Fab’)2 , Fab) 1 squamous epithelium 124-127
Antigenic determinant (see Epitope) Bacterial contamination 12-13
Antigen retrieval (AR) 7-10, 15-18, 38, B cell(s) 5-7

41-45, 50, 71, 99, 123, 134-136, 138, 142 antigens and fixation 43
162
Index
and Fc receptors 58, 126 EPOS™ system 50

neoplasms 7, 127 and rapid staining 37
nonreactive 5-7 “spine molecule” 51
Beta-lipoproteins 12-13 Checkerboard titrations 116-18
Biotin (see also Avidin-biotin) 48 4-Chloro-1-naphthol (CN) 21-22

endogenous 50, 121-122, 146-148, 151
Chloroform 27-33
Biotinylated antibody 49, 128, 149
Chromatin 27-33
Biotinylated probes 90-91
Chromatolysis 27-33
Blood smears 21-22, 27
Chromogen(s) (see also specific
Bouin’s fixative 127 chromogens) 15–17
Bovine albumin 12 Chymotrypsin 27-33
Bromelain 41 Collagen 127
5-Bromo-4-chloro-3-indoxyl phosphate College of American Pathologists (CAP)

(BCIP) 23-24 controls 11, 117, 153
Buffer 71, 82-86, 103, 128-129, 134 Complement 14, 52, 59, 78, 110, 128
Tris buffered saline (TBS) 82-84
wash buffers 71, 82 Conjugation 11, 21-22, 57
enzyme-antibody (see also
Carcinoembryonic antigen (CEA) Glutaraldehyde)
9-10, 127 and hydrophobicity 11, 127-128, 136,
138, 142
Calcium 12-13 of peroxidase-avidin 21-22
of peroxidase-biotin 21-22
Carbohydrates 2, 52, 73
Connective tissue 127
CAP (College of American Pathologists)
controls 11, 117, 153 Contrast 57
differential interference contrast 57
Catalases 119, 143 Hoffman modulation contrast (HMC) 57
Catalyzed signal amplification (CSA) 49 Controls 52, 60, 100, 110, 113-117,
and ABC 49 131-132, 140, 153-154, 160
amplification reagent 49 affinity-absorbed antiserum 1, 8, 10, 13,
and antigen retrieval 7-10, 15-18, 38, 15, 58, 125-127, 133, 148, 157, 159-160
41-45, 50, 71, 99, 123, 134-136, 138, 142 and antigen retrieval 7-10, 15-18, 38,
biotinyl-tyramide 48 41-45, 50, 71, 99, 123, 134-136, 138, 142
sensitivity 52, 65 and automation 103-107
cell line controls 116-118
Cell membrane 43, 57, 72, 97, 99, 45
diluent, use of 16, 71, 79-81, 113,
Cell smears 23-24, 62, 96 128, 134
internal tissue controls 115
Cell surface markers 47 non-immune serum 114
and irrelevant specificity 1-9, 51, 53, 71,
Chain polymer-conjugated 83, 113, 115, 117, 125, 127
technology 36, 47, 105 negative 52, 60, 115, 153
dextran 11, 13, 50 omission of 32
EnVision™ system 45, 50, 65 purified antigen 11, 126
and doublestaining 64-65 quality assurance 33
163
quality controls 7, 81, 113, 117-118, 128 and monoclonal antibodies 7-8, 15-16
quality control programs 128
reagent controls 113-114, 160 Direct method 63-64
dilution of 113-118
and soluble aggregates 113-118 Dissociation
monoclonal antibodies, for 113-118 of immune complexes 1, 7-8
polyclonal antibodies, for 113-118 reductive 1
and tissue culture media 113-118
Disulfide bridges 2-4
irrelevant antibodies 113-118
“standardization” 113-118 DNA analysis (see also In situ
tissue controls 113-118 hybridization) 89-93
internal (“built-in”) 113-118
negative 113-118 Double diffusion 113
positive 113-118
sensitivity 113-118 Doublestaining 64-65
tissue reference 113-118 and acid elution 64-65
Counterstain 23-24 41-45, 50, 71, 99, 123, 134-136, 138, 142
and chromogens 64-65
Cross-linking 11, 29, 38, 41, 43, 99, 127, and EnVision™ procedure 64-65
136, 138, 142
Elastin 127
Cross-reactivity 7, 9, 11, 62-65, 126, 138
Electronmicroscopy 67
Cryostat sections 58
morphology 29, 41, 43, 47, 66, 87, 93, Electrostatic interactions (see also Ionic
96, 98-99 interactions) 7-8, 128
Cytochrome 118 Embedding (see also Paraffin) 43, 51-52,

103, 105, 129
Cytocentrifuge preparations 96
Endogenous (strept)avidin-binding
activity (EABA) 121-123
Cytology 43, 90, 98, 100 and biotin 50, 121-122, 146-148, 151
Cytology smears 43-44 blocking of 128
Cytoplasmic antigens 10 Endogenous enzyme activity 20, 78
catalase 119, 143
Decalcification 47-53
cytochrome 118
Dextran 11, 13, 50 hemoglobin 118
intestinal 20, 120
Dextran sulfate 11-13, 50 non-intestinal 20. 120
quenching of 20, 57, 119-121, 143
Diagnostic cytology 47-53 liver 20, 51, 115, 119, 121
myoglobin 118
Diagnostic markers suppression of 20
and antigen retrieval 7-10, 15-18, 38, 41-
45, 50, 71, 99, 123, 134-136, 138, 142 Energy loss 57
non-radiative 57
3’-Diaminobenzidine tetrahydrochloride radiative 57
(DAB) 21-24
Environmental antibodies 124
Differential interference contrast (DIC) 57
EnVision technique 45, 50, 65
4,4’ Difluoro-3,3’ dinitrophenyl sulfone
\(FNPS) 21-22 Enzyme(s)
(see also specific enzymes) 19-25
Diluent buffers 7-8, 129
164
Index
activity 19-21 Fast Red LB 23-24

endogenous 20, 78
chromogens 21-24 Fast Red TR 23-24
classification 19-21
conjugation 12-13, 21-22, 57 Fast Red Substrate 23-24
definition 19-21
Fc receptor 58, 126
digestion (see also specific enzymes)
1, 2, 38-44, 58, 61, 73, 91-92 Ficin 41
inhibitors 19-21, 74
and metal ions 19-21 Fixation 9-10, 27-33, 35, 37, 39, 42-45, 50,
prosthetic groups 19-21 53, 58, 60, 71, 75, 91, 97-98, 113, 115-116,
reactions 19-21 119, 124, 127, 129, 131
selection 19–24 by air drying 58, 97
substrates 21-25 and antigen retrieval 7-10, 15-18, 38,
41-45, 50, 71, 99, 123, 134-136, 138, 142
Enzyme-antienzyme Immune Complex and artifactual staining 36
(see APAAP and PAP) 10,17, 21, 47-48, 53 of cell smears 23-24, 62, 96
and chromatolysis 27-33
Enzyme-substrate reactions
and conformation changes 81, 97, 99
(see also Enzyme) 19
of cryostat sections 58
Enzymology 19-25 of cytocentrifuge preparations 96
of cytology smears 43-44
Epithelium 124-127 cytoplasmic antigens 10
ethanol 30-37, 73, 96-98, 119
Epitope 3, 6-9, 16, 27, 30, 41, 45, 60, 71-73, excessive 27-33
78, 80, 87, 115, 135, 152, 154, 157, 159 formalin 27-33
and antibody dissociation 1 standard method 27-33
and antigen retrieval 7-10, 15-18, 38, 41- by heat 27-33
45, 50, 71, 99, 123, 134-136, 138, 142 and hydrophobicity 11, 127-128, 136,
carbohydrate-containing 2, 52, 73 138, 142
conformational changes 81, 97, 99 for immunoelectronmicroscopy 22
and digestion 2, 38-44, 58, 61, 73, 91-92 of leukocyte surface markers 27-33
and fixation 7-8, 27-45 of lymphoid tissue 27-33
formalin-resistant 40 and monoclonal antibodies 27-33
formalin-sensitive 40 of paraffin-embedded sections 27-33
masking 41-42 post-fixation 27-31
and paraffin 7-8 and proteolytic digestion 2, 38-44, 58,
reactivity 1-13 61, 73, 91-92
uniqueness 6-10, 52, 90 spray 27-33
Epitope retrieval Fixatives 27-31, 35-41, 43, 73, 95-98, 123,

(see Antigen retrieval) 7-10, 15-18, 38, 134, 152 (see also specific fixatives)
41-45, 50, 71, 99, 123, 134-136, 138, 142 acetic acid-zinc chloride 30
acetone 30-31, 58
Equilibrium action of 27-33
of antigen-antibody binding 9-10, 16-18 additive 27-33
of injected immunogen 2-4 alcoholic fixatives 31
aldehyde-based fixatives 31
EPOS™ technique 50 Bouin’s solution 127
B5 30, 126
Ethanol 30-37, 73, 96-98, 119
cell smears 23-24, 62, 96
Fading 57 carbowax 27-33
coagulant 41
Fast Garnet GBC 23-24 cryostat sections 58
effects of 27-33
Fast Blue BB 23-24
165
on cell membrane 43, 57, 72, 97, neutral buffered 27-33

99, 45 ten percent neutral buffered formalin 28
on cytoplasm 27-33
ethanol 30-37, 73, 96-98, 119 Freezing 13
formaldehyde (formalin)-based 27-33 of antibodies 10-11
and methylene bridges 27-33 of tissue 7, 36, 50, 120-121, 129
neutral buffered formalin 27-33
formal-acetone-based 27-33 Frozen sections 13, 30, 31, 58, 107,
glutaraldehyde 10-11, 21-22 119, 126
infra-red heating 27-33 and Fc receptor(s) 58, 126
mercuric chloride-based 27-33
Giemsa staining 27-33
methanol 30-37, 73, 96-98, 119
molecular fixatives 36 Glutaraldehyde 10-11, 21-22
non-coagulant 41 and electron microscopy 67
and paraffin-embedding 43, 51-52, 103, and hydrophobicity 11, 127-128, 136,
105, 129 138, 142
penetration of 10, 29-30, 129 and peroxidase conjugation 11,
paraformaldehyde-glutaraldehyde 27-39 21-22, 57
periodate-lysine-paraformaldehyde conjugation 11, 21-22, 57
(PLP) 27-39 one-step 21-22
and potassium dichromate (PLDP) two-step 21-22
27-39
spray 19 Granulocytes 35, 3774, 119-121, 126
Zenker’s solution 30, 126
Hanker-Yates reagent 22
Fluorescein Isothiocyanate 55-57
Hardening agents 27-33
Fluorescence In Situ Hybridization (FISH)
90 Hemoglobin 118
Fluorescence Resonance Energy Hemolysis 13

Transfer (FRET) 57
HercepTest™ 114-116
Formal
acetone 27-33 Hoffman modulation contrast (HMC) 57
sublimate 27-33
Horseradish peroxidase (see Peroxidase)
Formaldehyde 28, 36, 86, 98, 114 19, 53, 74, 128-129, 143, 145
action of 27-33
HPV 93
and conformational changes 81, 97, 99
and monoclonal antibodies 27-33 Humidity chamber 16-18
and proteolytic digestion 2, 38-44, 58,
61, 73, 91-92 Hybridoma 6
-based fixatives 27-33
Hydrogen peroxide 20-24. 51-52, 99-100,
Formalin 120, 146, 151
composition of 27-33
fixation 27-33 Hydrophobicity 11, 127-128, 136, 138, 142
and immunization 5-7 and adipocytes 127
inconsistency 27-33 and aggregation 9-11, 127
and proteolytic digestion 2, 38-44, 58, and aldehyde fixation 10-11, 27-31
61, 73, 91-92 and anions 127
-resistant epitopes 27-33 and antibodies 127
-sensitive epitopes 27-33 and antigen-antibody binding 127
standard method 27-33 and background 127-129
and hydrophobicity 11, 127-128, 136, and beta-lipoproteins 12-13
138, 142 and biotinylated antibodies 49, 128, 149
166
Index
and blocking protein 128 intrinsic affinity of FcR for 124-127

bovine albumin 12 soluble enzyme-antienzyme (see
casein 129 APAAP and PAP) 17
non-fat dry milk 129 Immunization 2-8
and cations 127
and conjugation 11, 21-22, 57 Immunoalkaline phosphatase method 1,
and connective tissue 127 100 (see APAAP)
and cross-linking 124-127
and diluent buffer 124-127 Immunoenzymatic staining method
and epithelium 124-127 (see APAAP and PAP) 19
and fixation 27-31
Immunocytochemistry
and formalin 124-127
fixation 27-31
and glutaraldehyde 124-127
and immunoglobulins 124-127 Immunodiffusion 125
and ions 3124-127
and ionic strength 124-127 Immunoelectronmicroscopy
and nonspecific binding 124-127 fixation for 27-31
and stability 10-11, 124-127
and storage of antibody 10-11 Immunoelectrophoresis 113, 125
postfixation 27-31
reduction of 124-127 Immunogen 2-4
tissue 9-10 adjuvant 5-7
dose 5-7
Hyperimmunization 2-4, 7-8 injection 5-7
purity 11. 126
IgA 1
Immunoglobulins
IgD 1 (see also IgG and IgM) 5–11
chains 1
IgE 1 class 1
cytoplasmic 10, 26, 96, 122
IgG (see Immunoglobulin G) 1
disulfide bridges 1
IgG1 2-4 fraction 1, 6, 10-16, 114, 127
and hydrophobicity 1, 127-128, 136,
IgG2 2-4, 124-127 138, 142
light chains 2-4
IgG2a 2-4, 124-127 membrane-bound 27
purification 10-11, 56, 64
IgG2b 2-4, 10-11 stability 111
structure 1–7
IgG3 2-4, 124-127 subclass 2-4, 10-11
surface membrane 26, 42, 56, 72, 96,
IgG4 2-4, 124-127
99, 126
IgM (see Immunoglobulin M) 2-4, 124-127
Immunoglobulin G 1-4, 5–13
IgM1 2-4 affinity 7-8
aggregates 10-11
IgM2 2-4 allotypic marker 2-4
amino terminal 2-4
Image analysis 67, 111-112 and blocking protein 128
and controls 52, 60, 100, 110, 113-117,
Immune complex 7-8, 21 131-132, 140, 153-154, 160
and hydrophobicity 7-8, 11, 127-128, and hydrophobicity 11, 127-128, 136,
136, 138, 142 138, 142
dissociation 7-8 and hyperimmunization 2-8
insoluble 9 antigen-combining site 2-4
167
carbohydrate moiety 2-4 Indirect method 63-64

carboxyl terminal 2-4 three-step 47-53
chains 1 two-step 47-53
disulfide bridges 1
domains 1-4 In situ hybridization (see also DNA and
formula 1 RNA analyses) 36-38, 89-93, 105, 116
fragments 1-4 target retrieval for 44, 63, 91, 114,
molecular weight 1 116, 129
glutaraldehyde-reactive sites 10-11
half-life 2-4 Iodonitrotetrazolium Violet (INT) 23
hinge region 1-4
Ionic interactions 7-8, 79, 128
human 1
and antibody affinity 7-8, 79, 128
hypervariable region 2-4
idiotypic determinants 2-4
41-45, 50, 71, 99, 123, 134-136, 138, 142
isoelectric points 50, 79, 127
and background 79, 128
kappa/lambda ratio 2-4
and HRP conjugates 79, 128
molecular weight 1
monoclonal (see Monoclonal
138, 142
antibodies)
reduction of 79, 128
mouse 2-4
and papain 1 Isolation
pepsin 1 of antibodies 5-7, 10-11, 127
polyclonal (see Polyclonal antibodies)
proteolytic digestion 1, 2, 38-44, 58, 61, Labeled avidin-biotin method
73, 91-92 (LAB) 16-18, 48-49
reductive dissociation 5 Labeled streptavidin-biotin method
storage 10-13 (LSAB) 16-18, 21, 49
structure 1
subclasses 2-4 Laminin 127
surface charge 128
Leukocyte
survival time 2-4
surface markers 27-33
Immunoglobulin M 2-4 Fc receptors 58, 126
chains 2-4
Levamisole 21, 24-25, 120-121, 143, 147,
disulfide bridges 5
151
enzymic digestion 2, 38-44, 58, 61, 73,
91-92 Link antibody 16
fragments 2-4 affinity-absorbed 1, 8, 10, 13, 15, 58,
molecular weight 2-4 125-127, 133, 148, 157, 159-160
formation 2-4 biotinylated 49, 128, 149
formula 2-4 cross-reactivity 7, 9, 11, 62-65, 126, 138
half-life 2-4 and non-specific binding 82, 114, 128
J chain 2-4 requirements 48, 50, 63-64, 80, 144
purification, sensitivity to 10-11, 56, 64
reductive cleavage 2-4 Lipemia 12-13
storage, sensitivity to structure 2-4
subclasses 2-4 Lipids 13
survival time 2-4 and aerosil 13
tissue penetration of 2-4
Lipolysis 13
Incubation temperature and
time 7-8, 15–18, 42, 58, 64, 73, 103 113- Lipoproteins 12-13
116, 119, 122, 125, 128, 132-142
and antibody reaction rates 15-18 Lymphocyte(s) 5-7
and antibody titer 15-18 markers 6, 30
168
Index
Lymphoid tissue 6, 30 Naphthol AS-BI phosphate 23-24
Macrophages 127 Naphthol AS-MX phosphate 23-24
Mercuric chloride-based fixatives 73 Naphthol AS-TR phosphate 23-24

metal activators 21
Natural antibodies 125
Methanol 30-37, 73, 96-98, 119
Necrotic tissue 29
Methanolic H2O2 30-37, 73, 96-98, 119
Negative control 52, 60, 115, 153
Monoclonal antibodies 1, 6-12, 15-16, 27,
30, 84, 125-128, 132-133, 140, 149 Neutral buffered formalin 27-30
advantages 7-8
affinity 7-8 New Fuchsin 23-25
and ascites fluid 15-18
New Zealand White Rabbit 5-7
and background 79, 128
and controls 116-118 Nitro blue tetrazolium (NBT) 23-24
and cell culture supernatant 15-18
concentration 15-16 Noncoagulant fixatives 41
diluent buffer 7-8, 15-18 Nonimmune serum (see also Preimmune
dilution 15-16 serum) 159
optimal 15-16
preparation of 15-18 Nonprecipitating antibodies 5-8
disadvantages 7-8
Nonspecific antibodies 5-7
expiration dates 10-11
Fc receptors 58, 126 Nonspecific binding (see Background)
and formalin-fixation 19–22 Nonspecific cross-reactivity 7, 9, 11,
and frozen tissue 7-8 62-65, 126, 138
and precipitation 9-10
and staining procedures 7-8, 49 Nonspecific staining (see Background)
performance 10-11
and PBS 15-16, 26 Nordic Immunohistochemical Quality
and pH 15-16 Control (NordiQC) 117, 129
and pI 15-16
production 5-10 Northern blots 89, 91
propagation 5-10
Nucleic Acid Probes 35-37, 44, 158
properties 7-8
composition 89-93
detection methods 89-93
screening clones 7-8
labels for 89-93
sensitivity 8-15
labeling methods 89-93
to solutes 7-8, 15-16
probe length 89-93
to pH 7-8, 15-16
and protease treatment 89-93
specificity 10-11
sample complexity 89-93
stability 10-11
size 89-93
storage 10-11
sensitivity 89-93
titer 15-16
and target retrieval 44, 63, 91, 114,
Morphology 29, 41, 43, 47, 66, 87, 93, 96, 116, 129
98-99 types 89-93
Myeloma cells 5-7 Osmium tetroxide 21-22
Myoglobin 118 Omnifix 31
Papain 1
169
Papanicolaou’s staining 112 and polyclonal antibodies 15-16
Paraffin embedding 43, 51-52, 103, Phagocytes 124, 145

105, 129
Phase contrast 57
Paraformaldehyde-glutaraldehyde
solution 27-39 p-Phenylenediamine dihydrochloride
21-22
PBS (see Phosphate-buffered saline)
Phosphate-buffered saline (PBS) 15-16,
Penetration 10, 29-30, 129 81-82
of antibodies 9-10 and monoclonal antibodies 5-16, 81-82
of fixative 27-33
Photobleaching 57
Pepsin 1-2, 41, 92
pI 15-16
Peptide nucleic acid probes (PNA) 88
Picric acid 27-33
Periodate-lysine-dichromate-
paraformaldehyde (PLDP) 27-39 Polyclonal antibodies 5-7, 114, 127, 140
(see also Antiserum) 5, 7
Periodate-lysine-paraformaldehyde affinity 7-8
(PLP) 27-39 background 127-129
Peroxidase 19-21, 31, 47-53, 74-78, 99-100, hemolysis 12-13
119-121, 128-129, 131, 143, 145, 146, 149 hyperimmunization 2-4
active site 19-21 production 5-7
activity 21-22 proteolytic digestion 2, 38-44, 58, 61, 73,
endogenous 19-22, 119-120 91-92
antibodies to 19-21 purification 10-11, 56, 64
-conjugated antibodies 21-22 rabbit primary 5-7
conjugation 11, 21-22, 57 titer 15-16
covalent binding 21-22
endogenous 19-22, 119-120 Pools of antisera 5-7
enzyme classification 19-21
inhibition 19-22 Postfixation 27-31
ionic interactions 119-120
molecular weight 19-21 Preimmune serum 159
noncovalent binding 19-22
Primary antibody 10, 16, 48-51, 62-64, 67-
prosthetic group 19-21
69, 79-80, 103, 114, 129
reactive groups 19-21
affinity 7-8
soluble immune complex (see also
and background 127-129
APAAP and PAP) 21-22
and blocking reagent 79, 99-100, 135,
substrate-chromogen reagents 23-24
146
streptavidin conjugate 21-22
and checkerboard titration 16
Peroxidase-antiperoxidase (PAP) and controls 116-118
complex 9, 13, 15, 27, 28 and incubation time 115-18
and endogenous peroxidase 19-22, 31, and negative control 52, 60, 115, 153
76-77, 99, 119, 120-121, 143, 146 precipitation of immune complexes 7-8
composition 40, 89 and prozone 9-10
method 49 concentration 15-16
molecular weight 9-10, 21-22 specificity 1-9, 51, 53, 71, 83, 113, 115,
production 40, 49, 89 117, 125, 127
sensitivity 40, 48, 89 storage 10-13
tissue penetration 9-10
pH
and monoclonal antibodies 15-16 Prosthetic group 19-21
170
Index
Pronase 23 Sodium chloride 25, 81-82

and monoclonal antibodies 15-16, 81-82
Protein blocks 78
Sodium thiosulfate 27-33
Protein structure
conformational changes 81, 97, 99 Soluble enzyme immune complex
(see APAAP and PAP)
Proteinase K 73
Southern blots 89-93
Proteolytic digestion (see also Trypsin
and Protease) 2, 38-44, 58, 61, 73, 91-92 Specific background staining 127-129
and antigen retrieval 7-10, 15-18, 38, 41-
45, 50, 71, 99, 123, 134-136, 138, 142 Specificity (see Controls) 1-9, 51, 53, 71,
and coagulant fixatives 41 83, 113, 115, 117, 125, 127
and noncoagulant fixatives 41
Specimen processing 93
Proteolytic enzymes 41, 45, 71, 73 bone marrow smears 21
cell smears 23-24, 62, 96
Prozone 9-10 cytocentrifuged cells 96
leukocyte smears (buffy coats) 27-33
Pseudoperoxidase activity tissue sections 16, 18, 25, 28, 31, 32,
(see Endogenous peroxidase activity) 41-42, 50, 58, 100, 114, 119, 120-122, 131
frozen sections 3, 30, 31, 58, 107, 119,
Quality control 7, 81, 113, 117-118, 128 126
paraffin sections 16
Quantum dots 61
Stability 10-11, 124-127
Quenching 20, 57, 119-121, 143
Rabbit antiserum 5, 50, 125 138, 142
conferred by fixation 27-31
Rapid staining 37, 47, 105 of antibodies 10-13
and EPOS™ system 50 of immunoglobulins 10-11
“quick” staining method 37 of prediluted antibodies 10-11
of purified IgG fractions 10-11
Reagent cost 16-18
Staining
Regulatory requirements 10-11 amplification of 36, 38, 51-54, 62-66,
89-93, 116
Retrieval solution 42-43, 123 background (see Background)
consistency 10-11
RNA analysis
controls (see Controls)
(see also In situ hybridization) 89-90
cost 16-18
Rocket immunoelectro-phoresis 113, 125 intensity 21-22, 26–31
interpretation 10, 18, 27-32, 44, 53, 95,
Romanowsky-type methods 27-33 111, 113, 117, 119-120, 131
methods (see specific methods)
Shelf life of reagents 10-11 quality 21-22
rapid staining 36-37, 47, 105
Signal enhancement 47-53 specific validation (see Controls)
Signal-to-noise ratio 15-18 Streptavidin 15, 28, 36, 37
Silanized slides 58, 97 (Strept)avidin-biotin

technologies 15-22, 28–3048-49, 121-122,
Smears (see Blood smears and Cytology 146-148
smears) 23-24, 62, 96 background in 127-129
modifications 26, 42-43, 103
Sodium azide 83, 99, 100, 119
171
Substrates 19-25, 51-52, 65-66, 74-75, Washing 42, 71, 82, 114, 129, 140
114, 120, 131, 133-134, 137, 151, 159
Wet-fixation 27-33
Substrate-chromogen solutions 23,
133-134 Zenker’s fixative 30, 126
Surface membrane antigens 26, 42, 56,

72, 96, 99, 126
Target retrieval 44, 63, 91, 114, 116, 129

(see also Antigen retrieval)
T cell
and Fc receptors 58, 126
Temperature
antigen-antibody reaction 15-16
enzyme activity 19-21
fixation 27-31
and incubation time 15-16
and storage 10-11
Thyroglobulin 124
Thyroid follicular epithelium 124-127
Tissue controls 116-118
Tissue marker 42, 53, 123-124

diffusion of 66, 112, 118, 122-125
Tissue processing (see Specimen

processing)
Titer of antibodies (see Antibodies)
Troubleshooting 131-155
background 127-129
buffers 134
demasking 135
staining 131
inadequate 132
undesired 144
tissue specimen 150
Trypsin 41, 73
Tumor differentiation 16-18
Unlabeled antibody method 21, 64

(see APAAP and PAP)
United Kingdom National External

Quality Assessment Service
(UK NEQAS) 117, 129
van der Waals forces 7-8, 79, 126
Virtual microscopy 110-112
172
Notes
173
174
Training & Education
Dako continues its commitment to training and education

with an extensive curriculum including instrument
training, slide interpretation workshops, and courses
related to immunohistochemistry, in situ hybridization,
special stains and flow cytometry.
Tear off your bookmark

before mailing.
S END ME MOR E . . .
Shipping Address:
Name
Bldg./Dept./Room No.
Institution
Address
City
State Zip
Corporate Headquarters Australia Czech Republic Ireland Norway Switzerland
Phone Denmark +61 2 9316 4633 +420 541 42 37 10 +353 91 768150 +47 23 14 05 40 +41 41 760 11 66
+45 44 85 95 00
Austria Denmark Italy Poland United Kingdom
E-mail +43 1 408 4334 50 +45 44 85 97 56 +39 02 58 078 1 +48 58-661 1879 +44 (0)1 353 66 99 11
08002 25MAY06
Belgium France Japan Spain United States of America
www.dako.com +32 016 38 72 20 +33 1 30 50 00 50 +81 75 211 3655 +34 93 499 05 06 +1 805 566 6655
OTHER EDUCATIONAL GUIDES
Distributors in more Canada Germany The Netherlands Sweden
_____ Guide to Flow Cytometry _____ Guide to Special Stains than 50 countries +1 905 858 8510 +49 40 69 69 470 +31 20 42 11 100 +46 08 556 20 600
_____ Additional copies of Guide to Immunohistochemical Staining Methods
Fax: 805 566 6688 or drop this in the mail

Immunohistochemistry Guide Book From Dako

Uploaded by

Copyright:

Available Formats

Immunohistochemistry Guide Book From Dako

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Immunohistochemistry Guide Book From Dako

Uploaded by

Copyright:

Available Formats

PATHOLOGY

Dako provides cancer diagnostic

Our instrumentation portfolio is

Our instrumentation portfolio is

Legend for Schematics

primary antibody secondary antibody F(ab1)2 tissue

HRP AP biotin streptavidin biotinyl fluorescein DBA Fast Red polymer

Chapter 2 ° Basic Immunochemistry

Chapter 3 ° Basic Enzymology

Part II: Processing

Chapter 4 ° Fixation and Processing

Chapter 5 ° Molecular-Friendly Tissue Processing

Chapter 6 ° Antigen Retrieval

Part III: Methodologies

Chapter 7 ° Immunohistochemistry Staining Methods

Chapter 9 ° Multi-Staining Immunohistochemistry

Chapter 10 ° Ancillary Methods in Immunohistochemistry

Chapter 11 ° In Situ Hybridization

Chapter 12 ° Methods of Immunocytology for Slide-Based

Chapter 13 ° Automating Immunohistochemistry

Chapter 14 ° Virtual Microscopy and Image Analysis

Preface to the Fourth Edition of the Dako Educational

It is my pleasure to introduce this fourth edition of Dako’s Guidebook to

Dennis E. Chenoweth, Ph.D., M.D.

Corporate Vice President, Business Development

Depending on the immunogenicity of the antigen, doses of from 10 µg to 200 µg are

In immunohistochemistry, monoclonal antibodies have certain advantages over their

Screening methods also should consider that monoclonal antibodies, unlike

In immunohistochemistry, the functional affinity of an antibody or an antiserum can be

Because antigen-antibody reactions are reversible, the simple immune complexes

Prozone is a property that was first noted in antibody-induced agglutinations. It is the

Cross-reactivity of antibodies to human antigens with identical or similar antigens of

The terminology of cross-reactivity however is misplaced when describing any observed

Antibody Reaction Rates

In these situations equilibrium between antigen-bound and free antibody rarely is

Just as storage of purified antibodies may augment their hydrophobicity due to

Antibody stability in commercially produced reagents is determined best by real-time

The only possible corollary to these requirements is to allow laboratories to document

Use and Care

The appearance of immunochemical reagents, particularly undiluted antisera, is not

Mild to moderate hemolysis in antiserum resulting from suboptimal bleeding techniques

9. Alexander J and Dayal Y. Appl Immunohistochem 1997;5(4):252-3.

With polyclonal antisera, antibody titers have been expressed traditionally as

An optimal antibody dilution also is governed by the intrinsic affinity of an antibody. If

Table 2.1. Volumes of stock reagents and diluents.

Streptavidin-Peroxidase Primary Antibody Dilutions

Precise definition of the optimal signal-to‑noise ratio as a function of the primary

1. Larsson L-I. Immunocytochemistry: Theory and Practice. CRC Press, Inc.

*The term “equilibrium” here denotes saturation of antigen with antibody.

Thus before formation of the product, a transient enzyme-substrate complex is formed

are recognized: Competitive inhibition and noncompetitive inhibition. Competitive

The formation of the complex EI can be reversed by a change in the concentration of

In noncompetitive inhibition, the inhibition depends solely on the concentration of the

Selecting the enzyme most suitable for a particular immuno­histochemical application

Horseradish Peroxidase (HRP)

HRP can be attached to other proteins either covalently or noncovalently. Covalent

HRP also is conjugated to (strept)avidin using the two‑step glutaraldehyde procedure

Noncovalent binding of HRP to antibody, also known as unlabeled antibody binding, is

Calf Intestine Alkaline Phosphatase (AP)

Selecting the enzyme most suitable for a particular immunohistochemical application